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Abstract 
There is an unmet and continuing need for diverse compounds with appropriate 
physicochemical properties for screening collections. This thesis focusses on the 
preparation of diverse scaffolds which may provide access to lead-like compounds 
after decoration. The approach was underpinned by robust connective reactions and 
cyclisations. Computational tools were used in the design and subsequent analysis of 
the compounds obtained.  
Chapter 1 discusses the pharmaceutical sector and the challenges associated 
with creating and maintaining diverse screening colections. Molecular properties are 
key to the solving the problems with that industry. The concept of Lead-Oriented 
Synthesis (LOS) is introduced to help address these challenges. 
Chapter 2 details the significant challenges which were encountered when 
attempting to use the Petasis reaction for LOS. Ultimately however, it was not 
possible to retool this reaction for the synthesis a library of diverse lead-like 
compounds.  
Chapter 3 details the use of a computation protocol to direct the selection of a 
new connective reaction to support lead-oriented synthesis. The tools were used to 
compare five alternative connective reactions. On the basis of this analysis, the 
nitro-Mannich reaction was prioritised for experimental investigation. 
Chapter 4 describes the preparation of small functionalised nitro adducts and the 
exploitation of a small toolkit of robust methodologies to access seven scaffolds. A 
virtual library of 2413 compounds was enumerated from the scaffold, of which 46% 
were found to be lead-like. It was concluded that the nitro-Mannich reaction can 
support lead-oriented synthesis. 
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1 Introduction 
1.1 Introduction 
The drug discovery process has undergone a rapid revolutionary change in 
recent years.1 The growth of chemoselective transformations over the past decades 
has enabled the synthesis of previously challenging molecules. In addition, the 
advances made in understanding the cellular and molecular mechanisms behind 
diseases has allowed for the elucidation of additional drug targets.1 As such it could 
have been expected that productivity of pharmaceutical industry would have 
increased. However up to 97% of all potential clinical candidates which enter phase 
 clinical trials fail to progress to market.2 
1.2 Overview of the Drug Discovery Process 
The main objective of drug discovery process is to identify new drugs which are 
effective, safe and meet an unmet clinical need.3 The different stages within drug 
discovery programmes are outlined in Figure 1. The first objective is to identify a 
target which is associated with the disease.4–6 This can be a protein active in the 
disease pathway (or present within the microorganism causing the disease), an 
enzyme, ion channel or nucleic acids.  
 
Figure 1: Stages of drug discovery process. 
Once identified the target is then validated to ensure modulation provides relief 
from the disease state.3 A high throughput screen (HTS) can be implemented to 
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discover chemical compounds which interact with the target.5,6 As an alternative, 
computational docking may also be used to evaluate a library of compounds which 
are expected to interact with the target if its structure is known.4,5 A compound 
which binds and modulates the target is termed a “hit”.7 The best hits are then 
developed into leads and refined during lead optimisation to improve the potency, 
selectivity or safety of the compound.4,5,7 The final compound is designated the drug 
candidate; more extensive safety and metabolism studies are then performed.4,5,7 
This whole process is costly, time-consuming and complex.7–9 Clinical development 
of a drug candidate is routinely prone to failure due to the uncertainties associated 
with predicting pharmacological and toxicological effects in humans.7–9  
An analysis of the candidate’s pharmacokinetics properties can often prevent 
unsuitable molecules from advancing through the drug discovery process and thus 
help to decrease the number of failures.7,10,11 It has recently been recognised that the 
pharmacokinetic properties of the candidates are intrinsic properties of the 
molecules and it is therefore important for the medicinal chemist to optimise not 
only the drug-like properties but also the pharmacokinetic properties in lead 
molecules.12 
1.2.1 Characteristics of drug-like compounds. 
Drug-like properties refer to both the physical and adsorption, distribution, 
metabolism, excretion and toxicity (ADMET) properties of a molecule.4,13 For 
example, Lipinski’s “rule of 5” is a set of informal guidelines which take into 
account the molecular weight, hydrophobicity, hydrogen bond donor and acceptor 
capabilities of the molecule (summarised in Figure 2, Panel A entries 1-4).11,13,14 The 
guidelines are based on a statistical analysis of successfully marketed drugs and 
violation of more than one of these rules is unlikely to provide an orally viable 
drug.7,11 Shown in Figure 2 (Panel B) are the properties of the number one 
bestselling drug (as measured by sales from October-December 2013) Aripiprazole 
(1), an antipsychotic.15  
Arguably the most important property of a drug is the LogP (a measure of 
lipophilicity).7,16–18 The higher this value the less likely the substance dissolves in 
aqueous environment which could lead to transport issues (rate of metabolism and 
3 
 
plasma protein binding are amongst other sources of transport issues).7,19–22 In 
addition, there is a correlation between greater lipophilicity and an increase in 
promiscuity; the toxicity of the compound could be amplified as binding interactions 
towards other targets could be significantly improved.7,19,20 
 
 
Figure 2: Summary of  drug-like properties as defined by Lipinski and their idealised values (column 
1).23 The physiochemical properties of Aripiprazole (1), the bestselling drug in the final months of 
2013 (column 2).15 
Hydrogen bond donors and acceptors are atoms which either provide the 
hydrogen for a hydrogen bond or provide an electron rich atom to interact with the 
respective hydrogen.4 Too many of these interactions leads to poor membrane 
permeability, reducing the transport capability of the drug.4  
The polar surface area is the sum of surface area of all the polar atoms and 
attached hydrogens.19,22,24 Although not part of Lipinski’s original work, it is an 
additional parameter which has been shown to be a good indicator of how well a 
substance can be transported across cellular membranes.19,22,24   
Reactive functional groups are a further aspect to consider when evaluating the 
drug-like properties of a molecule. These groups are undesirable in a drug molecule 
as they could give a false hit (as it could react indiscriminately with the target) or 
increase the toxicity.7,25–29 In addition, some groups are undesirable as they are 
readily hydrolysed in vivo and as such are avoided as their hydrolysis could reveal a 
toxic function group or the molecule could lose some binding interactions. Common 
undesirable groups within drugs include (but are not limited to) electrophiles such as 
epoxides and Michael acceptors.25–28  
It should be noted however, that the above rules are only expected to serve as 
guidelines to the medicinal chemist and it is the balance of these properties which 
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determine the compounds suitability as a drug candidate.14,22 Indeed the rule of 5 is 
only applicable to orally bioavailable drugs and describes just adsorption issues, not 
the compounds bioavailability. If specific transport methods are employed, there is a 
more generous allowance for drug properties.14,30–32 There are also specific rules for 
drugs acting on the Central Nervous System.30,33–35  
1.2.2 Progression from leads to drug compounds: changing 
physiochemical properties 
As previously discussed the lead compound is often altered within the drug 
discovery process to yield the drug candidate. This is done for a number of reasons 
including (but not limited to) improving ADMET properties and increasing binding 
to the target. Dichloroisoproterenol (2) was the first -blocker to be developed 
(Figure 3 , Panel A).36  However the low potency observed and the fact it is partial 
agonist/antagonist of the  and -andrenergic receptors made it unsuitable as a 
drug.36 Subtle structural modification resulted in the development of Propranolol (3), 
the first -blocker to reach market which is a full antagonist of the  and -
andrenergic receptors.37 
 
Figure 3: Panel A: Physiochemical properties of Dichlorisoproterenol (2) and propranolol (3). Panel 
B: Changes in physiochemical properties of selected lead-drug pair. Panel C: Property analysis of 67 
lead and drug pairs. Values for the lead compounds were subtracted from matching properties of the 
drug molecules. Adapted from Teague et al.12  
The molecular weight increased during the development of Propranolol from 
Dichlorisoproterenol (Figure 3 , Panel B). The number of hydrogen bond acceptors 
also increased with a slight decrease in LogP. Teague and co-workers analysed the 
difference between 67 lead compounds and the drug candidates derived from them.12 
By using such a large data set they were able to highlight some trends; chiefly 
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molecular weight, LogP and complexity are increased throughout the drug discovery 
process. It is therefore better to start from a smaller fragment so as to remain in 
drug-like chemical space on optimisation to the final lead compound.7,13,30 
1.2.3 Characteristics of lead-like compounds 
If the information presented above is taken into account, a map of chemical 
space can be created such that the drug-like properties, as defined by Lipinski, 
represents the limits of chemical space. Since there is typically an increase in 
molecular weight and LogP throughout development12 Churcher et al. have defined 
a region termed lead-like chemical space (Figure 4, Panel A). By their definition the 
limits of lead-like space is defined by the molecular properties outlined in Figure 4 
(Panel B).7 By constraining the physiochemical properties of lead compounds, 
increases in molecular weight and LogP typically observed during development, the 
final compound should still remain within Lipinski’s drug-like chemical space.  
 
Figure 4: Panel A: Diagram of chemical space. Throughout lead optimisation, a compound tends to 
increase molecular weight and lipophilicity.12 Panel B: Limits for the molecular properties of lead-
like compounds as defined by Churcher et al.7 Panel C: Analysis of 4.9 million commercially 
available compounds for their lead-likeness.7 2.6% of the compounds (green) survive successive 
filtering by molecular size (14 ≤ number of heavy atoms ≤26; failures shown in red), lipophilicity (−1 
≤LogP ≤3; failures shown in orange) and presence of undesirable functional groups (failures shown 
in black). Panel D: Analysis of 13,194 compounds published in J. Org. Chem. 2009 for lead-likeness. 
Using the same criteria as before, on 2.0% of compounds pass all filters.7 
Churcher et al. analysed the physiochemical properties of 4.9 million 
commercially available compounds from a variety of vendors.7 They found the vast 
majority of compounds (97.4%) fail at least one descriptor of lead-like properties. 
(Figure 4, Panel C).7 The same analysis was performed on synthetic methodology 
reported in the Journal of Organic Chemistry during 2009 showed that of the ca. 
32,700 molecules synthesised only 690 (2.0%) of them would pass lead-like filters 
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(Figure 4, Panel D). As such there is an urgent need for the development of new 
methodology which is capable of reliably generating diverse compounds with 
properties within lead-like chemical space.7 
1.3 Availability of Lead Molecules. 
This section details traditional sources of lead compounds and their advantages 
and disadvantages before assessing the typical physiochemical properties associated 
with typical leads and assessing if they inhabit lead-like chemical space. 4 
1.3.1 Natural Products 
Natural compounds have evolved to interact with specific biological targets to 
achieve a precise response; as such the use of natural products as sources for leads 
has been extensive.4,5 However, natural products are often complex and while they 
can have excellent potency, they provide little room for further chemical 
manipulation.4 As a result they are not generally lead-like as defined by Churcher.7 
In addition, isolation of the active compound can prove difficult as it may be present 
in low concentration or unstable to purification techniques employed.38 Taxol (4, 
Figure 5) is a key example, originally isolated from the Pacific Yew. It required 
1,200 kg of bark to yield just 10 g of purified Taxol and it was not until 1993 (over 
30 years since it was initially isolated) that a practical semi-synthetic synthesis was 
developed by BristolMyersSquibb.38  
 
Figure 5: Taxol (4) is a complex anticancer agent, derived from natural sources.38 
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1.3.2 X generation: exploiting first in class 
As compounds with activity are identified, through academic research groups or 
within rival pharmaceutical companies, the reported structure can often be used as 
the lead compound.38 The so called “best in class” approach has been used 
widely.38,39 The scaffold of the molecule is generally retained but the appendages are 
altered to maximise its effectiveness. Pro-drug strategies or different formulations 
can be used to circumvent patent protection.38 Ranitidine (5, Figure 6), a histidine H2 
receptor agonist, was developed by the then Glaxo organisation in response to 
Cimetidine (6, Figure 6) developed by Smith, Kline and French.38,39  
 
Figure 6: Cimetidine (6) was used as a lead compound for the development of Ranitidine (5) a 
histidine H2 receptor agonists.38,39 
1.3.3 Fragment-based drug discovery. 
Traditional HTS requires a large library of compounds to be prepared and 
screened in order to identify suitable hits. This increases both cost of development 
and time required to identify suitable compounds. Fragment-based drug discovery 
(FBDD) has grown as a complementary method for lead identification within drug 
discovery programs.38,40–42  
A major advantage of screening fragments is that a library of smaller fragments 
represents a much larger proportion of the available chemical space than a similarly 
sized library for higher molecular weight compounds.39–41 In addition there are 
significantly more hits with a fragment-based screen compared to traditional HTS; 
the library screened therefore can be much smaller to obtain a comparable number 
of hits.39–41,43 This decreases both the time and cost associated with development of 
the screen.40,42  
A major disadvantage of this approach to lead identification is that the binding 
affinity of fragments is much lower than drug-like molecules. As a result, 
conventional HTS bio-assays for determining activity cannot readily be applied.38,40 
Other techniques such as X-ray crystallography and NMR spectroscopy must be 
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used.38,40,42 The use of such techniques requires significantly more time for data 
collection and consequently they are not suitable to HTS. The compounds screened 
must also be very soluble since high concentrations are required to detect the weakly 
bound species which limits the availability of certain fragments.40,42  
Vemurafenib (or PLX4720) is a kinase inhibitor, and the first FDA approved 
drug discovered by FBDD.38,44,45 7-Azaindole (7, Figure 7) was identified by Tsai 
and co-workers from an initial library of 20,000 fragments and was subsequently co-
crystallised with Pim-1; however, as with most low-binding fragments multiple 
binding modes were identified.45 Derivatisation of 7 quickly identified 8 which 
crystallised with Pim-1 in a single binding site. Derivitisation of 8 at the three and 
five positions as directed by the X-ray structure generated PLX4720 (9) which was 
found to be selective for B- RafV600E kinase (the most common oncogenic kinase) 
over wild type B-Raf (IC50 of 13 and 160 nM respectively). 
44,45
 
 
Figure 7: Azaindole (7) was the initial hit which was developed into a kinase inhibitor and the first 
FDA approved drug discovered from FBDD  (9).44,45 
1.4 Existing methodologies for generating diverse compound libraries 
Libraries of highly diverse small molecules are essential for enabling the 
efficient screening of chemical space. However diversity is a crude term often used 
to describe entirely different concepts. Lipkus et al. have used the concept of 
frameworks to quantitatively analyse the diversity of the CAS registry.46  The 
concept of frameworks is demonstrated with Amikaicin (10, Figure 8, Panel A).46    
By this method, it is only the constituent ring systems which are important, the 
side chain appendages are ignored for simplicity.46 The simplest level, the graph 
level, is simply the ring systems with connecting chain atoms. At this stage, 
tetrahydrofuran and pyrroles would be classed as the same scaffold. The next level, 
the graph/node level, simply includes the heteroatoms present within the graph 
framework. At this level, piperidine could be differentiated from benzene but it 
would still have the same scaffold as pyridine. This is also called the  
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Figure 8: Panel A: Amikacin, a dicarboxylate ACE inhibitor, shown at graph, graph/node and 
graph/node/bond level of frameworks. Panel B: A plot of the percentage of frameworks vs the 
percentage of compounds which have that framework. An expanded view is shown below. Adapted 
from.46   
heteroframework. The final level, the graph/node/bond level, includes the oxidation 
states of the heteroframework. In this way pyridine rings can be differentiated from 
piperidine rings. 
Lipkus et al. have used the concept of frameworks to analyse the diversity of 
the CAS registry.46 From the analysis, they concluded that the 5% most common 
heteroframeworks represent ~75% of all compounds synthesised (Figure 8, Panel B 
and C).46  Exploration of chemical space has therefore not been systematic, 
approximately half of all compounds synthesised are based on only 0.25% of known 
molecular scaffolds.46–49 The number of possible drug-like molecules is enormous 
and it is impossible to prepare all molecules to map the entire chemical space or 
indeed just biologically active space.46,50 As a consequence, skeletally-diverse 
structures must be synthesised to ensure maximal chemical space coverage.49 With a 
more systematic approach to exploring new molecular scaffolds, novel leads may be 
discovered.51 
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1.4.1 Diversity-oriented synthesis  
Diversity-oriented synthesis (DOS) is a technique aimed at the systematic 
exploration of chemical space. DOS aims to efficiently prepare libraries of 
compounds with diverse molecular structures.51–53 There are three general 
descriptors of diversity:47,48,52–54 
1. Appendage diversity – in which the substituents on the scaffolds are varied. 
2. Stereochemical diversity – in which the use of stereoselective reactions 
allows access to all possible stereoisomers. 
3. Skeletal diversity – in which the scaffolds of small molecules are varied.  
Target oriented synthesis (TOS) is used when there is a known compound of 
interest and the medicinal chemist will try many different types of chemistries to 
obtain the single scaffold (Figure 9, left). Combinatorial chemistry aims to explore 
the immediate vicinity of a particular target by variation of substituents, and is 
usually used in lead optimisation (Figure 9, centre). As a result, although many 
different compounds are synthesised they are often based on a conserved molecular 
scaffold. DOS differs considerably from combinatorial chemistry. Since it aims to 
explore broad areas of chemical space, few compounds with just the same molecular 
scaffold (Figure 9, right).47  
 
Figure 9: Schematic illustration of the major approaches to lead generation: target oriented synthesis 
(left), combinatorial chemistry (centre) and diversity oriented synthesis (right).47 
DOS employs a number of different strategies to obtain skeletal diversity (of 
which some can be used in combination to greatly increase complexity).52 Multi-
component reactions are often extensively used.55 Diversity can then be obtained by 
variation of each of the reactants. Three conceptually different approaches to 
exploration of chemical space using DOS are; 
1. Branching pathways (Section 1.4.1.1) 
2. Folding pathways (Section 1.4.1.2) 
3. Oligomer-based approaches (Section 1.4.1.3) 
Other approaches have been reviewed and are not discussed here.51,56,57  
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1.4.1.1 Branching Pathways 
Branching pathways (or ‘reagent based approaches’) are one of the more 
commonly employed strategies in DOS. Branching pathways involve the use of a 
substrate with many complementary functional groups (Figure 10) which are then 
exposed to a number of different reagents which couple the different functionalities 
in order to give distinct molecular scaffolds.47,49,52,54,58  
 
Figure 10: Schematic representation of a branching pathway route in Diversity-oriented synthesis. 
This method becomes extremely efficient when the product of the reactions 
retains complementary functional groups which allow further diversification.52,58 
Structural complexity is built up rapidly in four or five synthetic steps as shown in 
the work of Schreiber and co-workers.58 Schreiber utilised the Petasis reaction to 
create the amino alcohol 14 (Scheme 1). Additional functionality was then 
incorporated with the selective N-alkylation with propargyl bromide to give 15.58  
 
Scheme 1: Synthesis of amino alcohol 15 in two synthetic steps from available starting materials.58 
Alternative transition metal catalysis was employed to give products with 
distinct molecular scaffolds (Scheme 2): ruthenium-catalysed cycloheptadiene 
(→16), ene-yne metathesis (→17), palladium-catalysed cycloisomerisation (→18), 
electrophilic activation of alkyne with gold (→19), Pauson-Khand cyclisation 
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Scheme 2: The use of the Petasis reaction to create a polyfunctional starting material. Various transition metal catalysed reactions were then employed to couple the various 
functional groups and give access to distinct molecular scaffolds. Reaction conditions: a) [CpRu(CH3CN)3PF6] (10 mol%), acetone, rt; b) Hoveyda-Grubbs second generation 
catalyst (10 mol%), DCM, reflux; c) [Pd(PPh3)2(OAc)2] (10 mol%), benzene, 80 °C; d) NaAuCl4 (10 mol%), MeOH, rt; e) [Co2(CO)8], trimethylamine N-oxide, NH4Cl, benzene, 
rt; f) NaH, toluene, rt; g) mCPBA, THF, -78 – 0 °C; h] 4-methyl-1,2,4-triazoline-3,5-dione, DCM, rt; i) [Co2(CO)8], trimethylamine N-oxide, benzene, rt; [a] Single 
diastereoisomer; [b] > 10:1 d.r.; [c] trans/cis = 6.7:1; [e] from trans diene; [f] trans/cis = 3:1; [g] combined yield from the trans and cis dienes. mCPBA = m-chloroperbenzoic 
acid. 
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(→20), lactonisation (→21) and N-oxide mediated isomerisation (→22) which 
underwent the same gold mediated activation of alkyne previously (→23). 
After the first generation of cyclised products, some were suitable substrates for 
further manipulation. Thus dienes 17 and 23 underwent a Diels Alder reaction to 
give tricycles 24 and 25. The lactone 21 was subjected to some of the initial 
cyclisation used with 15 to give second-generation cyclisation products with 
increased complexity (26-30). In total, this strategy yielded over 15 distinct 
molecular scaffolds in two synthetic steps from a simple starting material (itself 
prepared in two steps from commercially available reagents).58 Although not 
explored here, with variation of the starting reactants, additional scaffolds could be 
readily synthesised. 
1.4.1.2 Folding Pathways 
Folding Pathways (or ‘substrate-based control’) are the converse of branching 
pathways. Diversity is built into the route by varying the building blocks used and 
then under the same reaction conditions one can generate different molecular 
scaffolds (Figure 11).47,49,52,53 Diversity of the starting materials could be the use of 
acyclic and cyclic starting materials or varying the distance between reactive 
functional groups as well as appendage diversification. 
 
Figure 11: Schematic representation of a folding pathway.54 
Oguri and Schreiber reported the use of one such folding pathway to three 
distinct indole alkaloid architectures (31-33, Scheme 3).51,53,55 The rhodium 
catalysed cyclisation produced distinct structures based on the relative locations of 
the α-diazo carbonyl and the indole groups. As a result of the different ring closures, 
quite diverse products was obtained. Complex alkaloid-like products was obtained in 
just four reactions from commercially available starting materials.53 
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Scheme 3: Three distinct alkaloid-like structures generated from folding pathway. The diverse 
structures were obtained by varying the distance between the reactive groups.53 
1.4.1.3 Oligomer-based Approaches 
Oligomer-based approaches combine elements from both branching and folding 
pathways to provide a vastly powerful tool for generation of diverse molecular 
scaffolds. The starting material is often immobilised on a tag or a polymeric support 
(Figure 12) then various coupling strategies are employed to obtain a larger bound 
substrate.48,59 Then using suitable reactions, the product can be released from the 
bound support (Figure 12). This release step often “re-programmes” the substrate 
giving access to the diverse structures.48,51  
 
Figure 12: Schematic representation of a folding pathway 
This strategy has been used within the Nelson group (Scheme 4).48,49 By using 
various a variable oligomer bound starting material (34) they were able, in a series of 
propagating and capping steps, add a variety of different building blocks (35-38) to 
synthesis a number of oligomer-bound structurally diverse intermediates. Then 
following alkene metathesis, the products were reprogrammed giving a large number 
of different scaffolds and removing the oligomer tag. 
Exploiting variation of the position of the alkene bonds in the substrates, and 
subsequent competition between the formation of different ring sizes, 84 distinct 
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molecular scaffolds were obtained from only 92 products, of which 65% were 
novel.48 A fact which demonstrates that the use of oligomer-based approaches can 
achieve the aims of DOS; the systematic exploration of chemical space. 
An important advantage of this method was the use of the fluorous-tagged linker 
(RF). This linker allowed rapid purification of all intermediates and final reagents 
with simple fluorous solid-phase extraction.48  The broad scope of the metathesis 
reaction was another key feature which allowed the high diversity. It is only through 
using similarly tolerant reactions that diversity on this scale could be achieved, with 
the use of only six optimised reactions.48  
 
Scheme 4: Example of the oligomer-bound  pathway used in DOS. The initial substrate is bound to a 
fluorous linker then rapidly extended before product release.48 Rf = Fluorous tag.  
One of the major challenges associated with DOS strategies is finding suitable 
reactions which tolerate a variety of functional groups.51 Since the aim of DOS is to 
achieve diversity in few steps, the use of protecting groups is avoided wherever 
possible.  
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1.4.2 Physiochemical properties of DOS libraries 
The products obtained from the DOS approaches described in Section 1.4.1.1-
1.4.1.3  were subjected to a computational analysis of their physiochemical 
properties. A plot of the molecular weight vs LogP was then created (Figure 13). 
From the data generated, only 10% of the scaffolds created have physiochemical 
properties suitable for the synthesis of a lead-like compounds (shown in green). Just 
55% of the scaffolds have properties suitable for Lipinski’s drug like space while the 
remaining 35% are outside lead-like chemical space. Since development of a drug 
candidate typically increases molecular weight and LogP, most of the products 
would be unsuitable for generation of a drug-like library. The products obtained are 
better described as drug-like or natural product-like due to the significant molecular 
weight which often lies well outside the lead-like chemical space as defined by 
Churcher (Section 1.2.2).7,51 
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Figure 13: Analysis of the molecular weight and LogP of the products obtained from three DOS 
campaigns.48,52,53 Compounds which pass lead-like filters (green), Lipinski’s rule of five (orange) and 
compounds beyond the Lipinski limit (blue).  
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1.4.3 Lead-oriented synthesis  
In their review, Churcher et al. establish that traditional chemistries are inclined 
to producing molecules outwith “lead-like” space.7,13,26,50 Arrays are designed to give 
molecules with a broad range of properties and structural characteristics. Typically 
however, not all products are obtained from a planned array and as such the property 
profile of the entire array is often skewed.7 Generally the molecules which 
systematically fail are often the polar, more hydrophilic products (either through 
failure of the reaction under standard conditions or poor product recovery from 
standard work-up procedures).7  
As such, the final array of compounds obtained often have a different 
physiochemical profile which a much higher mean LogP than planned (so called 
LogP drift).7 As a result, the authors call for new methodology to be developed to 
allow to more diverse and better quality lead compounds.7 Since the concept of 
Lead-Oriented Synthesis (LOS) was introduced a number of groups have attempted 
to address the need. Herein approaches which best attempt to address these 
challenges are discussed. 
1.4.3.1 Lead-oriented synthesis: Branching pathway 
Branching pathways (as seen in Section 1.4.1.1) can be used in the development 
of lead-like chemical libraries. “Rope-like molecules” as defined by Stockman et al. 
are linear compounds with complementary functional groups which allow the 
creation of fraction sp3 (Fsp3) carbon molecular structures.2 These structures contain 
a variety of ring systems and the heteroatoms incorporated allow further 
diversification and subsequent SAR type analysis. The methodology is exquisitely 
demonstrated in Figure 14 (Panel A) where an example of a “rope like molecule” 43 
gave rise to a small library of products with distinct molecular scaffolds; 6/5/5 fused 
tricycles (44, 45 and 46); 6/6 fused cycles (47, 48 and 49); 5/5 fused cycles (50 and 
51); spirocycle (52) and single cycles tetrahydropyran (53) and cycloalkane (54).2   
The products obtained from this small library were subjected to the same 
computational analysis of the physiochemical properties used in the DOS campaigns 
(Section 1.4.2). A plot of the molecular weight vs LogP was then created (Figure 14,  
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Figure 14: Panel A: An example of a “rope like molecule” 43 which undergoes a variety of cyclisation reactions to give scaffolds 44-57. Panel B: Analysis of the physiochemical 
properties of these scaffolds generated reveal they occupy lead-like  chemical space.  
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Panel B). As shown, seven out of the eleven scaffolds synthesised have molecular 
weight and LogP within lead-like chemical spaces as defined by Churcher et al.7 
Further elaboration of scaffold 44 resulted in an additional library of compounds 
which was screened against three cancer cell lines and exhibited a range of 
biological activity. This demonstrates this is a practical methodology for rapid 
access scaffolds with high Fsp3 which can be further elaboration to give a library of 
molecules suitable for biological screening. The scaffolds were delivered in an 
average 1.25 steps from 43 per new scaffold.2 
The only real disadvantage of this methodology is the limited number of sites 
remaining for diversification. Nine of the compounds only have the presence of one 
or two ester groups. Three of the scaffolds generated also have the presence of 
undesirable functional groups, namely N-O and N-N linkages.60 
1.4.3.2 Lead-oriented synthesis: Folding pathway (1) 
Folding pathways (as seen in Section 1.4.1.2) can be used in the development of 
lead-like chemical libraries. The use of multicomponent reactions which allow 
variation of the components allows rapid access to diverse small molecules if 
systematic variation of each component is tolerated. SnAP (Sn Amine Protocol) as 
re-introduced by Bode et al. attempts to deliver highly functionalised Fsp3 rich 
heterocycles (Figure 15).61–63 Treatment of an aldehyde with an amino tethered 
stannane in the presence of a copper catalyst led to the isolation of cyclic amines via 
radical addition to the imine (Figure 15, Panel A). A broad variety of (hetero) aryl 
and aliphatic aldehydes are tolerated with a variety of substitution patterns allowing 
the synthesis of six- to nine-membered heterocycles including diazapines and 
oxazepanes (55-60, Panel B). 61–63  
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Figure 15: Panel A: Bode et al. utilisation of a novel copper mediated radical addition to various 
imines allows the synthesis of diverse range of heterocycles. Panel B: Selected examples of products 
obtained from this folding pathway.61–63 Panel C: Analysis of the physiochemical properties of these 
scaffolds generated via SnAP protocol reveal they are sufficiently small that may retain useful 
properties even after decoration.  
When the molecular weight and LogP is calculated for the library members, as 
described previously (Section 1.4.2 and 1.4.3.1), data generated reveals that every 
compound except one falls within lead-like chemical space (Figure 15, Panel C). A 
key limitation of the SnAP protocol is that significant synthetic effort is required to 
make the tin reagents. The diversity of the subsequent library is also reduced since a 
common ring system would be present in a large percentage of the compounds 
generated. This could only be overcome by the synthesis of many different tin 
reagent.61–63  
1.4.3.3 Lead-oriented synthesis: Folding pathway (2) 
 Dixon et al. have recently disclosed a folding pathway towards highly 
functional, diverse pyrrolidinones employing a nitro-Mannich-lactamisation cascade 
(Figure 16, Panel A).64 Treatment of the nitro ester with the imine (formed from the 
condensation of aldehyde and amine) led to the isolation of pyrrolidones 61-66. 
Systematic variation of different amines, aldehydes and nitro components allowed 
the synthesis of a library of highly substituted scaffolds with good diastereocontrol 
(Panel B).64 
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Figure 16: Panel A: Overview of the nitro-Mannich lactamisation developed by Dixon. Panel B: 
Selected examples of diverse pyrrolidones generated.64 Panel C: Analysis of the physiochemical 
properties of these scaffolds reveal they occupy lead-like  chemical space.  
A plot of the physiochemical properties (Panel C) shows the majority of 
products obtained have physiochemical properties within lead-like chemical space. 
As seen with the work of Bode (Section 1.4.3.2) however, the only real limitation of 
this protocol is that the diversity of the subsequent library is reduced since a -
lactam is found within the every compound in the library. 
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1.5 Project Outline 
Traditionally within the Nelson group, DOS strategies implemented thus far 
have created libraries of compounds with unprecedented skeletal diversity (Section 
1.4.1.3).48,49 However, the control of the physiochemical properties of the 
synthesised libraries has not been attempted, and as such they often display natural 
product-like or drug-like properties with high molecular weight and LogP (Section 
1.4.2). 
Recently, in collaboration with the Marsden group, efforts have been directed 
towards the synthesis of libraries possessing lead-like properties (Figure 17). The 
approach uses a connective reaction to give a highly functional cyclisation 
precursor. The cyclisation precursors generated are then subjected to a maximum of 
two cyclisation reactions to obtain scaffolds. This has been shown superbly with the 
iridium-catalysed allylic amination,65 which has generated thirteen unique 
cyclisation precursors. (Figure 17, Panel A, selected example).  
 
 
Figure 17: Panel A: An iridium-catalysed reaction between an amine and allylic carbonate. 13 
cyclisation precursors synthesised.65 Panel B: Selected lead-like scaffolds (70-73) prepared 
cyclisation precursor 69.65 Panel C: Distribution of the molecular properties of the virtual library. 
59% of the compounds (green) survive successive filtering by molecular size (14 ≤ number of heavy 
atoms ≤ 26; failures shown in red) and lipophilicity (−1 ≤ ALogPP ≤ 3; failures shown in orange) and 
various structural filters; 0.27% of the compounds (shown in black) failed the structural filters.65 
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Using a toolkit of just six cyclisation reactions a total of 52 diverse molecular 
scaffolds was synthesised from the thirteen precursors (Panel B, selected scaffolds). 
The compounds were then virtually decorated with a number of different medicinal 
chemistry capping groups and the molecular properties were analysed. By 
successive filtering, using the method described by Churcher (Section 1.2.3), and 
59% of compounds were considered lead-like. (Panel C, Figure 17).  
The aim of this project was to expand the number of connective reactions which 
could be used for the generation of lead-like chemical libraries (Figure 18). The 
connective reaction had to be tolerant of a variety of building blocks with diverse 
functional groups to permit different scaffold generating cyclisations. The scaffolds 
synthesised should also retain suitable functionality which would allow late stage 
decoration to give a library of compounds with suitable physiochemical properties to 
target broad regions of lead-like chemical space and thus demonstrate the potential 
of this strategy to underpin early-stage drug discovery. Once a potential connective 
reaction had been identified, a key outcome was generating a library of scaffolds. 
 
Figure 18: Common starting reagents with different functionalities are combined to give a cyclisation 
precursor; exposed to different reaction conditions yields diverse scaffolds which can then undergo 
decoration with traditional medicinal chemistry groups to give lead-like scaffolds. This approach is 
illustrated using the Petasis reaction. 
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1.6 Summary 
In order to improve productivity in the pharmaceutical sector, where 
traditionally up to 97% of lead compounds fail to make it to market, a new 
approach, lead-oriented synthesis was envisioned.7 A key challenge in lead-oriented 
synthesis is the identification of complementary and robust reactions with broad 
functional group compatibility that may be used to link building blocks. The project 
aimed to use a computational method to identify connective reactions which create 
scaffolds with the potential, after decoration, to yield lead-like small molecules. 
Once identified, a key challenge was optimise these reactions, and to exemplify 
them in the synthesis of lead-like scaffolds. If successful, it could greatly expand the 
relevant chemical space accessible to drug discovery programs targeting scaffolds 
which have traditionally been underrepresented in screening collections and could 
therefore significantly address the productivity within the pharmaceutical sector. 
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2 Investigation into suitability of the Petasis reaction for lead-
oriented synthesis 
This Chapter describes the potential of the Petasis borono-Mannich reaction 
(hereafter referred to as the Petasis reaction) as a connective reaction to support 
lead-oriented synthesis. A literature review is first given before a detailed 
description of the development of the Petasis reaction to support lead-oriented 
synthesis (LOS).  
2.1 Petasis reaction: general characteristics 
Multicomponent reactions are convergent reactions in which three or more 
starting materials react to form a product and are one of the best tools available to 
explore chemical space.66–68 With a large variety of commercially available 
materials and mild reaction conditions,69–73 the Petasis reaction (Scheme 5) could be 
suitable for synthesising a range of cyclisation precursors with the aim to explore 
lead-like chemical space.  
 
Scheme 5: Proposed mechanism for the Petasis reaction. The rate determining step is irreversible C-C 
bond formation when transferring R2 moiety to imine. 
The Petasis reaction exploits the combination of a α-hydroxyaldehyde, boron 
nucleophile and an amine to give a variety of differentially substituted amines 
(Scheme 5). While the mechanism is not fully understood, it has been proposed to 
involve the co-ordination of the boron nucleophile with the α-hydroxyl group of the 
aldehyde to give an electron rich boronate species.67 Condensation with the amine 
gives an electrophilic iminium ion which facilitates the transfer of the R2 component 
of the boronate. A final hydrolysis of boric acid provides substituted amine. 
There are two major approaches to obtain enantio-enriched products from the 
Petasis reaction: the use of chiral substrates (e.g. chiral amines, boronic esters or  
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aldehydes) and organocatalysts. 
The use of chiral amines has been accomplished successfully.70,74,75 Sterically 
unencumbered (R)-methylbenzylamine has been shown to yield amino acid 77 with 
modest diastereoselectivity (Scheme 6).74 This methodology has been extended to 
electron rich aryl boron nucleophiles with slightly reduced selectivity (78).76 With 
(S)-phenylglycinol, Petasis and co-workers reported improved diastereoselectivity to 
yield 79 with high diastereoselectivity (Scheme 6).75  
 
Scheme 6: Application of Petasis reaction for synthesis of enantio-enriched amino acids 77-79 via a 
chiral amine.74–76 Conditions: a) DCM, rt, 48 h; b) toluene, 25 ˚C, 30 h.  
Schreiber and co-workers observed high diastereoselectivity in the Petasis 
reaction of a range of masked aldehydes (81-84, Scheme 7). This is shown with N-
benzylallyl amine and 1,1-aminocyclopentane carboxylic acid giving anti amino 
alcohols 81 and 82 with high diastereocontrol.69 The methodology has also been 
used with chiral amines; when using (R)-phenyl alanin emethyl ester, a different 
stereoisomer is obtained depending on the stereochemistry of the aldehyde 
(overriding the stereocontrol of amine) as shown with 83 and 84.58   
 
Scheme 7: Application of Petasis reaction for synthesis of diastereo-enriched amino acids 81-84 
using a chiral aldehyde ((S)-80 or (R)-80).58,69 *(S) or (R). Conditions: a) DCM-HFIP (90-10), rt; b) 
DCM-HFIP (75-25), rt; c) ethanol, rt. 
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The use of chiral boronic nucleophiles has received less attention, though 
Koolmeister and co-workers have successfully employed a range of chiral boronic 
esters 85-88 to give enantiomerically enriched amino acid 90 (Scheme 8).77 The low 
levels of enantioselectivity excess observed could result from competing hydrolysis 
of the chiral moiety prior to the Petasis reaction.  
 
Scheme 8: Application of Petasis reaction for synthesis of enantiomerically enriched amino acid 90 
via chiral boronic esters.77 
Recently, organocatalysts has been successfully employed to yield the first 
Petasis reaction products with syn relative configuration. Schreiber and co-workers 
employed BINOL ligand (91) to overcome the inherent anti-diastereoselectivity of 
the Petasis reactants which increases the number of potential stereoisomers that can 
produced. This is preliminary work but if successfully expanded, could overcome 
the major limitation of the Petasis reaction (92-93, Scheme 9) for library generation; 
namely that only one stereoisomer of product can be obtained. This is a complex 
reaction which is not fully selective as existing amine stereochemistry can override 
catalyst control giving anti isomer (e.g. with 95). 
 
Scheme 9: Application of Petasis reaction for synthesis of diastereo-enriched amino alcohols 92-95 
via BINOL catalyst (S)-91.78 
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2.1.1 Physiochemical properties of compounds within libraries 
generated from the Petasis reaction 
The Petasis reaction has been shown, by the Neilsen and Schrieber groups, to be 
suitable for the synthesis of diverse heterocycles.71,78–82 However the properties of 
the compounds created, specifically the LogP and molecular weight, lie outside 
lead-like chemical space. Indeed when the properties of the Petasis products and the 
scaffolds generated within these libraries are calculated, over half the compounds 
(both cyclisation precursors and scaffolds) have physiochemical properties outside 
of lead-like chemical space (Figure 19).  
 
Figure 19: Analysis of the physiochemical properties of the products obtained from Petasis reaction 
campaigns.71,78–82 Note the high molecular weight which puts them beyond lead-like chemical space 
and indeed in some cases beyond drug like chemical space. Cyclisation precursors with 
physiochemical properties within lead-like chemical space (green triangles) and those outwith lead-
like chemical space (red triangles). Scaffolds with physiochemical properties within lead-like 
chemical space (green squares) and those outwith lead-like chemical space (red squares).  
In addition, many of cyclisation precursors and scaffolds have molecular weight 
and LogP approaching the limits of lead-like chemical space (275-350 Da and LogP 
of 2-3). If these were decorated to give screening compounds, their physiochemical 
properties are likely to be beyond the scope of LOS. It was envisioned that the 
Petasis reaction could be retooled to allow for the synthesis of cyclisation precursors 
(and in effect scaffolds) for the exploration of lead-like chemical space. 
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2.2 Reaction optimisation 
Due to the conflicting reports in the literature, the first objective was to identify 
common reaction conditions before systematic investigation of different amines, 
boron nucleophiles and -hydroxy aldehydes could be undertaken. Accordingly, N-
methylallyl amine (96), trans-2-phenylvinylboronic acid (74) and glycolaldehyde 
(97) were used as model reactants for the Petasis reaction (Table 1). 
Table 1: Initial exploration of the Petasis reaction. 
 
Entry Solvent Temperature 
Equivalent 
of 97 
Yield (%) 
   1 Water rt 1 64 
   2 Water 40 ˚C 1 Trace 
   3 Water 80 ˚C 1 --♦ 
   4 Toluene rt 1 64 
   5 THF rt 1 65 
   6 DCE rt 1 74 
   7 9:1 DCE-HFIP rt 1 76a 
   8 Water rt 1 60b 
   9 Water rt 2 59b 
  10 Water rt 1.2 82c 
  11* DCE rt 2 55d 
  12 DCE rt 1.2 84c 
Unless otherwise stated 1 eq. 96, 0.5 eq. 97, 1 eq. 74, 48 h, rt a: 6 h; b: 1 eq. 96; c: 0.6 eq. 96; d: 1.2 eq. 
96; *4 Å MS; ♦No product observed by TLC or 500MHz 1H NMR spectroscopy 
It was found that even moderate heating led to significantly reduced isolated 
yields of the amino alcohol 98 (entries 1-3, Table 1). For the reaction at 40 °C, 
only a trace amount of product was observed in the crude reaction mixture by 
500MHz 1H NMR spectroscopy (entry 2). In addition no product was observed 
when the reaction was carried out at 80 °C (entry 3).  
Next, a range of solvents was investigated: for example, polar and non-
polar, protic and aprotic solvents (entries 1 and 4-6). Of these entries, most 
provided amino alcohol 98 in 60-65% yield. The maximum yield was obtained 
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in dichloroethane (74%, entry 6). It should be noted that the use of 
hexafluoroisopropanol (HFIP) as a co-solvent (entry 7) has been reported to 
significantly improve the yield of the Petasis reaction when using primary 
amines.67,69,83 Although having little effect on the yield when using amine 96 
this solvent did significantly improve the rate of reaction, as a comparable yield 
was obtained in only six hours (entry 6).  
Improved yields were obtained in when using 97 and 74 in slight excess 
(entries 10 and 12, greater than 80% yield). Having identified optimal reaction 
conditions, substrate scope was next explored. 
2.3 Scope and limitations of the Petasis reaction. 
2.3.1 Synthesis of starting materials 
In order to investigate the functional group tolerance and scope of the Petasis 
reaction in the generation of cyclisation precursors a selection of amines, boronic 
nucleophiles and aldehydes was required (Figure 20). The boronic nucleophiles, 
glycolaldehyde (97) and all amines except for 105 and 107 were commercially 
available. The amine 107 was obtained from ethylene diamine (111) by treatment 
with di-tert-butyldicarbamate.84 Reductive amination of 107 with benzaldehyde 
afforded the secondary amine 105 in modest yield (Figure 20).85 
 
Figure 20: Boron nucleophiles, aldehydes and amines selected to investigate the functional group 
tolerance and reactivity in the Petasis reaction. Synthesis of amines 105 and 107. 
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2.3.2 Synthesis of cyclisation precursors 
With the relevant starting materials in hand, the next step was to synthesise the 
cyclisation precursors outlined in Table 2. In general, the reactions were successful; 
a broad range of amines and boron nucleophiles were successfully reacted with 
glycolaldehyde to give the corresponding amino alcohols (112-126). A series of 
secondary amines reacted efficiently under the reaction conditions providing amino 
alcohols 112-116 in yields ranging from 53-86%. Notably, with the exception of the 
diamine 111, which required carbamate protection of the additional amine group, 
protecting groups were avoided. 
Table 2: Scope of the Petasis reaction. 
 
Unless otherwise stated: 1.2 eq. 97, 1 eq. amine, A: 1.2 eq. 74, H2O, 48 h, rt  B: 1.2 eq. 74, DCE, 48 
h, rt; C: 1.2 eq. 74, DCE:HFIP (90:10), 6 h, rt; D: 1.2 eq. 74, KOH, H2O, 48 h, rt; E: 1.2 eq. 99, 
H2O:THF (83:17), 48 h, rt then Ac2O, Pyridine, 18 h, rt; F: 1.2 eq. 74, H2O:THF (83:17), 48 h, rt; 
#reaction did not proceed as judged by TLC and 500 MHz 1H NMR Spectroscopy. 
Yields with primary amines were significantly lower than those obtained with 
secondary amines with similar appendages (117-120). For example, N-
methylallylamine provided the amino alcohol 98 in 84% yield, while butenylamine 
provided the amino alcohol 120 in 46% yield. Furthermore amino alcohol 114 was 
obtained in significantly greater yield than the amino alcohol obtained using N-
ethanolamine (119, 53% versus 39%). 
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Polar functional groups were also found to give reduced yields, N-
benzylethanolamine provided amino alcohol 113 in 63% yield, while bis(2-
hydroxyethyl)amine (104) gave amino alcohol 114 in a 53% yield. 
Vinyl boronic ester was unreactive under the conditions found to be effective 
for generation of the amino alcohol 121. Additional boronate esters (100-101, Figure 
20) were used but no conversion was observed with 500 MHz 1H NMR 
spectroscopy or TLC. After extensive solvent screening, it was found that a THF-
water solvent mixture was required to obtain sufficient reactivity (mass observed by 
LC-MS reaction monitoring and new alkene signals observed by 500 MHz 1H NMR 
spectroscopy); however it was not possible to isolate 121. Finally, after the Petasis 
reaction was complete, the reaction mixture was concentrated in vacuo then re-
dissolved in pyridine, and acetic anhydride was added to the reaction mixture and 
stirred for 18 hours. This allowed, after purification, isolation of 122 in a 13% yield. 
Together, these results demonstrate the difficulties of using the vinylboronic ester 
and highlighted potential problems with isolation of these extremely polar amino 
alcohols. 
The scope of additional amines was investigated (123-126) with the conditions 
developed for 100. Secondary amines continued to provide greater yields of the 
corresponding amino alcohols compared with primary amines (124 was obtained in 
a 71% yield while the amino alcohol 125 was obtained in a 39% yield). Amino 
alcohols which were more lipophilic were isolated in greater yields (125 isolated in 
39% yield but 126 was not isolated) as with trans-2-phenylvinylboronic acid 
products (118 obtained in 71% while 119 was obtained in a 51% yield). 
The yields obtained for the vinylboronic acid pinacol ester system continues to 
be lower than the corresponding trans-2-phenylvinylboronic acid system. This 
discrepancy in yields could be a result of reduced reactivity or poorer product 
isolation from the Petasis reaction as observed with reaction of N-methylallyl amine. 
This is particularly unsatisfactory since the products obtained from using the 
unsubstituted vinyl boron nucleophile are more attractive in library design; the 
phenyl group increases the LogP of the molecule by approximately two units86 and 
many potential cyclisation reactions identified are unproven on 1,2-disubstitued 
alkenes. 87,88 
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A literature search revealed there is only one previous example of using an 
unsubstituted vinyl boronic acid ester in the Petasis reaction. Wong et al. used vinyl 
boronic acid dibutyl ester (128) as a reagent in a key step towards sialic acid 
derivatives (Scheme 10).89 The ester was found to be unreactive in organic solvents 
but with a combination of ethanol and water, they obtained viable yields. They 
proposed that the ester is unreactive towards the Petasis reaction, but in the presence 
of water, the ester is hydrolysed to the more reactive vinyl boronic acid which then 
participates in the Petasis reaction to give 129.  
 
Scheme 10: Model proposed by Wong and co-workers to explain the reactivity of vinylboronic esters. 
The ester is first hydrolysed acid which is sufficiently reactive to participate in the Petasis reaction. 
Condition: EtOH-H2O (80:20), 50 ˚C, 72 h, 55%. R = bis(4-methoxyphenyl)methyl 
2.3.3 Factors influencing a diastereoselective Petasis reaction 
With a working protocol for the Petasis reaction, priority was concentrated on 
controlling the stereochemical outcome of the reaction. As described in Section 2.1, 
the two approaches involve the use of a chiral reagent or organocatalysts. Given 
limited precedent in using organocatalysts, a selection of enantiomerically enriched 
amines and aldehydes were chosen (Figure 21).  
 
Figure 21: Boron nucleophiles, aldehydes and amines selected to investigate the requirements of a 
stereoselective Petasis reaction. 
The boronic nucleophiles, glycolaldehyde (97) and all amines were 
commercially available. The masked α-hydroxyaldehyde 130 was obtained from 
acetonide formation of commercially available α-hydroxyacid 137. Subsequent 
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reduction of the lactone (138) with diisobutyl aluminium hydride afforded lactol 130 
(Scheme 11). With the relevant starting materials in hand, the diastereoselectivity of 
the Petasis reaction was explored. 
 
Scheme 11: Synthesis of lactol 130 from 137. 
2.3.3.1 Use of chiral amines  
With the relevant starting materials in hand, the next step was to determine their 
selectivity in the synthesis of the cyclisation precursors summarised in Table 3. In 
general, amino alcohols afforded reasonable diastereoselectivity (greater than 
≥75:25) and the best selectivities were observed with phenyl vinyl boronic acid as 
the boron nucleophile. 
Table 3: Investigation of factors required for the diastereoselective Petasis reaction. 
 
 
Unless otherwise stated: 0.6 eq. 97, 1 eq. amine, 48 h, rt; a) 1.2 eq. 74, DCE; b) 1.2 eq. 74, H2O; c) 
1.2 eq. 99, DCE:HFIP (90:10); d) H2O:THF (83:17); 
Both (R)- and (S)-methylbenzylamine (131 and 132) failed to give any 
stereochemical control and a 50:50 diastereomeric ratio of products was obtained in 
each case (139 and 140). Both Petasis and Southwood have reported moderate levels 
of control (83:17 and 76:24 respectively) when (S)-Methylbenzylamine was used as  
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in auxiliary in the synthesis of amino acid 76. 75,74  
Choice of solvent was found to be crucially important in obtaining suitable 
selectivity. (2S)-2-Amino-1-propanol (133) was entirely unselective, giving a 55:45 
mixture of diastereoisomers, when dichloroethane was the reaction solvent. 
However, switching the reaction solvent to water, a 75:25 ratio of diastereomeric 
products was obtained (as evidenced by 500 MHz 1H NMR spectroscopy).  
Given the proposed transition state, Figure 22, it is clear the steric clash 
between the methyl group and the styrenyl group of the boronic acid was 
insufficient to fully differentiate between the two possible diastereoisomers. The 
amino alcohol 145 (obtained from the Petasis reaction with (R)-2-amino-2-
phenylethanol) resulted in an improved d.r. (75:25) with dichloroethane as the 
reaction solvent. As seen with (2S)-2-amino-1-propanol (133), greater selectivity 
was obtained (90:10) when water was used as the reaction solvent. The significant 
difference in selectivity is surprising, given that the stereocentre is remote from the 
stereogenic centre the expected transition state for the two amino alcohols was 
expected to be similar. 
 
Figure 22: Proposed transition state for the synthesis of 141 and 142. 
Cyclic amines were found to be as efficient as acyclic secondary amines at 
controlling the stereochemistry of the reaction. The greatest diastereoselectivity was 
obtained with amino alcohols 143 and 144 obtained from L-proline and L-prolinol 
(d.r. ≥95:≤5 and 90:10 respectively). 
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To investigate the differences in selectivity between the boronic nucleophiles, 
the two of the best performing amines, (2R)-2-amino-1-phenylethanol and L-prolinol 
were selected. In the case of (2R)-2-amino-1-phenylethanol, amino alcohol 144 was 
formed in reduced yield and selectivity (44% and d.r. 83:17). The selectivity with L-
prolinol was completely lost, giving an equal mixture of diastereoisomers in a 
modest (43%) yield. The reduced diastereoselectivity observed cf. trans-2-
phenylvinyl boronic acid is likely due to the decreased steric clash between the 
smaller vinyl group with the prolinol ring.  
2.3.3.2 Use of chiral aldehyde  
As mentioned previously (Section 2.1), chiral aldehydes have been used to good 
effect to control the outcome of the Petasis reaction. N-Methylallyl amine (96) and 
ethanol amine (109) were selected to investigate the stereocontrol exhibited by the 
protected aldehyde 130. 
 
Figure 23: Secondary and primary amines 96 and 103 were chosen to investigate the stereochemical 
outcome of the Petasis reaction with aldehyde 130. 
With N-methylallyl amine, a single diastereoisomer was obtained, which is 
consistent with the reported literature (Figure 24).58,69 The selectivity observed is 
due to the aldehyde α-hydroxyl group being directly involved in the rate determining 
step. The proposed transition states for the two imines are shown in ( 
Figure 24). The reduced 1,3-allylic strain in TS2 ensures the anti diastereoisomer is 
the only product. 
 
Figure 24: Diastereoselective transition state. The unfavourable 1,3-allylic strain is minimised in B 
yielding the anti diastereoisomer. Conditions: DCE-HFIP (90:10), rt, 30 h. 
The reaction between that of 74, ethanolamine (109) and 130 was unsuccessful. 
The amine (109) had previously given low yields when used with glycolaldehyde 
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and trans-phenylvinylboronic acid and had failed entirely when vinylboronic acid 
ester (99) was used. The reaction with ethanolamine, glyoxylic acid and trans-2-
phenylvinylboronic acid (74) had also been previously attempted but as in this case, 
no reaction was observed when monitoring the reaction by TLC or LC-MS. 
 
2.4 Design of cyclisation precursors from Petasis reaction 
With a robust, stereoselective Petasis reaction protocol developed, the focus 
progressed to generating cyclisation precursors which would allow the synthesis of 
lead-like scaffolds. In total, six amines were chosen for the generation of cyclisation 
precursors (Figure 25).  
 
Figure 25: Amines selected to investigate the potential for the Petasis reaction to deliver scaffolds 
suitable for interrogating lead-like chemical space.  
The amines were chosen based on a compromise between the observed 
reactivity in the scope and limitations of the Petasis reaction and a strong 
requirement to maintain the physiochemical properties. Thus primary amines 148, 
151 and 135 were chosen due to the success of related substrates and the potential to 
greatly increase the scaffold count by introducing a variety of different alkylating 
reagents. It had been found that secondary amines reacted more efficiently, thus 149, 
150 and 152 were chosen.  
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2.4.1 Synthesis of starting materials 
Amine 149 was readily accessed via reductive amination of 
ortho-bromobenzaldehyde with N-nosyl-ethylenediamine (148) in modest yields 
(Scheme 12).90 Diamine 153 was commercially available and protected as the 
carbamate 150 (Scheme 12). Finally ethanolamine (109) was coupled with 4-bromo-
1-butene in the presence of sodium iodide to give amino alcohol 152.91 
 
 
Scheme 12: Synthesis of amines 149, 150 and 152. 
2.4.2 Synthesis of cyclisation precursors 
With the relevant starting materials in hand, they were next reacted under 
conditions previously optimised (Section 2.2). Disappointingly amine (148) was 
unsuccessful in the optimised conditions. In each attempt, starting materials was 
recovered. Given the reduced reactivity for primary amines, coupled with the 
reduced reactivity of vinyl boronic ester (cf. trans-phenylvinylboronic acid), this 
substrate was expected to be difficult and subsequently deprioritised in favour of the 
remain amines. 
Surprisingly amine 149 failed to give the tertiary amino alcohol 155. This was 
particularly surprising given the success of the model system. The crude 500 MHz 
1H NMR spectrum did show diagnostic signals at 5.6 and 5.1ppm which correspond 
with equivalent signals observed with other cyclisation precursors; however the 
major component was unreacted amine and vinylboronic acid MIDA ester. Given 
the limited utility of the precursor, it was decided to prioritise another cyclisation 
precursor. 
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Table 4: Attempted synthesis of cyclisation precursors from Petasis reaction. 
 
 
Unless otherwise stated: 0.6 eq. 97, 1.2 eq. boron nucleophile, 1 eq. amine, 48 h, rt A: H2OTHF 
(84:16),  B: DCE:HFIP (90:10), 6 h, rt; C: H2OTHF (83:17), 48 h, Et3N (1.5 eq.) rt; #reaction did 
not proceed as judged by TLC or 500 MHz 1H NMR  spectroscopy. B: 40 C  
Amino alcohol (150) gave the expected cyclisation precursors (156) in a 32% 
yield. Allyl amine (151) and butenylethanolamine (152) gave the corresponding 
amino alcohols (157 and 158) in yields exceeding 60%. The use of trans-
phenylvinylboronic acid greatly increased the yield and viability of the reaction. 
2.5 Utilising cyclisation precursors in subsequent cyclisation reactions 
With the chosen cyclisation precursors in hand we next looked at cyclisation 
reactions. This Section outlines the attempts with three cyclisation reactions; iodine 
mediated etherification87,92, carbodiimidazole coupling93–95 and ring closing 
metathesis.96–98 
2.5.1 Iodine-mediated cyclisation 
Iodoetherification has been shown to be an efficient method for the synthesis of 
morpholine rings.87,92 Cyclisation precursors 113, 124 and 146 wa0s selected to 
determine if this was a suitable reaction. Accordingly molecular iodine was added to 
a solution of amino alcohol 113 and heated to 65 ˚C (Table 5, entry 1). However, 
only starting materials was observed. The solvent was changed and amino alcohol 
re-subjected to the reaction conditions however after 18 hours only starting material 
was observed by LC-MS and TLC (entry 2). Heating the reaction at reflux for an 
additional day still led to recovered starting material (entry 2).  
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Table 5: Studies towards iodine mediated cyclisation 
 
Entry Substrate Conditions Outcome 
1 
 
I2, 65 °C, MeCN NR# 
2 
I2, rt, THF, 18 hr 
then 65 °C, 18 hr 
NR# 
3 
 
I2, rt, THF 
then 65 °C, 18 hr 
NR# 
4 
 
I2, 65 °C, MeCN NR# 
5 NIS, Et3N, MeCN, 65 °C, 18 hr. NR# 
6 NIS, TFA, MeCN, 65 °C, 18 hr. NR# 
#reaction did not proceed as judged by LC-MS (M+H for SM observed) or 500 MHz 1H NMR  
spectroscopy (only evidence of starting material). 
Given the precedent for the reaction used a monosubstituted alkene, amino 
alcohols 124 and 146 were selected (entries 3 and 4). However as with 113, only 
starting material was observed. A different iodine source (entry 5) and reaction 
conditions were attempted, including stirring the amino alcohol 146 in TFA (an 
attempt to form the salt and quench the basic nitrogen), but suitable conditions were 
not obtained. 
In addition to the precedent using only monosubstituted alkenes, basic amines 
were not used as substrates. Given the problems encountered with tertiary amine 
substrates, it was decided to use amino alcohol 145 and make the tosyl protected 
derivative (Scheme 13). However a complex mixture was obtained (as evidenced by 
TLC) and the expected mass was not observed by LC-MS. Given it was a 
significantly hindered secondary amine; it was possible either alcohols were 
tosylated and thus making them prone to elimination. Alternative protecting group 
such as tert-butyl carbamate returned unreacted starting materials, even after the 
addition of many equivalents, prolonged reaction times and heating. 
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Scheme 13: PG manipulation of cyclisation precursor 145. Conditions: R = Ts; Et3N, 4-TsCl, DCM, 
16 h. PG = Boc; Et3N, di-tert-butyl dicarbonate (1.5 eq. – 5 eq.), DCM, rt to 40 ˚C, 16-48 h. 
2.5.2 Ring closing metathesis 
A ring closing metathesis (RCM), to give the tetrahydropyridine core, was 
attempted on amino alcohol 156 (Scheme 14). However only starting materials was 
recovered. Substrates containing a high density of heteroatoms have previously been 
shown to form chelates with the Ru catalyst with the Lewis-basic sites.99 To 
circumvent this problem, the hydroxyl groups could have been protected however 
the steps required to attached, perform the RCM and subsequent removal would 
significantly reduce the synthetic utility of the process. This was especially true 
given that only a single scaffold could have been made. 
 
Scheme 14: Attempted ring closing metathesis with amino alcohol 161. 
2.5.3 Carbodiimidazole coupling 
Given the significant problems encountered with tertiary amine substrates for 
subsequent cyclisations, it was found that coupling of the secondary amine and 
primary alcohol group with carbodiimidazole furnished 162 in 49% yield (Scheme 
15). This substrate was subjected to ring closing metathesis conditions attempted 
with 156 and gratifyingly fused bicyclic 163 was obtained (Scheme 15).  
 
Scheme 15: Synthesis of bicyclic urea 163 from amino alcohol 157. 
Although the product only has one site for decoration, the success does suggest 
that the difficulties encountered with the use of the Petasis reaction was the presence 
of the basic nitrogen. Given the requirement of the amine for the Petasis reaction to 
proceed, and given the fact secondary amines reacted more efficiently, this is a 
limitation that was not possible to overcome.    
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2.6 Conclusions and summary 
This chapter has detailed the significant challenges which were encountered 
when attempting to use the Petasis reaction for LOS. It was found that each building 
block required an optimised set of reaction conditions which meant it is less suitable 
for library design. The development of a diastereoselective protocol was detailed 
and it was found that the hydroxyl group of the amine and a large -substituent was 
essential for good diastereo-stereocontrol. Ultimately however, the cyclisation 
precursors generated were unsuitable for further elaboration to give a diverse lead-
like chemical library.  
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3 Development of methodology to determine the suitability of a 
reaction to support lead-oriented synthesis 
This Chapter describes the use of a computation protocol to direct the selection 
of a new connective reaction to support lead-oriented synthesis. The computational 
approach was developed within the group by Dr Richard Doveston and has been 
used to direct the synthesis of over 50 lead-like molecular scaffolds.65 An overview 
of the approach, including a description of the computational tool is given in Section 
3.1. A detailed description of the process used to robustly compare different 
connective reactions is given in Section 3.2 and the process used to select a new 
connective reaction is described (Section 3.3).  
3.1 Protocol to assess the lead-likeness of molecular scaffolds. 
Previously within the group, Pipeline Pilot (Accelrys®) and Vortex (Dotmatics) 
software has been used to produce a robust tool for directing synthetic programmes 
towards the synthesis of novel lead-like scaffolds.65 An overview of the functionality 
of the protocol is given in Figure 26. The protocols were designed to perform:  
1. Enumeration of virtual compound libraries. 
2. Novelty assessment of molecular scaffolds. 
3. Lead-likeness assessment of physical properties of final compounds. 
3.1.1 Enumeration of virtual compound libraries. 
A virtual library of compounds was created by means of a three-step process. A 
connective reaction of interest, such as iridium-catalysed allylic amination100–106 was 
identified; the reactants specified and all possible product outcomes enumerated 
(step 1, Figure 26). The cyclisation precursors were then subjected up to two virtual 
cyclisation reactions (for a complete list of the cyclisation reactions used within the 
enumeration see Appendix 1 Figure 47) to generate a set of scaffolds (step 2, Figure 
26). The number of scaffolds derived from a single cyclisation precursor was 
calculated and referred to as scaffold frequency.   
 44 
 
These scaffolds were subsequently decorated virtually (at up to two sites) with a 
standard set of capping groups (for a complete list of capping groups see Appendix 2 
Figure 50) to create the virtual library of final compounds (step 3, Figure 26). 
      
Figure 26: The computational protocol developed within the group. Step 1: Cyclisation precursors are 
generated from combinations of available building blocks. Step 2: Up to two cyclisation events 
generate a set of scaffolds which are then assessed for novelty. Step 3: Scaffolds were then decorated 
virtually using a standard set of capping groups to give final compounds which are assessed for lead-
likeness. 
3.1.2 Novelty assessment of molecular scaffolds. 
Novelty was assessed at the scaffold level by way of a substructure count 
against a reference database (Figure 27). Murcko fragments107 without α-
attachments are generated for each scaffold and these are compared with Murcko 
fragments without α-attachments  generated from a random 2% of compounds 
(~150,000 compounds) from the ZINC database of commercially available 
compounds.108 A penalty is incurred for the scaffold each time a match within the 
ZINC database is found. 
In addition, Murcko fragments with α-attachments are generated and these are 
also compared with the same randomly selected compounds from the ZINC 
database. With these two scores, it is possible to investigate both skeletal novelty (is 
the specific known without substituents) and appendage novelty (is the scaffold 
substitution pattern of the scaffold known). 
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Figure 27: Novelty assessment. Two fragments are generated for each scaffold and compared with 
the ZINC database. The approach is illustrated for two exemplar scaffolds 
3.1.3 Lead-likeness assessment of physical properties of final 
compounds. 
Churcher et al. defined lead-like chemical space in their seminal paper.7 The 
properties (Section 1.2.3) include molecular size, lipophilicity, the potential for 
biological interaction and the presence of any un-desirable functional groups.7 A 
lead-likeness penalty scoring system has been devised; a penalty is incurred for each 
physical property which lies outwith lead-like chemical space (Figure 28). The 
further from those idealised values, the greater the penalty incurred. 
The lead-likeness penalty was assessed for each final compound generated and 
these scores were combined to give a mean lead-likeness penalty score for each 
scaffold. As demonstrated in Figure 28 169 has just one additional heavy atom 
compared with idealised values so incurs a small penalty for molecular weight but 
all remaining properperties are within limits so it has an overall leadlikeness penalty 
of 1.  
In contrasnt 170 has a higher molecular weight (32 heavy atoms) and a higher 
log P (3.8) so it incurs significant penalty in these areas and has a leadlikeness 
penalty score of 5. This would not be prioritised for synthesis. The scoring system 
implemented is outlined in Table 6, was based upon the optimal values previously 
defined and subsequent discussion with the authors.7 
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Figure 28: Lead-likeness assessment. The scoring system implemented is outlined in for the heavy 
atom count. For the full scoring penalty system see Appendix 1-4. 
 
Table 6: The full scoring system used in generating a lead-likeness penalty 
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3.2 Evaluation of Potential Reaction 
Before the Pipeline Pilot protocol could be utilised, the expected functional 
group tolerance, yields, diastereo- and enantioselectivity were thoroughly evaluated. 
With this information in hand, a selection of simple building blocks was then 
selected on the basis of the precedent for the potential connective reaction 
investigated and a virtual library was enumerated. 
The lead-likeness penalty data was then examined for each reaction. For each 
scaffold, the number of compounds that can be derived and their average 
leadlikeness penalties are shown. In total, five potential reactions were evaluated for 
their applicability towards LOS 
1) Lactam Synthesis (Section 3.2.1) 
2) C-H Insertion (Section 3.2.2) 
3) SOMO-Activation  (Section 3.2.3) 
4) Nucleophilic opening of cyclic sulfamidates (Section 0) 
5) nitro-Mannich reaction (Section 3.2.5) 
3.2.1 Evaluation of Lactam Synthesis to support LOS 
A possible route towards cyclisation precursors considered was β-lactam 
synthesis (Kinugasa109–111 or Staudinger reaction112–115) followed by subsequent 
lactam opening with various reagents (Panel A, Figure 29). A virtual library was 
created using the protocol outlined above. For computational simplicity, 8 ketenes 
and 5 imines were used in the enumeration but these represent building blocks for 
both connective reactions (Panel B, Figure 29). In total 120 cyclisation precursors 
(lactam opening using 3 different reagents) and over 97,000 virtual final compounds 
were generated (Panel C, Figure 29). 
Analysis of the enumerated library revealed that the majority of the scaffolds 
generated had a mean scaffold lead-likeness penalty greater than three (only 14% of 
final compounds generated had a lead-likeness penalty <3.2). Furthermore only 233 
scaffolds were generated from the cyclisation precursors demonstrating poor 
synthetic economy. 
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Figure 29: Panel A: Two representative examples of -lactam synthesis. Panel B: The library of 5 
imines, 8 ketenes and 3 ring opening reagents used in the virtual library enumeration. Panel C: 
Output for virtual library created, plot of scaffold frequency (total number of compounds generated 
from a single scaffold) vs the lead-likeness penalty. Highlighted area represents the most valuable 
area. Panel D: Representative scaffolds generated via library enumeration. 
3.2.2 Evaluation of C-H Insertion to support LOS 
Carbenoid insertion into C-H bonds α to heteroatoms has been studied 
extensively.116–124 As such they could provide cyclisation precursors with a desirable 
motif; namely four variable functional groups which could be reliably programmed 
(Panel A, Figure 30). A virtual library of 6 diazo compounds and 15 amine and 
alcohol coupling partners (Panel B, Figure 30) used to give 90 cyclisation precursors 
and over 472,000 virtual final compounds were generated (Panel C, Figure 30). 
Subsequent analysis of the enumerated library revealed that the mean lead-
likeness penalty was 3.66 (50% of all final compounds generated within the library 
had a lead-likeness penalty <3.2). Low novelty scores were obtained when scaffolds 
were compared with ZINC database (high degree of skeletal novelty) which 
established this as a promising connective reaction.  
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Figure 30: Panel A: Two representative of CH insertion into bonds α to heteroatoms. Panel B: The 
library of 6 diazo compounds and 15 amine and alcohol reagents used in the virtual library 
enumeration. Panel C: Output for virtual library created, plot of scaffold frequency (total number of 
compounds generated from a single scaffold) vs the lead-likeness penalty. Highlighted area represents 
the most valuable area.  Panel D: Representative scaffolds generated via library enumeration. 
3.2.3 Evaluation of SOMO-Activation to support LOS 
SOMO-Activation, popularised by MacMillan125–129, is a further potential 
connective reaction. High levels of enantioselectivity had been demonstrated and a 
high number of suitable starting materials could readily be obtained (Panel A, Figure 
31).125–129 A virtual library of 6 SOMO donors and 11 SOMO acceptors (Panel B, 
Figure 31) was used to create 55 cyclisation precursors with over 748,000 virtual 
final compounds were generated (Panel C, Figure 31).  
Following analysis of the enumerated library revealed a reasonable portion of 
scaffolds generated had a mean scaffold lead-likeness penalty less than three (50%  
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Figure 31: Panel A: Two representative examples of the SOMO activation. Panel B: The library of 11 
SOMO acceptors and 6 SOMO donors used in the virtual library enumeration. Panel C: Output for 
virtual library created, plot of scaffold frequency (total number of compounds generated from a single 
scaffold) vs the lead-likeness penalty. Highlighted area represents the most valuable area. Panel D: 
Representative scaffolds generated via library enumeration. 
of final compounds generated within the library had a lead-likeness penalty <3.2). 
However high novelty scores were observed across the majority of the library (Panel 
C, Figure 31) indicating low appendage novelty and skeletal novelty. In addition 
there were concerns over adequate diastereoselective control of the reaction.125–129 
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3.2.4 Evaluation of nucleophilic opening of cyclic sulfamidates to 
support LOS 
Cyclic sulfamidates are versatile electrophilic reagents.130–136 They have been 
shown to undergo a facile, regiospecific nucleophilic substitution at the O-bearing 
centre (Panel A, Figure 32), yielding a valuable cyclisation precursor with the 
potential to vary each functional group.130–136 A virtual library of 6 cyclic 
sulfamidates and 4 nucleophiles (Panel B, Figure 32), gave 36 cyclisation precursors 
which resulted in over 459,000 virtual final were compounds (Panel C, Figure 32). 
 
Figure 32: Panel A: Two representative examples of nucleophilic opening of cyclic sulfamidates. 
Panel B: The library of 6 cyclic sulfamidates and 4 nucleophile used in the virtual library 
enumeration. Panel C: Output for virtual library created, plot of scaffold frequency (total number of 
compounds generated from a single scaffold) vs the lead-likeness penalty. Highlighted area represents 
the most valuable area. Panel D: Representative scaffolds generated via library enumeration. 
Resulting analysis of the virtual library contained very novel scaffolds as there 
are no substructure hits against the ZINC database. The scaffolds generated have a 
mean lead-likeness penalty >3, which may be attributed to the high number of 
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diversification sites (39% of all final compounds have a lead-likeness <3.2). 
However, there is poor stereocontrol when nucleophiles such as enolates are used 
(synthetically more attractive nucleophiles since a lactam would not be present in 
every compound), which make this connective reaction less suitable for LOS. 
3.2.5 Evaluation of nitro-Mannich reaction to support LOS 
The addition of a nitro reagent to imines is a reaction which gives access to 1,2 
diamines upon reduction of the nitro functional group.137 This powerful 
transformation has been studied extensively and with judicious choice of catalyst 
potentially all four stereoisomers of cyclisation precursors could be generated (Panel 
A, Figure 33).138–146 A virtual library, 10 imines and 7 nitro-components (Panel B, 
Figure 33) was used to give 70 cyclisation precursors with over 450,000 virtual final 
were compounds generated (Panel C, Figure 33). 
 
Figure 33: Panel A: Two representative examples of the nitro-Mannich reaction. Panel B: The library 
of 8 imines and 7 nitro compounds used in the virtual library enumeration. Panel C: Output for virtual 
library created, plot of scaffold frequency (total number of compounds generated from a single 
scaffold) vs the lead-likeness penalty. Highlighted area represents the most valuable area. Panel D: 
Representative scaffolds generated via the virtual library enumeration. 
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Ensuing analysis of the virtual library revealed a large number of scaffolds with 
a mean scaffold lead-likeness penalty less than three (49% of final compounds 
generated within the library had a lead-likeness penalty <3.2). In addition a 
substantial number of the scaffolds generated were extremely novel and a significant 
number of scaffolds could generate over 100 virtual final compounds which 
demonstrate the high diversity potential of the scaffolds. 
3.2.6 Further interrogation of the virtual libraries generated 
In addition to looking at the entire virtual library generated for each potential 
connective reaction, the libraries were further interrogated in order to identify the 
most promising cyclisation precursors. The data could be manipulated to give a plot 
of the final compound frequency vs. scaffold mean lead-likeness penalty for each 
individual cyclisation precursor. Representative cyclisation precursors generated 
from the nitro-Mannich reaction library are shown in Figure 34. 
Each cyclisation precursor gives rise to over 20 highly novel scaffolds. In 
addition many scaffolds have suitable residual functional groups which could be 
exploited to create a plethora final compounds. However cyclisation precursors such 
as 206 are unsuitable for LOS as the majority of the scaffolds generated give a mean 
lead-likeness penalty >3, indicating poor physiochemical properties. 
 
Figure 34: Output for two representative cyclisation precursors created from the nitro-Mannich 
reaction, plot of scaffold frequency (total number of compounds generated from a single scaffold) vs 
the lead-likeness penalty. Highlighted area represents the most valuable area. 
In contrast, cyclisation precursor 207 would be prioritised since 32 scaffolds 
with over 30 virtual final compounds could potentially be synthesised. In addition 
 54 
 
there are a further scaffolds with a favourable lead-likeness penalty but generate less 
than 30 virtual final compounds.  
With the cyclisation precursors identified, a series of key reactions was then 
conceived to quickly determine the reactions suitability. If these preliminary 
reactions proved successful, the reaction could then be selected. For example, 
efficient access to required starting materials (if not commercially available) and 
suitable catalyst preparation had to be identified. Functional group interconversion 
conditions had to be identified and quickly realised (conversion of CN to amine, 
acid and aldehyde for cyclic sulfamidates or the reduction of the nitro functional 
group in nitro-Mannich library).  
3.3 Reaction selection: nitro-Mannich reaction 
The most valuable connective reactions can be identified by considering the 
novelty score, lead-likeness penalty, and synthetic economy involved (i.e. number of 
valuable scaffolds from a single cyclisation precursor) for a given reaction. Of the 
five reaction types, the nitro-Mannich reaction was selected due to the high number 
of potential cyclisation precursors generating scaffolds with favourable 
physicochemical properties (approximately one third of all scaffolds generated has a 
mean lead-likeness penalty <3.2).  In addition, with the extensive use of various 
organocatalysts, potentially every stereoisomer of cyclisation precursors (and 
therefore scaffolds) could be synthesised. 
The key reactions for demonstrating the potential of this reaction for LOS was 
the reduction of the nitro group. This was essential to realise the synthetic potential 
for the cyclisation precursors as well as removing an un-desirable functional group. 
In addition the reaction had to be diastereoselective therefore preparation of a 
suitable catalyst was required.  
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4  Investigation into suitability of the nitro-Mannich reaction to 
support lead-oriented synthesis 
This Chapter describes the use of the nitro-Mannich reaction as a connective 
reaction to support lead-oriented synthesis. A literature review is first given before a 
detailed description of the development of the nitro-Mannich reaction towards the 
support of lead-oriented synthesis and the exemplification of this strategy.  
4.1 nitro-Mannich reaction: general characteristics 
The formation of C-C bonds is a fundamental process in organic chemistry.137 
The nitro-Mannich (or aza-Henry) reaction is an underutilised reaction which may 
have value in the synthesis of scaffolds due to the large variety of commercially 
available starting materials and mild reaction conditions.137 Chapter 3 demonstrated 
that these scaffolds were lead-like (Section 3.2.5). 
The mechanism of the nitro-Mannich  reaction (Scheme 16)147 is essentially the 
addition of a nitronate species to an imine electrophile creating the new C-C bond 
which upon protonation gives the product -nitroamine (Scheme 16). The 
eponymous nitro group allows access to a wide range of synthetic targets through 
simple functional group interconversion to amine,148 acid,149 ketone,150 and nitrile.150 
 
Scheme 16: Proposed mechanism for the nitro-Mannich reaction. The rate determining step is the 
irreversible C-C bond formation.  
Early reports on the nitro-Mannich reaction were of limited synthetic use, being 
unselective137 and often low yielding138,139. The first stereoselective protocol with 
acyclic starting materials was reported in 1998140. There now exist a large number of 
both enantio141,142- and diastereoselective143,144 methods using a wide range of 
organometallic145 and organo- catalysts146. 
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Anderson described a diastereoselective method for the preparation of nitro 
amino alcohols (208-210, Scheme 17).151 The scope of the nitro component was not 
investigated and thus limited to nitropropane (207). More importantly however, 
electron rich imines could be used which is complementary to the electron deficient 
imines described below. 
 
Scheme 17: Application of nitro-Mannich reaction for diastereoselective synthesis of nitroamines 
208-210. Panel A: An overview of the reaction described by Anderson.151 Panel B: Specific examples 
of diastereoselective products obtained using this method (208-210). 
Shibasaki described a selective method using an organometallic catalyst (211-
214, Scheme 18) which yielded products with good enantio- and 
diastereoselectivity.152 The catalyst exploits the dual activation of Brønsted basic and 
Lewis acidic sites, allowing excellent control in the synthesis of aryl substituted 
amines. The scope of the nitro component was limited to alkyl R2 groups. 
 
Scheme 18: Application of nitro-Mannich reaction for enantio-enriched synthesis of nitroamines 211-
214 using an organometallic aluminium complex.152 Panel A: An overview of the reaction discovered 
by Shibasaki. Panel B: Specific examples of enantio- and diastereoselective products obtained using 
this method. 
Palomo has released, independently from Herrera153,154, an organocatalytic 
protocol using phase transfer catalysis (215-219, Scheme 19).155–157 Using a simple 
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commercially available cinchona-derived catalyst 220 good enantioselectivity was 
observed, with modest mixtures of diastereoisomers obtained in most cases. 
Significantly, in contrast to previously highlighted reports, a variety of 
functionalised nitro compounds were utilised giving nitro adducts with suitable 
functional groups and high cyclisation potential in practical diastereoselectivity (215 
to 219). 
 
Scheme 19: Application of nitro-Mannich reaction for enantio-enriched synthesis of nitroamines 215-
219 using a cinchona-derived catalyst. Panel A: An overview of the reaction discovered by 
Palomo.155–157 Panel B: Specific examples of enantio- and diastereoselective products obtained using 
this method.155–157  
4.2 Selection of a diastereoselective protocol for the nitro-Mannich 
reaction 
Two cyclisation precursors were selected from the nitro-Mannich reaction 
library to investigate the diastereoselectivity of the reaction. A thorough 
investigation of the functional group tolerance of the reaction was not undertaken as 
the nitro-Mannich reaction is well-documented (Figure 35).137 In addition to the 
cyclisation precursors, the cinchona-derived catalyst 222 was also chosen based on 
literature precedent (Figure 35).143  
 
Figure 35: Two cyclisation precursors (220) and (221) identified from the computational protocol as 
having potential to explore lead-like chemical space. Cinchona-derived catalyst 222 was also selected 
as a catalyst system to identify suitable reaction conditions. 
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4.2.1 Synthesis of starting materials 
The amidosulfone starting materials were readily obtained in a single step from 
commercially available materials. Accordingly ortho-bromobenzaldehyde (225) and 
pentenal (227) were condensed with tert-butyl carbamate (223) and benzenesulfinic 
acid (224) to give the corresponding amidosulfones 226 and 228 (Scheme 20)158 
 
Scheme 20: Synthesis of amidosulfone 226 and 228. 
Nitrobutene (204) was readily prepared from 4-bromobutene (229) via 
displacement of the bromide group with sodium nitrite according to a modified 
literature procedure in modest yield (Scheme 21).159 Nitroethanol (231) was 
protected by tert-butyldiphenylsilylation (230, Scheme 21).  
 
Scheme 21: Synthesis of nitro compounds 204 and 231. 
The cinchona-derived catalyst (222) was selected as it was reported to give 
good enantio- and diastereo-control at mild reaction conditions.143 Accordingly, a 
Mitsunobu reaction with DPPA and quinine (233) afforded primary amine 234 upon 
reduction of the azide with triphenylphosphine (Scheme 22). 
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Scheme 22: Synthesis of catalyst 222 from quinidine (232). Ar = 3,5-trifluoromethylphenyl 
Subsequent urea formation with 3,5-trifluorophenylisocyanate gave the catalyst 
precursor 234. A final alkylation with benzyl bromide gave the phase transfer 
catalyst 222 in modest yield (Scheme 22). Given the reaction route, and the modest 
yield of the alkylation step, the catalyst precursor 234 was also screened as a 
potential catalyst for the nitro-Mannich reaction.  
4.2.2 Synthesis of cyclisation precursors 
With the relevant catalysts and starting materials in hand, the nitro-Mannich 
reaction was then investigated. Initially the amidosulfone was added to a solution of 
the nitro component then the reaction mixture was cooled to –20 ˚C. The catalyst 
and potassium hydroxide was then added. The products (221 and 235) were obtained 
in good yields using the reaction conditions described without the addition of the 
organocatalysts (Table 7, entries 1 and 4).  
Under the same reaction conditions, but with the addition of 5 mol% of catalyst 
222, the nitro adducts were again obtained in good yield (64-69%) and poor 
diastereocontrol (Table 7, entries 2 and 5). Although no ortho-substituted aryl 
components had been described143 the result was surprising. In addition, the few 
examples of alkyl amidosulfones and alkyl nitro components reported, involve quite 
sterically large reagents which may have aided their control.   
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Table 7: nitro-Mannich reaction to give the cyclisation precursors 221 and 235. 
 
Entry Product Organocatalyst d.r. anti:synA,B Yield 
1 
 
-- 50:50 75% 
2 222 55:45 64% 
3 234 35:65 73% 
4 
 
-- 50:50 64% 
5 222 60:40 69% 
6 234 35:65 61% 
ADetermined by 500 MHz 1H NMR Spectroscopy of the crude reactions. B anti:syn w.r.t NHBoc and 
NO2. 
The most surprising result, the addition of 5 mol% of catalyst 234, favoured the 
formation of the syn diastereoisomer albeit with modest control (entries 3 and 6). 
There are no reports of unalkylated cinchona-derived catalyst used in the nitro-
Mannich reaction.  
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4.3 Selection of a diastereoselective nitro-Mannich reaction protocol (2) 
4.3.1 Catalyst screen 
Given the poor diastereocontrol observed using both cyclisation precursors, a 
more thorough investigation of a suitable catalytic system was then undertaken. As 
such, the bifunctional organocatalysts 220, 236-240 (Figure 36) were selected based 
on the following criteria; coverage of a range of organocatalyst classes and ready 
availability. 
 
Figure 36: Chiral catalysts chosen for a screening of the nitro-Mannich reaction. 
4.3.1.1 Synthesis of selected catalysts  
The cinchona-derived phase-transfer catalyst 220 was commercially available. 
Additional catalysts 236 and 237 were readily synthesised from alkylation of 
quinine (241) and cinchonine (242) with 2-chlorobenzamidazole in 65% and 58% 
yields respectively (Scheme 23).160  
Scheme 23: Synthesis of Zhang’s cinchona alkaloid catalyst 236 and 237.160 *R or S 
Zhao’s catalyst 238 required the protection of tert-leucine 243 with tert-butyl 
carbamate, subsequent amide formation and deprotection gave the dimethyl amide 
derivative 244 (Scheme 24).161 This intermediate was then reduced to give diamine 
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245 with lithium aluminium hydride before thiourea formation with 
phenythioisocyanate furnished 246. Finally, alkylation with benzyl bromide gave 
phase transfer catalyst 238 in 11% yield from tert-leucine (243).161 
 
Scheme 24: Synthesis of Zhao’s thiourea catalyst 238 from tert-Leucine 243.161 
Anderson’s catalyst 239 was readily prepared in a similar route from valine 
(247).162  The amino acid was first protected as the carbamate derivative before 
amide formation with dimethylamine and deprotection gave the dimethyl amide 
derivative 248 (Scheme 25). Subsequent thiourea formation on the crude material 
afforded 239 in 32% yield from valine.162  
Scheme 25: Synthesis of Anderson’s thiourea catalyst 239 from valine. 
The final organocatalyst, Johnson’s chiral bis (amidine) (BAM) Brønsted basic 
catalyst (240), was readily available in two steps.148,163 Regioselective Buchwald 
coupling of 2,4-dichloroquinoline with diaminocyclohexane 249 gave the amino 
chloro derivative 250 (Scheme 26). A final SnAr reaction using pyrrolidine gave the 
catalyst precursor 251 (Scheme 26).148,163  
 
Scheme 26: Synthesis of precursor for Johnsons BAM Brϕnsted basic catalyst 251. 
The active catalyst (240) was formed immediately prior to its use by the 
addition of a sub stoichiometric amount of triflic acid to 251 (Scheme 27). Johnson 
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has shown that the amount of triflic acid added had a direct effect on the 
diastereoselectivity of the system.148,163 
 
Scheme 27: BAM Brϕnsted basic catalyst 240 was prepared by the addition of sub stoichiometric 
amount of triflic acid to (251) and used without further purification/analysis as described. 
4.3.2 Catalyst screen to identify suitable diastereoselective conditions  
With a number of different catalysts synthesised, a common set of reaction 
conditions were then established to compare the effectiveness of each catalyst. 
Amidosulfones 253 and 255, readily prepared from the corresponding aldehydes 
(252 and 254, Scheme 28).  
 
Scheme 28: Synthesis of amidosulfones 253 and 255. 
The amidosulfones were dissolved in toluene with nitroethane and 10 mol% of 
the catalyst then cooled to -50 ˚C. At this point, caesium hydroxide was added and 
the reactions stirred for 48 h. The conditions chosen had previously been used by 
Palomo et al. with their work using catalyst 220 (see Section 4.1, Scheme 19). 
Summarised in Table 8 are the results from the catalyst screen with amino sulfone 
255. 
The catalysts 220, 236 and 237 performed best, with each giving >60% 
conversion and good diastereoselectivities (Table 8, entries 1-3). As the conditions 
employed had previously been optimised for cinchona catalyst 220 this was 
expected. Disappointingly, very little conversion was obtained with the use of 
catalyst 238 and when no organocatalyst was used (Table 8, entries 4 and 7). 
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Table 8: Screening of catalysts in the asymmetric nitro-Mannich reaction between phenyl 
amidosulfone (257) and nitro ethane. 
. 
Entry Organocatalyst Conversiona d.r.a 
1 220 (10 mol%) >90% 95:5 
2 236 (10 mol%) >60% 95:5 
3 237 (10 mol%) >90% 95:5 
4 238 (10 mol%) <5% -- 
5 239 (10 mol%) ndb -- 
6 240 (10 mol%) >50% 60:40 
7 7 -- <5% -- 
a) Determined by 500 MHz 1H NMR spectroscopy of crude reaction mixture. b) 500 MHz 1H NMR 
spectroscopy signals were extremely broad and therefore analysis was inconclusive. 
Catalyst 239 provided reasonable conversion albeit with relatively poor 
diastereocontrol (60:40) which was significantly lower than that reported (entry 
6).163 This is likely due to the combination of two variables; under the literature 
procedure, there was no external base added to the reaction system, which may have 
limited the non-catalysed background reaction. In addition, the optimised conditions 
for Johnson’s catalytic system were at higher temperatures (-20 ˚C).  
Given these results, catalyst 220 and 237 were selected for further evaluation. 
The results are summarised in Table 9. Both catalysts were effective at promoting a 
diastereoselective nitro-Mannich reaction with amidosulfone 253, in each case 257 
was obtained with d.r. of 90:10 after purification (entries 1 and 3). The reaction was 
also scalable, allowing the synthesis of grams of 257 with catalyst 220 while 
maintaining high levels of diastereoselectivity (85:15, entry 2). 
However, when 255 was used as the coupling partner, catalyst 220 was 
superior, with the nitro adduct 258 being isolated in a 60% yield with 93:7 d.r.  
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Table 9: Screening of catalysts (220) and (237) in the asymmetric nitro-Mannich reaction between 
model substrates on a preparative scale. 
 
Entry Substrate Catalyst Crude d.r.a Yield Purified d.r.a 
1 255 220 82:18 83% 90:10 
2 255 220 nd 43%b 85:15 
3 255 239 75:25 76% 90:10 
4 257 220 75:25 60%c 93:7 
5 257 239 -- 61% 60:40 
aDetermined by 500 MHz 1H NMR spectroscopy. b50% conversion (85% BRSM). Reaction on 3.2 
mmol scale. cMinor fraction isolated as 50:50 mixture of diastereoisomers in 19% yield. 
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4.4 Design of Cyclisation precursors  
With a working diastereoselective protocol for the nitro-Mannich reaction, the 
pipeline pilot protocol was then used to identify the most useful cyclisation 
precursors. In total 18 imines and 11 nitro-components, were used to create a library 
with over two million virtual final compounds.  
Because such a large amount of data was generated during the enumeration, the 
cyclisation precursors were first sorted according to the following criteria; 
cyclisation precursors ≤ 30 scaffolds with suitable physiochemical properties to 
interrogate lead-like chemical space was discarded. This left a focused library of 42 
cyclisation precursors based on the combinations of aldimines with nitro 
components (Figure 37). 
 
 
Figure 37: Amidosulfones and nitro compounds used to generate lead-like scaffolds. 
From the list of 42 cyclisation precursors, 220 and 259 were chosen because 
they had over 30 potential scaffolds that could be accessed from each precursor 
(Figure 38). In addition, subtle variation of each reactant (n = 0, 1 or 2 respectively) 
the number of scaffolds obtained could be readily doubled or tripled from a common 
set of reaction conditions. 
 
Figure 38: Output cyclisation precursors 220 (left) and 259 (right) selected for investigation. Plot of 
scaffold frequency (total number of compounds generated from a single scaffold) vs the lead-likeness 
penalty. 
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4.4.1 Synthesis of starting materials 
With the selected cyclisation precursors, synthesis of the amidosulfones and 
nitro compounds was then undertaken. Amidosulfone 261 was prepared via Parikh-
Doering oxidation of aminoethanol 165. Subsequent amidosulfone formation with 
223 and 224 provided 261 (Scheme 29).  
Scheme 29: Synthesis of amidosulfone 261. 
3-Bromopropanol (262) was protected by tert-butyldiphenylsilylation (263, 
Scheme 30) then subsequent displacement of the bromide group with sodium nitrite 
gave the silyl protected nitropropanol 267. (Scheme 30). Preparation of remaining 
starting materials has previously been described (Section 4.2.1). 
 
Scheme 30: Synthesis of 267. 
4.4.2 Synthesis of cyclisation precursors 
With a significant number of starting materials prepared, the diastereoselectivity 
of the nitro-Mannich reaction was investigated. In general good levels of 
diastereocontrol was observed from a broad range of amidosulfones.  
Cyclisation precursors 221 and 235 could now be synthesised in good yield and 
diastereocontrol (Table 10). After purification, both nitro amines could be obtained 
as almost a single diastereoisomer (d.r. 87:13 and 90:10 respectively). 155 Additional 
nitro compounds, 267 and nitroethane (256) were successfully reacted with aldimine 
227 to give cyclisation precursors 265 and 266 respectively (Table 10). 
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 Table 10: Scope of the nitro-Mannich reaction. 
 
^Yield and diastereomeric mixture of purified product determined by 500MHz 1H NMR 
spectroscopy. *Determined by reduction of the nitro group, formation of diastereomeric Moshers 
amides. AMinor diastereoisomer isolated 13% (d.r. 60:41). BMinor diastereoisomer isolated 7% (d.r. 
90:10) and a third fraction with a d.r. 60:40 (5% yield) was obtained.  cee not determined due to the 
presence of significant amount of the other diastereoisomer. 
Disappointingly however, amidosulfone 261 gave nitro adduct 267 in poor yield 
and diastereocontrol. In addition, a large amount of the enamine side product was 
observed which was difficult to remove. The poor diastereo control could be the 
result of coordination of NHCbz to the catalyst in place of the NHBoc. This 
alternative mode of coordination could give rise to another diastereoisomer. 
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4.4.2.1 Determining relative configuration of the nitro-Mannich reaction 
The relative stereochemistry of the nitro-Mannich reaction had until now been 
assigned by analogy to the results of Palomo who had demonstrated that the anti 
diastereoisomer was obtained through suitable functional group manipulation.155 In 
this study, the relative stereochemistry was independently confirmed when the 
minor diastereoisomer of nitro adduct 265, syn-265, was crystallised from ethyl 
acetate and petrol (Figure 39) displaying syn relationship between nitro and NHBoc 
groups. 
 
Figure 39: Confirmation of the relative configuration of a product of the nitro-Mannich reaction. The 
minor diastereoisomer of 265 was crystallised from EtOAc–petrol. Ellipsoids at 50% probability. 
4.5 Reduction of the nitro group 
With a suitable route for the synthesis of cyclisation precursors, the next aim 
was to reduce the nitro group to give access to 1,2-diamines. Using standard 
conditions143, nickel chloride and sodium borohydride were added to a solution of 
265. After 60 minutes, TLC indicated the complete consumption of starting material 
however LC-MS analysis showed a mass of 231 (M+3) (Table 11 entry 1). After 
quenching and workup, 500 MHz 1H NMR analysis of the crude reaction did not 
show any alkene signals, suggesting 268b had been formed recovered 268a.  
Given the unexpected result, the reaction was repeated and at various time spots 
the reaction was quenched and analysed by LC-MS. At two minutes, 229 was 
observed by LC-MS corresponding to MH+ for amine 268a. 1H NMR analysis of the 
crude reaction showed a mixture of 265 and 268a (based on the presence of two 
different terminal alkene signals in the 500 MHz 1H spectrum obtained). However 
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by five minutes, only the fully reduced amine 268b was observed by LC-MS and 
500 MHz 1H NMR. Although an unusual outcome, the reduction of alkenes with 
nickel and sodium borohydride is not unprecedented.164  
Table 11: Screening of conditions for the reduction of the nitro group in the presence of an alkene 
and carbamate group. 
 
Entry Conditions Time Outcomea 
1 NiCl2
, NaBH4
 
20°C 
2 minutes 
5 minutes 
Mixture of 265 and 268a 
268b 
2 Zn, AcOH, 75°C 16 hr Mixture of 268a and 268c 
3 LiAlH4 16 hr 268a present by LC-MS 
aDetermined by 500 1H NMR spectroscopy and LC-MS 
Zinc has been extensively used with acid to reduce aryl nitro groups.165 To this 
end, the nitro amine 265 was dissolved in acetic acid and heated to reflux for 16 
hours. Pleasingly, these conditions did reduce the nitro group while leaving the 
alkene untouched however the carbamate protecting group was partially removed 
and a mixture of amine 268a and diamine 268c was obtained (entry 2). While the 
loss of the carbamate group was not unexpected, given the instability of tert-butyl 
carbamate groups to cleavage under acidic conditions,166 the nitro-Mannich reaction 
is known with other protecting groups on the nitrogen (e.g. benzyl carbamate) which 
are stable to acid.  
Fortunately, when a solution of cyclisation precursor 265 in THF was added to 
lithium aluminium hydride (1M in THF), amine 268a in obtained. (entry 3). Amines 
such as 268a are difficult to handle and analyse. Consequently, it was found to be 
more efficient to trap the amine with a protecting group complimentary to tert-butyl 
carbamate. Shown in Scheme 31 is the various differentially protected amines 
obtained from 265. 
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Scheme 31: Synthesis of differentially protected diamines 269-272. Conditions; (i) 265 (1 eq.), THF, 
1 M LiAlH4 (2.1 eq.) then (ii) 269: DCM, NaHCO3, Cbz-Cl 18 h; 270: DCM, benzyl anhydride, E3N 
18 h; 271:  Toluene, phthalic anhydride, E3N, 110 °C, 48 h; 272:  TFA-Cl, E3N, 18 h. 
4.5.1 Determining the enantiomeric excess of the nitro-Mannich 
reaction 
With a suitable route for the synthesis of cyclisation precursors and the 
reduction and more importantly a method for reducing the nitro group, the 
enantioselectivity of the diastereoselective adducts had to be determined. This was 
done via Moshers amide analysis1.  
Accordingly, the nitro group of each cyclisation precursor was reduced with 
lithium aluminium hydride as described previously. Too determine the enantiomeric 
excess, the amine was then reacted with (R) or (S) -methoxy--
trifluoromethylphenylacetyl chloride to give a pair of diastereoisomers (273-277, 
Scheme 32). The ee was determined via integration of the corresponding 
diastereoisomers within the crude 500 MHz 1H NMR signals (e.e given in Table 10).  
  
Scheme 32: Preparation of Moshers amide derivatives. 273 R1 =  H (from 268), 274 CH2OTBDPS 
(from 237), 275 CH2CH2OTBDPS (from 269).  
                                                 
1 The pseudo enantiomer of cat 220 was prepared and opposite configuration of nitro adducts was 
prepared. In addition, reduction of nitro group and preparation of benzamide derivaties was prepared. 
However a suitable method was not obtained. 
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4.6 Utilising cyclisation precursors in subsequent cyclisation reactions 
4.6.1 Cyclisation precursor 265 
4.6.1.1 Cyclisation by Aminoarylation 
With the cyclisation precursors in hand, next the potential for making scaffolds 
was investigated. For this, the cyclisation precursors 235 and 265 were used. There 
had been success within the group using a palladium-catalysed aminoarylation 
reaction to give a range of pyrrolidine products.65 Accordingly, 269 was treated with 
5 mol% palladium acetate and 3-bromopyridine then heated to 110 ˚C. However the 
expected product was not observed (Scheme 33). 
 
Scheme 33: #No mass observed by LC-MS analysis. 500 MHz 1H NMR spectroscopy showed 
presence of starting material. 51% recovered starting material 
When heated for longer, 48 hr, still only 269 was observed. Attempted use of 
270 also failed to give any of the desired product. Given the presence of the 1,2 
nitrogen atoms, it was possible that co-ordination with the Pd between these atoms 
was preventing completion of the catalytic cyclic. To test this, the nitro adduct 265 
was subjected to aminoarylation conditions. Pleasingly, the pyrrolidine 278 was 
obtained in reasonable yield albeit with poor stereochemical control. This was 
perhaps unsurprising, given the possibility of epimerisation α to the nitro group but 
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it does demonstrate that with judicious choice of protecting group, aminoarylation 
was possible. 
Pleasingly with the phthalimide protected amine (271), the pyrrolidine (279) 
was obtained with high diastereoselectivity in 31% yield. It should be noted that 
51% of starting material was recovered indicating potential difficulty with these 
cyclisation reactions.  
4.6.1.2 Cyclisation by Cross-metathesis 
The cyclisation precursor 271 underwent efficient cross metathesis with ethyl 
acrylate to give αβ unsaturated ester 280 (Scheme 34). The crude product was then 
reacted with sodium tert-butoxide without isolation to give pyrrolidine 281. 
Unfortunately poor diastereocontrol was observed (d.r. 66:34, Scheme 34). 
Alternative bases were investigated but the diastereoselectivity could not be 
improved.  
Scheme 34: Cross metathesis and aza-Michael reaction to give 281. Aternative conditions were 
attempted (variation of base and solvent, see page 137 for full detailes) but the diastereoselctivity 
remained at 65:35. 
4.6.2 Cyclisation precursor 235 
Cyclisation precursor 235, with additional functionality could be used in two 
cyclisation reactions to give access to bicyclic scaffolds. To make use of the 
different functional groups, 235 was reduced with lithium aluminium hydride, and 
protected with dimethoxy benzaldehyde and benzyl chloroformate to give 282 and 
283 respectively (Scheme 35).  
The reduction of 235 was complicated due to the partial loss of the TBDPS 
group. While removal of a silyl group with lithium aluminium hydride is known166 it 
was unexpected. However, the addition of an equivalent of TBDPS-Cl with 
imidazole prior to the amine protecting group was sufficient to solve this problem.  
 74 
 
Scheme 35: Preparation of the differentially protected diamines 282 and 283. (i) 235 (1 eq.), THF, 1 
M LiAlH4 (2.1 eq.) then (ii) 282: MeOH, 2,4 dimethoxybenzaldehyde, MS, 65 °C 18 h then NaBH4; 
18 h, 43%; 283: DCM, NaHCO3, Cbz-Cl, 18 h, 48%. 
 With 282 the silyl protecting group was removed with TBAF to give the 
corresponding amino alcohol which was reacted directly with carbonyldiimidazole 
to give the oxazolodinone 284 (Scheme 36). In addition, the tert butyl carbamate 
group of amine 282 could be removed with TFA to give the corresponding diamine, 
which after the addition of carbodiimidazole gave the urea 285 (Scheme 36). 
Scheme 36: Synthesis of first generation scaffolds. By judicious choice of protecting group 
manipulation, 3 scaffolds were obtained from the one reaction class (CDI coupling). 
With amine 283, the silyl protecting group was removed with TBAF and the tert 
butyl carbamate group was removed with TFA to give the corresponding amino 
alcohol, which after the addition of carbodiimidazole gave the six membered 
carbamate 286 (Scheme 36).  
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4.6.2.1 Aminoarylation with 284 
It was envisaged that the aminoarylation chemistry and cross metathesis 
described with cyclisation precursor 265 could be used with the remaining 
functionality present in 284-286. Taking the aminoarylation conditions developed 
within the group, 284 was added treated with 5 mol% of palladium acetate, 3-
bromopyridine and heated to 110 ˚C (Table 12, entry 1). However the expected 
pyrrolidine was not obtained. Only starting material was observed by LC-MS and 
500 MHz 1H NMR spectroscopy. Heating for extended times, and addition of more 
palladium catalyst, the pyrrolidine was still not observed (Table 12, entries 2-3).  
A series of different aryl bromides was then investigated to ensure that lack of 
activity observed was not the result of poor selection of coupling partner. In each 
case, however, only starting material was observed (Table 12, entries 4-5). 
Table 12: Attempted aminoarylation with substrate 287 
 
Entry Catalyst Time Ar Outcome 
1 5 mol% Pd(OAc)2  18 h 3-bromopyridine NR# 
2 5 mol% Pd(OAc)2 36 h 3-bromopyridine NR# 
3 10 mol% Pd(OAc)2 48 h 3-bromopyridine NR# 
4 5 mol% Pd(OAc)2 18 h 5-bromopyrimidine NR# 
5 5 mol% Pd(OAc)2 18 h 1-chloro 2-bromobenzene NR# 
6 1 mol% Pd2(allylCl)2 18 h 3-bromopyridine NR# 
Unless otherwise state, dioxane, CsCO3 (2 eq.) and 10 mol% of ligand DPE-Phos used.#Mass for 
pyrrolidine was not observed by LC-MS. 500 MHz 1H NMR showed starting material present after 
the specified time. 
A different palladium source was also used; again only starting material was 
observed (entry 6). Given the comprehensive set of conditions attempted, it is clear 
that substrate 284  is not suitable for the aminoarylation reaction. 
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4.6.2.2 Cyclisation with Aminoarylation 285 
 Aminoarylation of cyclic carbonates had previously been described. In their 
system, the oxazolidinone was treated with 2 mol% of palladium allyl chloride, aryl 
bromide and heated to 80 ˚C. A range of different 5/5 fused systems was created 
with excellent stereocontrol. Accordingly, urea 285 was treated under the conditions 
with 1-bromo-2-chlorobenzene (287) and the imidazolone 288 was obtained 
(Scheme 37).  
 
Scheme 37: Aminoarylation with urea 285 to give 288-291 
The presence of the silyl protecting group greatly complicated interpretation of 
the 500 MHz 1H NMR  spectra. It was therefore not trivial to determine the 
diastereoselectivity of the aminoarylation reaction. Consequently, the silyl 
protecting group was removed with TBAF to give imidazolone 289. From this data, 
it was clear that the compounds was obtained in a  65:35 mixture of 
diastereoisomers (Scheme 37).  
An additional scaffold was obtained when using 3-bromopyridine (290) as the 
coupling partner to give 291 in a modest yield and same diastereoselectivity (as 
observed in the preparation of 289). The aminoarylation was attempted with 5-
bromopyrimidine, however although the mass of the imidazolone was observed it 
was not possible to isolate cleanly and determine if the reaction had occurred. In 
each case, LC-MS analysis showed the [M-TBDPS], i.e. loss of the silyl protecting 
group however this was never isolated.  
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4.6.2.3 Aminoarylation with 286 
Given the success of the amino arylation with 285, 286 was treated with 
2 mol% of palladium allyl chloride and 1-bromo-2-chlorobenzene (287) and heated 
to 80 ˚C and the pyrroloxazinone 293 was obtained (Scheme 38). As before, scaffold 
293 was obtained in a 65:35 mixture of diastereoisomers. The methodology was 
exploited with 3-bromopyridine (290) as the coupling partner to give 294 in a 
modest yield and same diastereoselectivity. 
 
Scheme 38: Aminoarylation with carbamate 286. 
4.6.3 Cyclisation with substrate 289 
Given the poor diastereocontrol observed, something which was unexpected and 
at odds with the precedent, an alternative diastereoisomer of urea 285b was prepared 
(Scheme 39) according the same reaction route; syn diastereoisomer from the nitro-
Mannich reaction was reduced, protected with dimethoxybenzyl group and urea 
formed with CDI (as described for the anti diastereoisomer Scheme 36). 
 
Scheme 39: Aminoarylation of substrate 285b. 
Using the same reaction conditions as for the anti, the aminoarylation reaction 
provided 295 as a single diastereoisomer. This result indicates that the poor 
diastereoselectivity observed with 285 was the result of the configuration set at the 
nitro-Mannich reaction and that there is a matched and mismatched effect with the 
relative configuration of the starting material and stereochemical outcome of the 
aminoarylation. As shown in Figure 40, conversions of 289b and related substrates 
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is believed to occur through transition states such as TS1 which minimises the ring 
strain.167,168  In the case of 285b this is the lowest energy conformation which leads 
to the observed pyrroloimidazolone 295 in good diastereoselectivity.  
 
Figure 40: Transition state of 285b towards pyrroloimidazolone 295 
The aminoarylation chemistry is well precedented to give the trans ring system 
with cyclic carbonates.167,168 Thus the stereochemical outcome of the aminoarylation 
was independently confirmed through a 500 MHz 1H NMR 2D-NOESY experiment 
with 295 as depicted below. The stereochemistry of the remaining adducts was 
assigned by analogy. 
 
Figure 41: Structural confirmation about pyrroloimidazolone core came from the NOESY correlation 
between the 4-methyl protons (red), 7-H (blue) and 1-methyl protons (green) (see Section 6.8 for full 
details). 
Given that failing, and the observation that an unalkylated cinchona urea 
catalyst 234 gave an enriched syn diastereoisomer, the nitro-Mannich reaction was 
attempted with this catalyst under the optimised reaction conditions.  
 
 
Scheme 40: nitro-Mannich reaction with organocatalysts 234. 
Pleasingly, catalyst 234 provided syn-235 as the major diastereoisomer in a 
75:25 ratio (Scheme 40). On a preparative scale, the diastereoisomers could be 
separated to give an increased yield of the syn diastereoisomer. 
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4.7 Review of molecular properties of compounds derived from 
prepared scaffolds 
To assess the value of the seven scaffolds prepared, a virtual library of 
functionalised compounds was enumerated using the protocol described previously. 
Except, the exemplar medicinal chemistry capping groups used in this enumeration 
was a carefully chosen sub section of the list used previously to more fully represent 
traditional capping groups used by medicinal chemists. In addition, the scaffolds 
prepared by aminoarylation reaction, only one capping group was exploited due to 
the variable nature of the reactant. The resulting virtual library comprised 2414 
likely synthetically-accessible small molecules. 
4.7.1 Assessment of Molecular weight and ALogP 
First, the lead-likeness of the members of the virtual library was assessed 
(Figure 42). Compounds were successively filtered by molecular size (14 ≤ number 
of heavy atoms ≤ 26), lipophilicity (−1 ≤ ALogP P ≤ 3) and undesirable structural 
features (Appendix 7: Table 15 for specific structural filters) using the same protocol 
as described. About 46% of the compounds in the virtual library had lead-like 
molecular properties, and the majority of the outlying compounds only narrowly 
failed the molecular property filters (heavy atoms: μ = 25.9, σ = 5.2; ALogP P: μ = 
0.89, σ = 1.6). By comparison, the ZINC database has just 23% of commercially 
available compounds which were lead-like. 
Remarkably, it is also evident that, each one of the seven scaffolds allowed 
significant regions within lead-like chemical space to be targeted (For individual 
PMI scaffold graphs see Appendix 7: Figure 52). This unified synthetic approach 
thus specifically targeted lead-like chemical space. 
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Figure 42: Analysis of the molecular properties of a virtual library of 2413 compounds derived from 
the seven molecular scaffolds and 2% of the ZINC database (90 911 randomly-selected compounds). 
Panel A: Distribution of the molecular properties of the virtual library. 46% of the compounds 
(green) survive successive filtering by molecular size (14 ≤number of heavy atoms ≤26; failures 
shown in red) and lipophilicity (−1 ≤ALogP ≤3; failures shown in orange) and various structural 
filters; 0.03% of the compounds (shown in black) failed the structural filters. Panel B: Distribution of 
the molecular properties of the compounds from the ZINC database. Using the same approach, 23% 
of the compounds survive the iterative filtering process, and 9% of the compounds fail a structural 
filter.  
4.7.1.1 Assessment of Fraction of sp3 carbons 
Second, we determined the fraction of sp3 hybridised carbon atoms (Fsp3) in the 
virtual compounds (Figure 43). It has previously been shown that Fsp3 correlates 
strongly with success because compounds in the discovery phase have lower Fsp3 
than marketed drugs.169 It has thus been stated that accessing more three-
dimensional lead compounds is a desirable goal.169 
 
Figure 43: Mean Fsp3 of the compounds from the ZINC database (red) and our virtual library (mean 
for the compounds based on each of the seven scaffolds, green). 
The mean Fsp3 of the virtual compounds (0.52) compared very favourably with 
that of the random sample of compounds from the ZINC database (0.33). Thus, our 
synthetic approach can yield compounds with significantly greater sp3 character than 
most commercially-available compounds, thereby expanding the range of molecular 
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architectures available within lead-like chemical space and offering more flexibility 
in lead optimisation. 
4.7.2 Assessment of Novelty 
Third, the novelty and diversity of the seven scaffolds was assessed. A 
substructure search was performed in which the ZINC database was interrogated 
with each of the deprotected scaffolds. In general the bicyclic scaffolds were 
extremely novel with no substructures found within the ZINC database or CAS 
registry.  
The diversity of, and relationship between, the scaffolds was assessed using a 
hierarchical analysis. The hierarchical framework analysis applied the ‘scaffold tree’ 
approach described by Schuffenhauer and co-workers. The results are summarized 
in Figure 44.  
 
Figure 44: The hierarchal relationship between the 7 distinct molecular frameworks at the 
graph/node/bond level (black) and 5 parental frameworks (blue). Daughter frameworks are shown in 
red. Daughter frameworks are shown in red. The scaffolds that represent each framework are 
indicated.  
It was found that seven frameworks were represented at the graph-node-bond 
level, which were related hierarchically to 4 “parent” frameworks. There is 
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significant scaffold diversity at each level of hierarchy, meaning that the scaffolds 
are not simply closely related derivatives. 
4.7.3 Principle moments of inertia study 
An alternative metric to access the three dimensionality of the compound was to 
conduct a Principal moments of inertia (PMI) study. The same 90,911 randomly 
selected compounds from the ZINC database used in Figure 45 was used to compare 
the shape diversity of the virtual library created from the scaffolds. For each 
compound, the two normalised PMI values were determined for a low energy 
conformation (For individual PMI plots of each scaffold, see Appendix 7: Figure 
52).  
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Figure 45: A normalised principal moment of inertia plot to show the shapes of the 2413 virtual 
compounds in relation to three idealised shapes; a rod, disk and sphere. A systematic shift away from 
the flat-linear edge of the graph can be observed for the virtual compounds derived from seven 
scaffolds (blue) when compared to 90 911 randomly selected compounds from ZINC database (grey). 
By dividing the PMI plot into 20 bins (Figure 46), the three dimensionality of 
the library can be assessed by comparison to the same fraction of the ZINC database 
used in Figure 42. Notably, while 44% of the compounds in ZINC database fall 
within the first bin (i.e. lie along the flat-linear edge of the PMI plot in Figure 45), 
only 1.3% of the 2413 virtual library compounds fall within this bin. In addition, 
more than >80% of the virtual compound library falls in bins ≥4 (cf. <10% of the 
ZINC library of compounds). This is an additional indication that the methodology 
developed will target Fsp3 rich compounds which may serve as better leads for drug 
discovery. 
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Figure 46: The relative proportions of the compounds found when the PMI was divided into twenty 
bins for 2% of the ZINC database (grey) versus the virtual library of compounds (blue). As a greater 
percentage of the virtual compound library occupies bins >3 a systematic shift away from the flat-
linear edge of chemical space is observed. 15 of 20 bins shown. 
4.7.4 Assessment of Synthetic economy 
In total, seven diverse molecular scaffolds were prepared from just two different 
cyclisation precursors. Initially, pairs of building blocks were combined using a 
single connective reaction, the nitro-Mannich reaction, before a divergent synthetic 
approach was used to convert these cyclisation precursors into seven molecular 
scaffolds. This approach exploited a toolkit of just four cyclisation reactions, and 
required on average just 1.57 operations per scaffold from the key connective 
reaction (nitro-Mannich reaction). Furthermore, the unified and modular nature of 
the strategy means that it has the potential to deliver many additional scaffolds 
through expansion of the range of building blocks used (e.g. by use of homologated, 
and stereo- or region isomerically substituted variants). 
 84 
 
4.8 Conclusions 
This thesis has detailed the significant problems associated with the drug 
discovery. It described a new approach, termed lead-oriented synthesis, and 
highlighted the problems and potential advantages associated with this methodology 
(Chapter 1).  
In Chapter 2, the problems encountered when attempting to re-tool the Petasis 
reaction for LOS was described in detail. While the reaction had been shown 
repeatedly71,78–82 it was suitable for the generation of chemical libraries, the 
properties of these compounds were outwith lead-like chemical space and it proved 
difficult to adapt the reaction.  
Chapter 3 described the use of a computation protocol to direct the selection of 
a new connective reaction to support lead-oriented synthesis. The computational 
approach was developed within the group previously.65 It then described the process 
used to robustly compare different connective reactions is given to select a new 
connective reaction.  
 This chapter has described the use of the nitro-Mannich reaction in support of 
lead-oriented synthesis. In combination of with the computation protocol, a 
diastereoselective protocol was identified. The unified synthetic approach yielded 
molecular scaffolds that were novel, diverse and lead-like. It was shown that 
functionalization of the scaffolds would allow significant lead-like chemical space to 
be targeted that complements that occupied by commercially-available molecules.  
A key challenge in lead-oriented synthesis is still the identification of 
complementary and robust reactions with broad functional group compatibility, 
particularly convergent reactions that may be used to link building blocks. As such 
an increased armoury of such robust convergent reactions would crucially expand 
the relevant chemical space accessible to drug discovery programmes, and may help 
to address the grand challenge of increasing productivity in the pharmaceutical 
sector. 
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5 Experimental 
5.1 Instrumentation and General Information  
All non-aqueous reactions were performed under an atmosphere of nitrogen 
unless otherwise stated. Water-sensitive reactions were performed in oven-dried 
glassware, cooled under nitrogen before use. Solvents were removed in vacuo using 
a Büchi rotary evaporator and a Vacuubrand PC2001  
Tetrahydrofuran (THF), DCM, toluene and CH3CN were dried and purified by 
means of a Pure Solv MD solvent purification system (Innovative Technology Inc.). 
Anhydrous N,N-dimethylformamide (DMF) and 1,4-dioxane was obtained in 
SureSeal bottles from Sigma-Aldrich. All other solvents used were of 
chromatography or analytical grade. Petrol refers to petroleum spirit (b.p. 40-60 °C). 
Ether refers to diethyl ether. Commercially available starting materials were 
obtained from Sigma-Aldrich, Fluka, Acros or Alfa-Aesar and were used without 
purification unless stated. 
Thin layer chromatography (TLC) was carried out on aluminium backed silica 
(Merck silica gel 60 F254) plates supplied by Merck. Visualisation of the plates was 
achieved using an ultraviolet lamp (λmax = 254 nm), KMnO4, anisaldehyde or 
ninhydrin. LC-MS was performed using an Agilent 1200 series LC system 
comprising of a Bruker HCT Ultra ion trap mass spec, a high vacuum degasser, a 
binary pump, a high performance autosampler and micro well plate autosampler, an 
autosampler thermostat, a thermostat column compartment and diode array detector.  
The system used Phenomenex Luna C18 50 x 2mm 5 micron column and two 
solvent systems: MeCN/H2O + 0.1% Formic acid or MeCN/H2O. 
Flash chromatography was carried out using silica gel 60 (60-63 μm particles) 
supplied by Merck or using Biotage silica. Strong cation exchange solid phase 
extraction (SCX-SPE) was carried out using pre-packed Discovery DSC-SCX 
cartridges supplied by Supleco. Mass-directed HPLC purification was carried out 
using an Agilent 1260 Infinity HPLC system comprising an Agilent 6120 
Quadrupole LC/MS and Agilent G1968D active splitter. 
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Optical rotation measurements were carried out at the sodium D-line (589 nm) 
on a Schmidt and Haensch H532 or an Optical Activity AA-1000 polarimeter 
instrument; concentrations are g/100 mL, temperatures given in °C, optical rotations 
are given in 10-1degcm2g–1 (units are omitted). Infrared spectra were recorded on a 
Perkin-Elmer One FT-IR spectrometer with absorption reported in wavenumbers 
(cm–1).  
High resolution mass spectra (HRMS) were recorded on a Bruker Daltonics 
micrOTOF or Bruker MaXis Impact spectrometer with electrospray ionisation (ESI) 
source. Where EI ionisation was required, a Waters/Micromass GCT Premier 
spectrometer was used.  
Proton (1H) and carbon (13C) NMR spectral data were collected on a Bruker 
Advance 400, 500 or 600, Bruker DPX500 or DPX300 spectrometers. Chemical 
shifts (δ) are quoted in parts per million (ppm) and referenced to the residual solvent 
peak or downfield of tetramethylsilane. Coupling constants (J) are quoted in Hertz 
(Hz) and splitting patterns reported in an abbreviated manner: app. (apparent), s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Assignments were made 
with the aid of COSY, DEPT-135, HMQC, HMBC, TOCSY and NOESY 
experiments.  
A Julabo FT902 Immersion Cooler was used to cool the reaction mixture to  
-50 ˚C where required. 
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General Method A1 
Glycolaldehyde dimer (97) (0.6 eq.) was added to a stirred solution of trans-2-
phenylvinylboronic acid (74) (1.2 eq.) in water (10 mL/mmol substrate). The 
reaction mixture was stirred at rt for 10 mins. The amine (1 eq.) added, stirred for 48 
hr and 5M HCl(aq) was added until the pH of the reaction mixture was 1. The 
aqueous layer was washed with DCM (3 × 30 mL/mmol substrate), K2CO3 was 
added until the pH of the reaction mixture was 10 and the aqueous layer was 
extracted with DCM (3 × 30 mL/mmol substrate), dried (MgSO4), filtered and 
concentrated in vacuo to give a crude product. 
General Method A2 
This procedure is identical to procedure A1 except DCM (10 mL/mmol 
substrate) was used as a solvent.  
General Method A3  
This procedure is identical to procedure A1 except DCEHFIP (9:1 v/v, 10 
mL/mmol substrate) was used as a solvent.  
General Method A4 
Glycolaldehyde dimer (97) (0.6 eq.) was added to a stirred solution of vinylboronic 
acid pinacol ester (100) (1.2 eq.) in waterTHF (83:17 v/v, 10 mL/mmol substrate, 
10 mL/mmol substrate). The reaction mixture was stirred at rt for 10 mins. The 
amine (1 eq.) added, stirred for 48 hr and 5M HCl(aq) was added until the pH of the 
reaction mixture was 1. The aqueous layer was washed with DCM (3 × 30 mL/mmol 
substrate), K2CO3 was added until the pH of the reaction mixture was 10 and the 
aqueous layer was extracted with DCM (3 × 30 mL/mmol substrate), dried 
(MgSO4), filtered and concentrated in vacuo to give a crude product. 
General Method B 
Aldehyde (1.5 eq.), tert‐butyl carbamate (1 eq.) and sodium benzenesulfinate (1 
5 eq.) were suspended in H2O–MeOH (66:34) and formic acid was added (0.32 
mL/mmol substrate) and the reaction mixture was stirred in a sealed flask at rt for 2 
days. The reaction mixture was filtered, yielding a white precipitate which was 
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washed with ether (20 mL/mmol substrate) and water (20 mL/mmol substrate) and 
concentrated in vacuo to give the title compound. 
General Method C 
To a stirred solution of sodium nitrite (1.05 eq.) in DMSO (0.3 M) was added 5-
bromobut-1-ene (1 eq.), and the reaction mixture was stirred at rt for 2 hr. The pale 
yellow solution was then partitioned between water (50 mL/mmol substrate) and 
ether (50 mL/mmol substrate), and the organic phase was separated. The aqueous 
layer was extracted with ether (5 × 30 mL/mmol substrate), and the combined 
organic extracts were washed with brine (3 × 30 mL/mmol substrate) then dried 
(MgSO4), filtered and concentrated in vacuo to give a crude mixture. 
General Method D 
According to the procedure84 tert-butyl-diphenylsilyl chloride (1.1 eq.) added 
dropwise to the stirred solution of alcohol (1 eq.) and imidazole (3 eq.) in DMF (0.4 
M) over 1 hr. The reaction mixture was left to stir for a further 12 hr then water and 
DCM was added. The phases were separated and the aqueous phase was extracted 
with DCM (3 × 10 mL/mmol substrate). The combined organic phase was washed 
with sat. NaHCO3(aq), water, and brine, then dried (MgSO4), filtered and 
concentrated in vacuo to give a crude mixture. 
General Method E 
Amidosulfone (1 eq.) was suspended in toluene (0.2 M) and the nitro compound 
(5 eq.) was added and the resulting mixture was cooled to –50 °C. Freshly acquired 
CsOH.H2O (5 eq.) was added and the resulting suspension was stirred vigorously for 
48 h. 1 M HCl (until pH 3) was added and the solution was allowed to warm to 
ambient temperature. The aqueous layer was extracted with DCM (3 × 30 mL/mmol 
substrate), then the combined organic extracts were dried (Na2SO4), filtered and 
concentrated in vacuo to give a crude product. 
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General Method F 
Substrate (1 eq.) was dissolved in THF (0.4 M) and added drop wise to stirred 1 M 
solution of LiAlH4 (2.1 mL/mmol substrate). The mixture was stirred for 18 h then 
H2O (1 mL per 1 g of LiAlH4), 2 M NaOH (2 mL per 1 g of LiAlH4) and H2O (3 mL 
per 1 g of LiAlH4) was added in that order and left to stir for 30 mins. The reaction 
mixture was then concentrated in vacuo, dissolved in EtOAc (50 mL/ mmol 
substrate) washed successively with water (3 × 30 mL/mmol substrate) and brine (3 
× 30 mL/mmol substrate), and then dried (MgSO4), filtered and concentrated in 
vacuo to give a crude product. 
General Method G 
By General Method F, then crude amine was dissolved in DCM (0.2 M) then Et3N 
(3 eq.) and (R)-MPTA-Cl (1.2 eq.) or (S)-MPTA-Cl (1.2 eq) was added and the 
reaction stirred for 19 h. The reaction mixture was diluted with ether (3 ml) and 
water (1 ml) and the layers separated. The aqueous layer was extracted with ether 
(3 × 3 mL), the organic layers dried (Na2SO4), filtered and concentrated in vacuo. 
The crude material was then analysed by 500 MHz 1H NMR spectroscopy to 
determine the diastereomeric ratio. 
General Method H 
 [(allyl)Pd(Cl)]2 (1 mol%), CyJohnPhos (4 mol%), and NaO
tBu (1.2 eq.) then a 
solution of the substrate (1 eq.) and the aryl halide (1.2 eq.) in toluene (4 mL/mmol 
substrate) was added and heated to 80 ºC for 18 h. The reaction mixture was cooled 
to rt and sat. NH4Cl(aq) (2 mL/mmol substrate) and EtOAc (5 mL/mmol substrate) 
were added. The aqueous layer was extracted with ethyl acetate (4 x 5 mL/mmol 
substrate). The combined organic layers were dried (Na2SO4), filtered, and 
concentrated in vacuo.  
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(3E)-2-[Methyl(allyl)amino]-4-phenylbut-3-en-1-ol (98) 
By General Method A1, using N-allylmethylamine (0.16 mL, 1.67 
mmol), filtered through a silica plug, eluting with DCM–MeOH 
(90:10) gave the amino alcohol 98 (0.241 g, 84%) as a yellow liquid; Rf 0.20 (90:10 
DCM–MeOH); δH (500 MHz, CDCl3); 7.41 (2H, d, J 7.5, Ar), 7.36 (2H, t, J 7.5, 
Ar), 7.29 (1H, t, J 7.5, Ar), 6.56 (1H, d, J 16.0, 4-H), 6.17 (1H, dd, J 16.0 and 9.0, 3-
H), 5.87 (1H, ddd, J 17.2, 13.7 and 10.2, allyl 2-H), 5.23 (1H, d, J 17.2, allyl 3-HA), 
5.19 (1H, d, J 10.2, allyl 3-HA), 3.66 (1H, app t, J 10.4, 1-HA), 3.60 (1H, dd, J 10.4 
and 5.4, 1-HB), 3.44 (1H, td, J 9.0 and 5.4, 2-H), 3.27 (1H, dd, J 13.7 and 6.5, allyl 
1-HA), 3.08 (1H, dd, J 13.7 and 6.5, allyl 1-HB) 2.31 (3H, s, NMe); δC (75 MHz, 
CDCl3); 136.5 (Ar), 136.0 (4-C), 134.9 (allyl 2-C), 128.6 (Ar), 127.8 (Ar), 126.4 
(Ar), 123.7 (allyl 1-C), 117.5 (3-C), 65.8 (2-C), 61.1 (1-C), 56.9 (allyl 3-C), 36.5 
(NMe), OH not observed; νmax/cm-1 (neat); 3401, 2977, 1449 and 1045; m/z (ES) 
218.2; HRMS Found: 218.1537, (C14H19NO MH
+ requires 218.1539). This 
compound has previously been prepared but characterisation data has not been 
reported. 
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tert-Butyl-N-[2-(benzylamino)ethyl]carbamate (105)85 
tert-Butyl-N-(2-ethylamino)carbamate (107) (0.31 g, 1.9 mmol), in 
MeOH (1 mL, 2 M) was added to benzaldehyde (1.2 eq.), 4 Å MS 
in MeOH (20 mL, 0.1 M) and stirred for 16 hr. Sodium borohydride (5 eq.) was 
added in small portions over 60 mins and reaction mixture stirred for 4 hr. The 
reaction mixture was concentrated in vacuo, partitioned between EtOAc (80 mL) 
and water (80 mL), the organic layer was extracted with 0.5 M HCl(aq)  (5 × 30 mL) 
and the combined aqueous layers were neutralised by the addition of 2 M NH4OH 
(pH 10). The aqueous layer was then extracted with chloroform (5 × 20 mL), 
combined, dried (MgSO4), filtered and concentrated in vacuo then purified by 
column chromatography eluting with DCM–EtOH–NH4OH (84:14:2)85, to give the 
amino carabmate85 105 (0.27 g, 64%) as a colourless oil; Rf 0.35 (90:10 DCM–
MeOH); δH (500 MHz, CDCI3); 7.35-7.30 (4H, m, Ar), 7.26-7.21 (1H, m, Ar), 4.92 
(1H, bs, NH), 3.79 (2H, s, benzyl 1-H2), 3.24 (2H, t, J 5.5, ethyl 2-H2), 2.75 (2H, t, J 
5.5, ethyl 1-H2), 1.49 (1H, bs, NH), 1.44 (9H, s, Boc); δC (125 MHz, CDCI3); 156.1 
(C=O), 139.0 (Ar 1-C), 129.0 (Ar), 128.7 (Ar), 127.3 (Ar), 92.0 (Boc 2-C), 53.5 
(benzyl C-1), 47.5 (ethyl C-2), 40.6 (ethyl C-1), 28.5 (Boc 3-C); m/z (ES) 251.2; 
HRMS Found: 251.1752, (C14H22N2O2 MH
+ requires 251.1754). 
 
tert-Butyl-N-(2-ethylamino)carbamate (107)84  
According to the procedure84 di-tert-butyl dicarbonate  (2.3 g, 10.6 
mmol) was dissolved in DCM (200 mL) and added dropwise to the stirred solution 
of ethylene diamine (3.7 mL, 54.6 mmol) in DCM (200 mL) over 8 hr. The reaction 
mixture was left to stir for a further 12 hr and then concentrated in vacuo. The crude 
mixture was purified by flash chromatography, eluting with DCM–MeOH (90:10), 
to give the aminocarbonate84 107 (1.20 g, 71%) as a viscous yellow oil; Rf 0.10 
(90:10 DCM–MeOH); δH (500 MHz, CDCI3); 4.96 (1H, bs, NH), 3.17 (2H, d, J 5.4, 
2-H2), 2.81 (2H, t, J 5.4, 1-H2), 1.54 (2H, bs, NH2), 1.45 (9H, s, Boc); δC (125 MHz, 
CDCI3); 156.2 (C=O), 79.2 (Boc 2-C), 43.3 (2-C), 41.9 (1-C), 28.4 (Boc 3-C); 
νmax/cm-1 (film); 3358, 2977, 1698, 1526, 1256; m/z (ES) 161.1; HRMS Found: 
161.1293, (C7H16N2O2 MH
+ requires 161.1290). 
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(3E)-2-(Diallylamino)-4-phenylbut-3-en-1-ol (112)170  
 By General Method A1170, using diallylamine (0.32 mL, 2.6 
mmol), filtered through a silica plug, eluting with DCM–MeOH 
(90:10) gave the amino alcohol170 112 (0.44 g, 70%). Rf 0.25 (90:10 DCM–MeOH); 
δH (500 MHz, CDCl3); 7.38-7.35 (5H, m, Ar), 6.52 (1H, d, J 16.0, 4-H), 6.11 (1H, 
dd, J 16.0 and 7.6, 3-H), 5.85 (2H, ddd, J 18.2, 10.0, 5.5, allyl 2-H2), 5.17-5.27 (4H, 
m, allyl 3-H), 3.55-3.67 (3H, m, 1-H and 2-H), 3.42-3.39 (2H, m, allyl 1-HB), 3.25 
(1H, bs, OH), 2.99 (2H, dd, J 8.1, allyl 3-HA); δC (75 MHz, CDCl3); 136.5 (Ar), 
136.2 (4-C), 135.0 (allyl 2-C), 128.7 (Ar), 127.9 (Ar), 126.4 (Ar), 123.8 (3-C), 117.7 
(allyl 1-C), 62.3 (2-C), 61.0 (1-C), 52.4 (allyl 3-C); νmax/cm-1 (neat) 3401, 2159, 
1449 and 1032; m/z (ES) 244.2; HRMS Found: 244.1704, (C16H21NO MH
+ requires 
244.1696).  
 
(3E)-2-[(2-Hydroxyethyl)benzylamino)-4-phenylbut-3-en-1-ol (113) 
 By General Method A1, using N-benzylaminoethanol (0.240 mL, 
1.69 mmol), filtered by through a silica plug, eluting with DCM–
MeOH (90:10) gave the amino alcohol 113 (0.30 g, 63%) as a brown oil; Rf 0.30 
(90:10 DCM–MeOH); δH (500 MHz, CDCl3); 7.36-7.22 (10H, m, Ar), 6.44 (1H, d, J 
16.0, 4-H), 6.06 (1H, dd, J 16.0 and 9.0, 3-H), 3.80 (1H, d, J 6.0, benzyl HA), 3.74 
(1H, d, J 6.0, benzyl HB), 3.67-3.54 (2H, m, hydroxyethyl 2-H), 3.52-3.38 (2H, m, 
hydroxyethyl 1-H), 2.91 (1H, ddd, J 14.0, 9.0 and 4.8, 2-H), 2.77-2.71 (1H, m, 1-
HA), 2.56 (1H, dt, J 14.0 and 3.4, 1-HB), 2.34-2.15 (2H, bs, OH); δC (75 MHz, 
CDCl3); 136.5 (Ar), 134.7 (4-C), 128.7 (Ar), 128.4 (Ar), 128.1 (Ar), 127.9 (Ar), 
127.6 (Ar), 126.9 (Ar), 126.4 (Ar), 123.4 (3-C), 69.7 (benzyl 1-C) 63.9 (2-C), 61.8 
(1-C), 59.6 (hydroxyethyl 1-C), 51.9 (hydroxyethyl 2-C); νmax/cm-1 (neat); 3368, 
2159, 1452; m/z (ES) 298.2; HRMS Found: 298.1803, (C19H23NO2 MH
+ requires 
298.1802). 
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(3E)-2-[Bis(2-hydroxyethyl)amino]-4-phenylbut-3-en-1-ol (114) 
By General Method A1, using bis(hydroxyethyl)amine (0.17 mL, 
1.42 mmol), filtered by through a silica plug, eluting with DCM–
MeOH (90:10) gave the amino alcohol 114 (0.24 g, 53%) as a pale yellow oil; Rf 
0.15 (90:10 DCM–MeOH); δH (500 MHz, CDCl3); 7.25-7.35 (5H, m, Ar), 6.51 (1H, 
d, J 16.0, 4-H), 6.05 (1H, dd, J 16.0 and 8.4, 3-H), 4.05 (3H, bs, OH), 3.76 (2H, dd, 
J 10.8 and 2.8, 1-H2), 3.62 (4H, dd, J 11.5 and 4.6, hydroxyethyl 1-H), 3.56-7.52 
(1H, m, 2-H), 2.88 (2H, J 13.8, 10.3 and 3.3, hydroxyethyl 2-HA), 2.60 (2H, dt, J 
3.3, hydroxyethyl 2-HB); δC (75 MHz, CDCl3); 136.5 (Ar), 134.7 (4-C), 128.7 (Ar), 
127.9 (Ar), 126.4 (Ar), 123.4 (3-C), 63.9 (2-C), 61.8 (1-C), 59.6 (hydroxyethyl 1-C), 
51.9 (hydroxyethyl 2-C); νmax/cm-1 (neat); 3368, 2159, 2030, 1976, 1072, 1033; m/z 
(ES) 252.2; HRMS Found: 252.1595, (C14H21NO3 MH
+ requires 252.1594). 
 
(3E)-2-[(tert-Butylethylcarbamate)benzylamino]-4-phenylbut-3-en-1-ol 
(115) 
 By General Method A2, using tert-butyl-N-(2-
{benzylamino}ethyl) carbamate (0.2 g, 0.8 mmol) in DCE (1 
mL), filtered by through a silica plug, eluting with DCM–MeOH (90:10) gave the 
amino alcohol 115 (0.26 g, 86%) as a yellow oil. Rf 0.15 (90:10 DCM–MeOH); δH 
(500 MHz, CDCl3); 7.43-7.19 (10H, m, Ar), 6.58 (1H, d, J 16.0, 4-H), 6.01 (1H, dd, 
J 16.0, 7.6, 3-H), 3.68 (1H, dd, J 10.6, benzyl 1-HA), 3.47 (1H, d, J 10.6, benzyl 1-
HB), 3.36 (1H, td, J 7.6 and 4.0, 2-H), 3.24-3.18 (1H, bs, OH or NH), 2.95-2.87 (4H, 
m, ethyl 1-H2 and 2-H2), 2.85 (1H, dd, J 12.3 and 4.0, 1-HB), 2.71 (1H, dd, J 12.3 
and 4.0, 1-HA), 1.26 (9H, s, Boc), NH or OH not observed; δC (125 MHz, CDCl3); 
158.7 (C=O), 136.4 (Ar), 135.7 (Ar) 132.4 (4-C), 128.6 (Ar), 128.5 (Ar), 127.9 (Ar), 
127.7 (Ar), 127.2 (Ar), 126.5 (Ar), 117.3 (3-C), 74.9 (Boc 2-C), 66.4 (1-C), 64.5 (2-
C), 61.3 (ethyl 2-C), 59.4 (ethyl 1-C), 40.8 (benzyl), 28.4 (Boc 3-C); νmax/cm-1 
(neat); 3353 2976 1693 1518 1392 1252 1170; m/z (ES) 396.24. 
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(3E)-2-(Benzyl(methyl)amino)-4-phenylbut-3-en-1 -ol (116)170  
 By General Method A2170, using N-methylbenzylamine (0.18 mL, 
1.4 mmol), filtered by through a silica plug, eluting with DCM–
MeOH (90:10) gave the amino alcohol170 116 (0.30 g, 79%) as a brown oil;  Rf 0.15 
(90:10 DCM–MeOH); δH (500 MHz, CDCI3); 7.41 (2H, d, J 7.4, Ar), 7.35-7.31 (6H, 
m, Ar), 7.28 (2H, d, J 7.4, Ar), 6.57 (1H, d, J 16.0, 4-H), 6.20 (1H, dd, J 16.0 and 
9.2, 3-H), 3.77 (1H, d, J 13.0, benzyl 1-HB), 3.69 (1H, app t, J 10.4, 1-HA), 3.58 
(1H, dd, J 10.4 and 5.4, 1-HB), 3.54 (1H, d, J 13.0, benzyl 1-HA), 3.46 (1H, dd, J 9.2 
and 5.4, 2-H), 2.48 (1H, bs, OH), 2.27 (3H, s, methyl); δC (125 MHz, CDCl3); 141.5 
(Ar), 130.9 (4-C), 130.2 (Ar), 129.6 (Ar), 129.5 (Ar), 129.6 (Ar) 129.0 (Ar), 128.7 
(Ar), 127.1 (Ar), 115.1 (3-C), 67.5 (benzyl 1-C), 60.9 (2-C), 59.5 (1-C), 36.2 
(NMe); νmax/cm-1 (neat); 3306, 2959, 1650, 1458; m/z (ES) 268.2; HRMS Found: 
268.1700, (C18H21NO MH
+ requires 268.1696). 
 
(3E)-2-[(tert-Butylethylcarbamate)amino]-4-phenylbut-3-en-1-ol (117) 
 By General Method A2, using butyl-N-(2-
ethylamino)carbamate (0.27g, 1.7 mmol, in 1 mL of DCE), 
filtered by flash chromatography, eluting with DCM–MeOH (90:10) gave the amino 
alcohol 117 (0.37 g, 71%) as yellow oil; Rf 0.22 (90:10 DCM–MeOH); δH (500 
MHz, CDCI3); 7.32 (2H, d, J 7.5, Ar), 7.25 (2H, t, J 7.5, Ar), 7.18 (1H, t, J 7.5, Ar), 
6.48 (1H, d, J 16.0, 4-H), 5.95 (1H, dd, J 16.0 and 7.9, 3-H), 5.42 (1H, bs, NH), 
3.69-3.64 (2H, m, OH and 2-H), 3.48-3.46 (1H, m, ethyl 1-H), 3.33 (1H, d, J 5.0, 1-
H), 3.19-3.17 (2H, m, ethyl 2-H2), 2.76 (1H, dd, J 11.7 and 5.5, 1-HB), 2.61 (1H, dd, 
J 11.7 and 5.5, 1-HA), 1.42(1H, bs, NH), 1.39 (9H, s, Boc); m/z (ES) 307.3. 
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(3E)-2-(Benzylamino)-4-phenylbut-3-en-1-ol (118)171 
 By General Method A3171, using N-benzylamine (0.15 mL, 1.4 
mmol), DCE–HFIP (14 mL), filtered by through a silica plug, eluting 
with DCM–MeOH (90:10) gave the amino alcohol171 118 (0.25 g, 70%) yellow oil;  
Rf 0.18 (90:10 DCM–MeOH); δH (500 MHz, CDCl3); 7.39 (2H, d, J 7.4, Ar), 7.37-
7.26 (8H, m, Ar), 6.58 (1H, d, J 15.9, 4-H), 6.06 (1H, dd, J 15.9 and 8.0, 3-H), 4.16 
(1H, bs, NH), 3.93 (1H, d, J 13.2, benzyl 1-HB), 3.74 (1H, d, J 13.2, benzyl 1-HA), 
3.70 (1H, dd, J 10.1 and 4.5, 1-HA), 3.51 (1H, app t, J 10.1, 1-HB), 3.41 (1H, td, J 
8.0 and 4.5, 2-H), 2.48 (1H, bs, OH); δC (125 MHz, CDCl3); 136.5 (Ar), 133.0 (4-
C), 128.6 (Ar), 128.5 (Ar), 128.2 (Ar), 127.8 (Ar), 127.6 (Ar) 127.4 (Ar), 127.1 
(Ar), 126.4 (3-C), 64.9 (benzyl 1-C), 61.6 (2-C), 51.0 (1-C); νmax/cm-1 (film); 3335, 
2970, 2873, 1594, 1371, 1264; m/z (ES) 208.1; HRMS Found: 208.1335, (C17H19NO 
MH+ requires 208.1332). 
 
(3E)-2-[(2-Hydroxyethyl)amino]-4-phenylbut-3-en-1-ol (119) 
By General Method A3, using N-ethanolamine (0.12 mL, 2 
mmol), DCE–HFIP (14 mL), followed by flash chromatography, 
eluting with DCM–MeOH (90:10) gave the amino alcohol 119 (0.16 g, 39%) as 
yellow oil; Rf 0.15 (90:10 DCM–MeOH); δH (500 MHz, CDCl3); 7.28-7.25 (5H, m, 
Ar), 6.46 (1H, d, J 15.8, 4-H), 5.96 (1H, dd, J 15.8 and 8.1, 3-H), 3.65 (3H, app bs, 
hydroxyethyl 2-H, 1-HA), 3.50 (1H, d, J 13.5, 1-HB), 3.33 (1H, app bs, 2-H), 2.84 
(1H, d, J 4.3, hydroxyethyl 1-HA), 2.68 (1H, app bs, hydroxyethyl 2-HB), 2.40 (3H, 
bs, NH, OH and OH); δC (75 MHz, CDCl3); 136.5 (Ar), 133.3 (4-C), 128.7 (Ar), 
128.6 (Ar), 128.2 (Ar), 126.4 (3-C), 65.0 (1-C), 62.6 (2-C), 61.1 (hydroxyethyl 2-C), 
48.7 (hydroxyethyl 1-C); νmax/cm-1 (neat); 3368, 2159, 2030, 1976, 1072, 1033; m/z 
(ES) 208.1; HRMS Found: 208.1335, (C12H17NO2 MH
+ requires 208.1332).  
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(3E)-2-(But-3-enylamino)-4-phenylbut-3-en-1-ol (120) 
 By General Method A1, using N-butenylamine hydrochloride 
(0.25 g, 2.3 mmol) and Et3N (1 eq.) followed by SCX column, 
eluting with sat. NH3 in MeOH, gave the amino alcohol 120 (0.23 g, 46%) as a dark 
yellow oil. Rf 0.21 (90:10 DCM–MeOH); δH (500 MHz, CDCI3); 7.38 (2H, d, J 7.4, 
Ar), 7.32 (2H, t, J 7.4, Ar), 7.23 (1H, d, J 7.4, Ar), 6.55 (1H, d, J 15.9, 4-H), 6.03 
(1H, dd, J 15.9 and 7.9, 3-H), 5.79 (1H, ddt, J 17.2, 10.2 and 6.8, 3'-H), 5.10 (1H, 
dd, J 10.2 and 1.6, butenyl 4-HA), 5.06-5.04 (1H, m, butenyl 4-HB), 3.68 (1H, dd, J 
10.5 and 4.6, butenyl 2-HA), 3.46 (1H, dd, J 10.5 and 7.9, butenyl 2-HB), 3.35 (1H, 
dt, J 7.9 and 6.0, 2-H), 2.82 (1H, dt, J 11.5 and 6.0, 1-HA), 2.63 (1H, dt, J 11.5 and 
6.0, 1-HB), 2.29-2.26 (3H, m, 1'-H and NH or OH), 2.02 (1H, bs, NH or OH); δC (75 
MHz, CDCI3); 141.4 (Ar), 136.3 (4-C), 132.6 (butenyl 3-C), 129.0 (Ar), 128.6 (Ar), 
127.7 (Ar), 126.4 (3-C), 116.6 (butenyl 4-C), 64.8 (1-C), 62.3 (butenyl 2-C), 46.1 
(2-C), 34.5 (butenyl 1-C); νmax/cm-1 (neat); 3436, 1976, 1416; m/z (ES) 218.2; 
HRMS Found: 218.1537, (C14H19NO MH
+ requires 218.1539. 
2-[(Allyl)methylamino]-but-3-enyl acetate (122) 
 By General Method A4, using N-allylmethylamine (0.14 mL, 1.5 
mmol) the solvent was removed in vacuo after 48 hr. The crude material 
was dissolved in pyridine (1.5 mL), acetic anhydride (0.14 mL, 1.45 mmol) was 
added and the reaction mixture stirred at rt for 18 hr. The solvent was removed in 
vacuo followed by flash chromatography, eluting with DCM–MeOH (90:10) gave 
the amino acetate 122 (36 mg, 13%) as a dark brown oil; Rf 0.30 (90:10 DCM–
MeOH); δH (500 MHz, CDCI3); 5.98 (1H, dddd, J 17.1, 10.2, 7.7 and 6.1, allyl 2-H), 
5.81 (1H, ddd, J 17.4, 10.4 and 9.1, 3-H), 5.51 (1H, dd, J 10.2 and 1.1, allyl 3-HA), 
5.43-5.40 (2H, m, 4-H2), 5.38 (1H, dd, J 17.1 and 1.2, allyl 3-HB), 3.80 (1H, dd, J 
12.3 and 4.8, 1-HA), 3.77 (1H, dd, J 12.3 and 4.8, 1-HB), 3.65 (1H, td, J 8.5 and 4.8, 
2-H), 3.55 (1H, dd, J 13.3 and 6.1, allyl 1-HB), 3.35 (1H, dd, J 13.3 and 7.7, allyl 1-
HA), 2.59 (3H, s, NMe), 2.02 (3H, s, acetate methyl); δC (75 MHz, CDCI3); 177.0 
(C=O), 129.9 (allyl 2-C), 128.5 (3-C), 124.2 (allyl 3-C), 122.8 (3-C), 67.4 (2-C), 
60.8 (1-C), 56.9 (allyl 1-C), 36.5 (NMe), 22.2 (acetate methyl); νmax/cm-1 (neat); 
3326, 2928, 1714, 1580, 1413; m/z (ES) 183.4; Unable to observe MH+ in mass 
spectrometer. 
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2-[Bis(allyl)amino]but-3-en-1-ol (123) 
 By General Method A4, using diallylamine (0.19 mL, 2.5 mmol), 
filtered through a silica plug, eluting with Petrol–EtOAc (50:50) gave 
the amino alcohol 123 (0.25 g, 62%) as an orange oil;  Rf 0.20 (90:10 DCM–MeOH); 
δH (500 MHz, CDCl3); 5.78 (2H, ddd, J 17.3, 10.2 and 8.1, allyl 2-H2), 5.70 (1H, 
ddd, J 17.3, 10.5, 8.1 3-H), 5.29 (1H, dd, J 10.5, 4-H), 5.17-5.12 (5H, m, ally 3-H, 
4-HB), 3.55-3.53 (2H, m, allyl 1-HA), 3.48-3.45 (2H, m, allyl 1-HB), 3.43 (1H, bs, 
OH), 3.33 (2H, app d, J 14.2, 1-H2), 2.90 (1H, dd, J 14.2 and 8.1, 2-H). δC (75 MHz, 
CDCl3); 136.2 (4-C), 135.0 (allyl 2-C), 123.8 (3-C), 117.7 (allyl 1-C), 62.3 (2-C), 
61.0 (1-C), 52.4 (allyl 3-C); νmax/cm-1 (film); 2978, 2930, 1473, 1452, 1145 ; m/z 
(ES) 168.2; HRMS Found: 168.1382, (C10H17NO MH
+ requires 168.1383). 
 
2-[Benzyl(2-hydroxyethyl)amino]but-3-en-1-ol (124) 
 By General Method A4, using N-benzylaminoethanol (0.21 mL, 
1.5 mmol) followed by flash chromatography, eluting with DCM–
MeOH (90:10) gave the amino alcohol 124 (0.26 g, 71%) yellow oil; Rf 0.25 (90:10 
DCM–MeOH); δH (500 MHz, CDCl3); 7.42-7.10 (5H, m, Ar) 5.74 (1H, ddd, J 17.3, 
10.5 and 8.3, 3-H), 5.33 (1H, dd, J 10.5 and 1.3, 4-HB), 5.18 (1H, dd, J 17.3 and 1.3, 
4-HB), 3.85 (1H, d, J 13.7, 1-HA), 3.62 (2H, app t, J 10.7, benzyl 1-H2), 3.50 (1H, 
dd, J 13.7 and 5.4, 1-HB), 3.34-3.32 (1H, m, 2-H), 2.90 (2H, dd, J 14.0, 4.0, 
hydroxyethyl 1-H2), 2.56 (2H, dt, J 14.0 and 4.0, hydroxyethyl 2-H2); δC (125 MHz, 
CDCl3); 139.3 (Ar), 130.5 (3-C), 130.0 (Ar), 129.8 (Ar), 129.3 (Ar), 124.7 (4-C), 
64.7 (benzyl 1-C), 60.4 (1-C), 57.5 (hydroxyethyl 2-C), 53.8 (2-C), 50.1 
(hydroxyethyl 1-C). νmax/cm-1 (film); 3321, 2932, 2879, 1472, 1371, 1265, 1025; m/z 
(ES) 222.2; HRMS Found: 222.1493, (C13H19NO2 MH
+ requires 222.1489). 
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2-(Benzylamino)but-3-en-1-ol (125)172  
 By General Method A4, using N-benzylamine (0.16 mL, 1.5 mmol) 
followed by flash chromatography, eluting with DCM–MeOH (90:10) 
gave the amino alcohol172 125 as a yellow oil (68 mg, 39%); Rf 0.15 (90:10 DCM–
MeOH); δH (500 MHz, CDCl3); 7.51-7.23 (5H, m, Ar) 5.72 (1H, ddd, J 17.2, 10.1 
and 8.1, 3-H), 5.26-5.20 (2H, m, 4-H2), 3.92 (1H, d, J 13.1, benzyl HA), 3.69 (1H, d, 
J 13.1, benzyl HB), 3.62 (1H, dd, J 10.6 and 4.4, 1-HA), 3.44 (1H, dd, J 10.6 and 8.1, 
2-H), 3.26 (1H, dd, J 10.6 and 4.4, 1-HB), 3.18 (2H, bs, NH, OH); δC (125 MHz, 
CDCl3); 138.9 (Ar), 136.4 (4-C), 128.6 (Ar), 128.5 (Ar), 127.4 (Ar), 118.6 (3-C), 
64.3 (1’C), 62.2 (2-C), 50.7 (1-C); νmax/cm-1 (film); 3292, 2930, 2875, 1602, 1453, 
1371, 1009; m/z (ES) 178.2; HRMS Found: 178.1223, (C11H15NO MH
+ requires 
178.1226). 
 
(5S)-5-Benzyl-2,2-dimethyl-1,3-dioxolan-4-ol (130)173  
According to the procedure173 138 was dissolved in dry toluene (20 
mL) under an inert atmosphere (N2) and stirred at -78 °C. DIBAL 
(1M, 3.9 mL, toluene) was added over 10 minutes and the reaction left 
to stir for 30 minutes. 1 M HCl(aq) (4 mL) was added over 15 mins and the reaction 
allowed00 to warm to rt. Dilution with water (100 mL) and extraction with EtOAc 
(150 mL), dried (MgSO4), and filtered then concentrated in vacuo gave the protected
 
aldehyde173 (130) (0.38 g, 76%) as a yellow oil; Rf 0.20 (90:10 DCM–MeOH);  δH 
(300 MHz, CDCl3); 7.34-7.19 (10H, m, Ar), 5.26 (1H, dt, J 6.9 and 2.5, 4-H
Maj), 
5.22 (1H, dt, J 7.0 and 3.4, 4-HMin), 4.28 (1H, td, J 6.9 and 2.5, 5-HMaj), 4.21 (1H, td, 
J 7.0 and 3.4, 5-HMin), 3.04 (2H, bs, OH), 2.96 (2H, dd, J 14.0 and 7.0, benzyl 
H2
Maj), 2.89 (2H, dd, J 14.0 and 6.5, benzyl H2
Min), 1.57 (3H, s, MeMin), 1.51 (3H, 
MeMaj), 1.46 (3H, s, MeMin), 1.34 (3H, s, MeMaj). 
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 (5S)-5-Benzyl-2,2-dimethyl-1,3-dioxolan-4-one (138)173  
According to literature procedure173 L-3-phenyllactic acid (0.54g, 3 
mmol) was added to a solution of p-toluenesulfonic acid (30 mg), 2,2-
dimethoxypropane (3 mL) in acetone (20 mL) and stirred at rt for 17 hr. 
The reaction mixture was concentrated in vacuo then dissolved in EtOAc (30 mL). 
This was washed with NaHCO3 (3 × 10 mL), brine (3 × 10mL), dried (MgSO4), and 
filtered through a plug of silica eluting with DCM–MeOH (90:10) to give the 
protected acid173 138 (0.54 g, 84%) as an amorphous solid; Rf 0.25 (90:10 DCM–
MeOH); δH (300 MHz, CDCl3); 7.33-7.08 (5H, m, Ar), 4.58 (1H, dd, J 6.3 and 4.2, 
5-H), 3.11 (1H, dd, J 14.5 and 4.2, benzyl 1-HA), 2.97 (1H, dd, J 14.5 and 6.3, 
benzyl 1-HB), 1.41 (3H, s, Me), 1.27 (3H, s, Me); δC (75 MHz, CDCl3); 151.5 
(C=O), 135.8 (Ar), 129.8 (Ar), 128.4 (Ar), 127.1 (Ar), 75.0 (benzyl 1-C), 37.7 (2C), 
26.9 (Me), 26.2 (Me); m/z (ES) 229.1; HRMS Found: 229.0825, (C12H14O3 MH
+ 
requires 229.0835). 
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 (3E)-2-[(1-Phenylethyl)amino]-4-phenyl-but-3-en-1-ol (139) 
 By General Method A2, using (R)-N-methybenzylamine (0.18 
mL, 1.4 mmol), filtered through a silica plug, eluting with DCM–
MeOH (90:10) and SCX column, eluting with sat. NH3 in MeOH gave the amino 
alcohol 139 (0.15 g, d.r. 50:50, 41%) as a dark brown amorphous solid; Rf 0.10 
(90:10 DCM–MeOH); δH (500 MHz, CDCl3); 7.32-7.17 (20H, m, Ar), 6.39 (1H, d, J 
15.8, 4-HDias A), 6.29 (1H, d, J 16.0, 4-HDias B), 5.90 (2H, ddd, J 16.4, 9.1 and 7.8, 3-
HDias A and B), 3.93 (2H, q, J 10.9 and 6.8, ethyl 1-HDias A and Dias B), 3.65–3.57 (1H, m, 
1-HA 
Dias B), 3.57–3.44 (1H, m, 1-HA Dias A), 3.38-3.31 (3H, m, 1-HB Dias B, 2-HDias A 
and 1-HB
Dias A), 3.04 (1H, dq, J 8.5 and 4.6, 2-HDias A), 2.08 (4H, bs, NH and OHDias A 
and B),1.30 (3H, d, J 5.0, ethyl 2-H3
Dias A), 1.29 (3H, d, J 5.1, ethyl 2-H3
Dias); δC (75 
MHz, CDCl3); 138.6 (4-C
 Dias B), 137.2 (4-C Dias A), 129.7 (Ar Dias A), 129.5 (Ar Dias B), 
129.2 (Ar Dias A), 129.1 (Ar Dias A), 129.0 (Ar Dias B), 128.8 (Ar Dias B), 128.7 (Ar Dias A), 
128.6 (Ar Dias B) 128.5 (Ar Dias A), 127.5 (Ar Dias B), 127.1 (Ar Dias B), 128.4 (Ar Dias A), 
127.9 (Ar Dias A), 127.6 (Ar Dias B), 127.1 (Ar Dias B), 127.0 (Ar Dias A), 120.2 (3-C Dias A), 
119.3 (3-C Dias B), 64.1 (ethyl 2-C Dias B), 63.5 (ethyl 2-C Dias A), 58.5 (1-C Dias A), 57.1 
(1-C Dias B), 43.5 (2-C Dias A + 2-C Dias B), 21.4 (ethyl 2-CDias A), 19.1 (ethyl 2-CDias B); 
νmax/cm-1 (neat); 3340, 3053, 2983, 1265, 736; m/z (ES) 168.2; HRMS Found: 
268.1697, (C18H21NO MH
+ requires 268.1696). 
Reaction was performed with (S)- N-methybenzylamine (0.18 mL, 1.4 mmol), 
filtered through a silica plug, eluting with DCM–MeOH (90:10) and SCX column, 
eluting with sat. NH3 in MeOH gave the amino alcohol 140 (0.15 g, 35%) as a dark 
brown amorphous solid. Data collected was identical to that obtained above. 
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(3E)-2(R)-{[(2S)-2-Hydroxy-1-methylethyl)]amino}-4-phenylbut-3-en-1-ol 
(141) 
 By General Method A1, using (S)-2-amino-1-propanol (0.14 mL, 
1.5 mmol)  followed by flash chromatography, eluting with DCM–
MeOH (90:10) gave the amino alcohol 141 (0.209 g, d.r. 75:25, 53%) (brown oil); 
Rf 0.15 (90:10 DCM–MeOH); δH (500 MHz, CDCI3); 7.38 (1H, d, J 7.5, Ar), 7.32-
7.30 (2H, m, Ar), 7.26 (2H, m, Ar), 6.56 (1H, d, J 15.9, 4-H ), 6.07 (1H, dd, J 15.9 
and 7.8, 3-H), 3.68 (1H, dd, J 10.8 and 4.5, 1-HA), 3.62 (1H, dd, J 10.8 and 4.5, 1-
HB), 3.52 (1H, dd, J 10.6 and 7.2, propanyl 1-HB), 3.47 (1H, dd, J 7.8 and 4.5, 2-H), 
3.36 (1H, dd, J 10.6 and 5.6, propanyl 1-HA), 2.95-2.91 (1H, m, propanyl H
Min), 
1.88 (3H, bs, NH, OH and OH), 1.12 (3H, d, J 6.6, propanyl 3-H); νmax/cm-1 (film); 
3380, 2987, 1607; m/z (ES) 222.2; HRMS Found: 222.1484, (C13H19NO2 MH
+ 
requires 222.1489). 
(3E)-2(S)-{[(2R)-2-Hydroxy-1-phenylethyl]amino}-4-phenylbut-3-en-1-ol (142) 
 By General Method A1, using N-phenylglycinol (0.20 g, 1.5 
mmol) followed by flash chromatography, eluting with DCM–
MeOH (90:10) gave the amino alcohol 142 (0.24 g, d.r. ≥95:≤5, 
58%) as brown amorphous solid; Rf 0.25 (90:10 DCM–MeOH); δH (500 MHz, 
CDCl3); 7.38 (2H, d, J 7.5, Ar), 7.32 (3H, m, Ar), 7.26 (5H, m, Ar), 6.56 (1H, d, J 
16.0, 4-H), 6.07 (1H, dd, J 16.0 and 7.6, 3-H), 3.68 (1H, dd, J 10.6 and 4.5, 1-HA), 
3.62 (1H, dd, J 10.6 and 4.5, 1-HB), 3.52 (1H, dd, J 10.8 and 7.2, 
hydroxyphenylethyl 1-H), 3.47 (1H, dd, J 7.6 and 4.4, 2-H), 3.36 (1H, dd, J 10.8 and 
5.6, hydroxyphenylethyl 2-HB), 2.97-2.92 (1H, m, hydroxyphenylethyl 2-HA), 1.88 
(1H, s, NH), 1.12 (2H, bs, OH). δC (75 MHz, CDCl3); 139.9 (Ar 1-C), 136.4 (Ar), 
133.6 (4-C), 129.7 (Ar), 128.8 (Ar), 128.5 (Ar), 128.0 (Ar), 127.8 (Ar), 127.7 (Ar), 
126.4 (3-C), 126.3 (3-C), 69.4 (hydroxyphenylethyl 1-C), 67.3 (hydroxyphenylethyl 
1-C), 66.5 (2-C), 61.7 (1-C), 61.1 (1-C), 60.2 (hydroxyphenylethyl 2-C); νmax/cm-1 
(neat); 3060, 2975, 2925, 1531, 1265, 1025; m/z (ES) 284.2. 
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(3E)-(2R)-[(2S)-2-(Carboxylic acid)pyrrolidine]-4-phenylbut-3-en-1-ol (143) 
 By General Method A2, using L-proline (0.16 g, 1.4 mmol) 
followed by flash chromatography, eluting with H2O–iPr–EtOH 
(45:33:22) gave the amino acid 143 (0.19 g, d.r. ≥95:≤5, 52%) as a clear oil; Rf 0.15 
(90:10 DCM–MeOH); δH (500 MHz, CDCI3); 7.46 (2H, d, J 7.5, Ar), 7.42 (2H, d, J 
7.5, Ar), 7.31 (1H, t, J 7.5, Ar), 6.78 (1H, d, J 15.9, 4-H), 6.06 (1H, dd, J 15.9 and 
7.6, 3-H), 4.20 (1H, d, J 10.4, pyrrolidine 2-H), 4.17 (1H, dd, J 8.4 and 3.4, 1-HA), 
3.86-3.79 (2H, m, 2-H and 1-HB), 3.59 (1H, dd, J 10.4 and 6.6, pyrrolidine 3-HA), 
2.99 (1H, ddd, J 12.9, 10.4 and 6.6, pyrrolidine 3-HB), 2.44 (1H, dd, J 12.9 and 6.4, 
pyrrolidine 5-HB), 1.98-1.92 (1H, m, pyrrolidine 5-HA), 1.85 (1H, dd, J 12.9 and 6.4, 
pyrrolidine 4-HB), 1.71 (1H, dd, J 12.9 and 6.4, pyrrolidine 4-HA), 1.25 (2H, bs, 
OH); δC (125 MHz, CDCI3); 173.8 (C=O), 141.4 (Ar), 134.8 (4-C), 127.7 (Ar-C), 
127.0 (Ar-C), 126.7 (Ar-C), 115.9 (3-C), 70.8 (2-C), 66.0 (1-C), 61.7 (pyrrolidine 2-
C), 56.7 (pyrrolidine 3-C), 30.1 (pyrrolidine 5-C), 23.6 (pyrrolidine 4-C); νmax/cm-1 
(neat); 3055, 1739, 1265; m/z (ES) 262.2; HRMS Found: 262.1435, (C15H19NO3 
MH+ requires 262.1438). 
(3E)-(2R)-[(2S)-2-(Hydroxymethyl) pyrrolidine]-4-phenylbut-3-en-1-ol 144 
By General Method A3, using L-prolinol (0.16 g, 1.4 mmol), 
DCE–HFIP (14 mL) ,filtered through a silica plug, eluting with 
EtOAc gave the amino alcohol 144 (0.19 g, d.r. 89:11, 68%) as a brown oil; Rf 0.20 
(90:10 DCM–MeOH)δH (500 MHz, CDCI3); 7.40 (2H, d, J 7.5, Ar), 7.42 (2H, d, J 
7.5, Ar), 7.31 (1H, t, J 7.5, Ar), 6.78 (1H, d, J 16.0, 4-H), 6.06 (1H, dd, J 16.0 and 
7.6, 3-H), 4.05-3.98 (3H, m, 1-HA, and hydroxymethyl H2), 3.86-3.76 (2H, m, 2-H 
and 1-HB), 2.99 (1H, ddd, J 12.4, 10.9 and 6.4, pyrrolidine 3-HB), 2.84-2.79 (1H, m, 
pyrrolidine 2-H) 2.38 (1H, dd, J 11.6 and 6.9, pyrrolidine 5-HB), 1.98-1.92 (1H, m, 
pyrrolidine 5-HA), 1.89-1.81 (1H, m, pyrrolidine 3-HA), 1.78 (1H, dt, J 12.4 and 6.5, 
pyrrolidine 4-HB), 1.73 (1H, dt, J 12.4 and 6.5, pyrrolidine 4-HA), 1.35 (2H, bs, 
OH); δC (125 MHz, CDCI3); 136.5 (Ar), 135.2 (4-C), 128.7 (Ar-C), 127.9 (Ar-C), 
126.4 (Ar-C), 123.7 (3-C), 63.4 (2-C), 63.7 (hydroxymethyl 1-C) 61.7 (1-C), 61.4 
(pyrrolidine 2-C), 46.5 (pyrrolidine 5-C), 27.7 (pyrrolidine 3-C), 24.6 (pyrrolidine 4-
C); νmax/cm-1 (neat); 3053, 2970, 1612, 1454; m/z (ES) 248.2; HRMS Found: 
248.1643, (C15H21NO2 MH
+ requires 248.1645). 
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(2S)-{[(1R)-2-Hydroxy-1-phenylethyl]amino}-but-3-en-1-ol (145) 
By General Method A4, using N-phenylglycinol (0.20 g, 1.5 mmol) 
followed by flash chromatography, eluting with DCM–MeOH (90:10) 
then DCM–EtOH–NH4OH (85:15:1) gave the amino alcohol 145 (0.24 g, d.r. 83:17, 
44%) as brown amorphous solid; Rf 0.10 (90:10 DCM–MeOH); δH (500 MHz, 
CDCl3); 7.37-7.33 (6H, m, Ar
Maj, Min), 7.29 (4H, m, J 7.5, ArMaj, Min), 5.69 (1H, ddd, 
J 17.3, 10.4, 6.6, 3-HMin), 5.60 (1H, ddd, J 17.1, 10.4, 8.4, 3-HMaj), 5.25 (1H, d, J 
17.1, 4-HA
Maj), 5.23 (1H, d, J 17.3, 4-HA
Min), 5.16 (1H, d, J 10.4, 4-HB
Min), 5.13 (1H, 
d, J 10.3, 4-HB
Maj), 3.93 (1H, dd, J 8.9 and 4.5, hydroxyphenylethyl 1-HMaj), 3.89 
(1H, dd, J 6.8 and 4.9, hydroxyphenylethyl 1-HMin),  3.76 (1H, dd, J 10.9 and 4.9, 
hydroxyphenylethyl 2-HA
Min), 3.66-3.63 (2H, m, 1HB
Maj and hydroxyphenylethyl 2-
HB
Min), 3.59 (1H, dd, J 10.6 and 4.5, 1HA
Maj), 3.55 (1H, dd, J 10.6 and 4.5, 
hydroxyphenylethyl 2-HB
Maj), 3.47-3.43 (2H, m, 1-H2
Min), 3.41 (1H, dd, J 10.6 and 
8.9, hydroxyphenylethyl 2-HA
Maj), 3.29 (1H, dd, J 12.0 and 6.6, 2-HMin), 3.09 (1H, 
app dd, J 8.4 and 4.5, 2-HMaj), 2.12 (3H, bs, 3 × NH or OH), 3 × NH or OH not 
observed; δC (125 MHz, CDCl3) 140.0 (Ar 1-CMaj), 141.1 (Ar 1-CMin), 137.7 (3-
CMin), 136.7 (3-CMaj), 128.7 (ArMaj), 128.6 (ArMin), 127.7 (ArMin), 127.6 (ArMaj), 
127.5 (ArMaj), 127.2 (ArMin), 118.5 (4-CMaj), 117.0 (4-C), 67.1 (hydroxyphenylethyl 
1-CMaj), 66.4 (hydroxyphenylethyl 1-CMin), 65.3 (2-CMaj), 64.0 (2-CMin), 61.7 (1-
CMin), 61.0 (1-CMaj), 60.4 (hydroxyphenylethyl 1-CMin), 59.6 (hydroxyphenylethyl 1-
CMaj); νmax/cm-1 (neat); 3082, 2980, 1602, 1454, 1264; m/z (ES) 208.2; HRMS 
Found: 208.1329, (C12H17NO2 MH
+ requires 208.1332). 
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2-[(2S)-2-(Hydroxymethyl)pyrrolidin-1-yl]-but-3-en-1-ol (146) 
By General Method A4, using (S)-(+)-2-Pyrrolidinemethanol (0.13 
mL, 2 mmol), filtered through a silica plug, eluting with DCM–MeOH 
(90:10) gave the amino alcohol 146 (0.15 g, d.r. 50:50, 43%); Rf 0.05 (90:10 DCM–
MeOH); δH (500 MHz, CDCI3); 5.80 (2H, m, 3-HDais 1 and Dias 2), 5.50 (1H, d, J 15.9 
4-HA
Dias1), 5.43(1H, d, J 15.7 4-HA
Dias 2), 5.35 (2H, m, 4HB H
Dais 1 and Dias 2), 4.17 (2H, 
dd, J 8.4 and 3.4, 1-HA), 3.86 (5H, m, 2-H
 Dais 1 and Dias 2and 1-HB
 Dais 1 and Dias 21-HA
 
Dias 2), 3.59 (1H, dd, J 10.4 and 6.6, pyrrolidine 3-HA
Dias 1), 3.59 (1H, dd, J 9.5 and 
6.8, pyrrolidine 3-HA
Dias 2), 3.20 (4H, m, pyrrolidine 2-HDais 1 and Dias 2), 2.99 (2H, m, 
pyrrolidine 3-HB
 Dais 1 and Dias 2), 2.44 (1H, dd, J 12.9 and 6.4, pyrrolidine 5-HB
Dais 2), 
2.45 (2H, dd, J 12.9 and 7.1, pyrrolidine 5-HB
Dais 1), 1.98-1.92 (2H, m, pyrrolidine 5-
HA), 1.87-1.86 (2H, m, pyrrolidine 4-HB
 Dais 1 and Dias 2), 1.74-1.71 (2H, m, pyrrolidine 
4-HA
Dias 1 and Dias 2), 1.25 (4H, bs, OH); δC (125 MHz, CDCI3); 134.5 (3-C Dais 1), 
134.8 (3-C Dias 2), 118.9 (4-C Dais 1), 117.7 (4-C Dias 2), 68.8 (2-C Dais 1), 70.8 (2-C Dias 
2), 66.2 (1-C Dais 1), 64.9 (1-C Dias 2), 62.4 (hydroxymethyl 1-C Dais 1), 61.4 
(hydroxymethyl 1-C Dias 2), 56.7 (pyrrolidine 3-C Dais 1), 55.7 (pyrrolidine 3-C Dias 2), 
48.9 (pyrrolidine 2-C Dais 1), 50.4 (pyrrolidine 2-C Dias 2), 30.6 (pyrrolidine 5-C Dais 1), 
30.5 (pyrrolidine 5-C Dias 2), 23.6 (pyrrolidine 4-CDias 1 and Dias 2); νmax/cm-1 (neat); 
3054, 2982, 1421, 1264; m/z (ES) 172.1; HRMS Found: 172.1332, (C9H17NO2 MH
+ 
requires 172.1332). 
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 (4E)-3-[(Allyl)methylamino]-1,5-diphenylpent-4-en-2-ol (147) 
 By General Method A3, using (5S)-5-benzyl-2,2-dimethyl-1,3-
dioxolan-4-ol (0.19 g, 0.9 mmol), N-methylallylamine (1 mmol), 
DCE–HFIP (14 mL), filtered through a silica plug, eluting with hexane then DCM–
MeOH (90:10) gave the amino alcohol (147) (0.20 g, d.r. ≥95:≤5, 72%) as a brown 
oil; Rf 0.35 (90:10 DCM–MeOH); δH (500 MHz, CDCl3); 7.43 (2H, d, J 7.5, Ar), 
7.35 (3H, t, J 7.5, Ar), 7.32-7.22 (5H, m, Ar), 6.50 (1H, d, J 16.0, 5-H), 6.31 (1H, 
dd, J 16.0 and 10.0, 4-H), 5.83 (1H, ddt, J 16.6, 10.2 and 6.5, allyl 2-H), 5.19-5.12 
(2H, m, allyl 3-H2), 4.19 (1H, dd, J 14.0 and 5.5, 1-HA), 3.24 (1H, dd, J 14.0 and 
5.5, 1-HB), 3.11 (1H, dd, J 10.0 and 5.5, 2-H), 2.94 (1H, dd, J 9.1 and 5.0, 3-H), 2.77 
(2H, d, J 6.5, allyl 1-H2), 2.31 (3H, s, Me), 1.66 (1H, bs, OH); δC (125 MHz, 
CDCl3); 138.5 (5-C), 136.3 (allyl 3-C), 134.3 (Ar), 133.8 (Ar),  129.3 (Ar), 128.7 
(Ar), 128.4 (Ar), 128.1 (Ar), 126.6 (Ar), 126.3 (Ar) 117.4 (4-C), 115.3 (allyl 3-C), 
71.1 (1-C), 70.5 (2-C), 57.8 (3-C), 40.4 (allyl 1-C), 39.0 (NMe); νmax/cm-1 (neat); 
3055, 2932, 1722, 1493, 1057; m/z (ES) 308.4; HRMS Found: 308.2024, (C21H25NO 
MH+ requires 308.2009). 
N-(2-Aminoethyl)-2-nitrobenzene-1-sulfonamide (148)90 
 According to the procedure90 Et3N (1.5 mL, 15 mmol) was added to a 
suspension of ethylene diamine (0.5 mL, 7.5 mmol) in DCM (20 mL). 
The suspension was stirred for 10 min until it became a clear solution, after which 2-
nitrophenylsulphonylchloride (1.7 g, 7.7 mmol) was added. The reaction mixture 
was stirred at rt for 16 hr and then diluted with DCM (100 mL) and water (100 mL). 
The phases were separated and the aqueous phase was extracted with DCM (3 × 100 
mL). The combined organic phase was washed with sat. NaHCO3(aq) (15 mL), water 
(15 mL) and brine (15 mL), dried (MgSO4), filtered and concentrated in vacuo to 
give the amine174 148 (0.78 g, 43%) as an yellow oil; Rf 0.05 (90:10 DCM–MeOH); 
δH (500 MHz, MeOD); 8.03-8.00 (1H, m, Ar), 7.80-7.78 (1H, m, Ar), 7.76-7.73 (2H, 
m, Ar), 3.21 (2H, t, J 6.0, 2-H2), 3.01 (2H, t, J 6.0, 1-H2); δC (75 MHz, MeOD) 
149.5 (Ar C-2), 135.5 (Ar C-1), 133.7 (Ar), 133.6 (Ar), 131.7, (Ar) 126.2 (Ar), 41.4 
(C-2), 40.6 (C-1); νmax/cm-1 (neat); 3736, 3650, 2918, 1541, 1275; m/z (ES) 268.1; 
HRMS Found: 268.0359, (C8H11N3O4S MH
+ requires 268.0362). 
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N-(2-{[(2-Bromophenyl)methyl]amino}ethyl)-2-nitrobenzene-1-sulfonamide 
(149) 
N-(2-aminoethyl)-2-nitrobenzene-1-sulfonamine (148) (0.43 g, 
1.72 mmol) was added to 2-bromobenzaldehyde (0.6 ml, 5.5 
mmol) in ethanol (15 mL) and stirred at 79 °C for 4 hr. Sodium borohydride (5 eq.) 
was added in small portions over 60 mins and reaction mixture stirred for 4 hr. The 
reaction mixture was concentrated in vacuo, partitioned between EtOAc (40 mL) 
and water (40 mL). The organic layer was then extracted with 0.5 M HCl(aq) (5 × 30 
mL) and the combined aqueous layers were neutralised by the addition of 2 M 
NH4OH. The aqueous layer was then extracted with DCM (5 × 20 mL), combined, 
dried (MgSO4), filtered and concentrated in vacuo and purified by column 
chromatography eluting with DCM–EtOH–NH4OH (84:14:2) to give the amino 
alcohol175 149 (0.41 g, 57%); Rf 0.10 (90:10 DCM–MeOH); δH (500 MHz, CDCl3); 
δC (125 MHz, MeOH);  8.30 (2H, d, J 8.7, Ns), 8.05 (2H, d, J 8.7, Ns), 7.55 (1H, d, 
J 7.5, Ar), 7.37 (1H, d, J 7.5, Ar), 7.29 (1H, t, J 7.5, Ar), 7.13 (1H, d, J 7.5, Ar), 
3.89 (2H, s, benzyl H2), 3.67 (2H, dd, J 5.5 and 4.9, 1-H2), 2.79 (2H, dd, J 5.5 and 
4.9, 2-H2), 2.35; δC (75 MHz, MeOH); 149.2 (Ns), 136.49 (Ns), 132.8 (Ns), 132.7 
(Ns), 128.84 (Ns), 138.8 (Ar C-2), 132.9 (Ar C-1), 130.4 (Ar), 128.8 (Ar), 126.2 
(Ns), 124.1 (Ar), 111.6 (Ar), 60.7 (benzyl 1-C), 53.2 (C-1), 50.3 (C-2); νmax/cm-1 
(neat); 3392, 2938, 1439, 1275; m/z (ES) 416.02 and 418.02. 
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tert-Butyl N-{2-[(2-hydroxyethyl)amino]ethyl}carbamate (150)176 
Et3N (0.48 mL, 3.47 mmol) was added to a suspension of N-(2-
hydroxyethyl)ethylene diamine (0.28 mL, 2.60 mmol) in DCM 
(10 mL). The suspension was stirred for 10 min, after which di-tert-butyl 
dicarbonate (0.38 g, 1.73 mmol) was added. The reaction mixture was stirred at rt 
for 16 hr and then diluted with DCM (10 mL) and water (10 mL). The phases were 
separated and the aqueous phase was extracted with DCM (3 × 10 mL). The 
combined organic phase was washed with sat. NaHCO3(aq) (15 mL) and brine (15 
mL),  dried (MgSO4) and concentrated in vacuo and purified by column 
chromatography  eluting with DCM–EtOH–NH4OH (84:14:2) to give the amine 
alcohol176 150 (0.21 g, 60%) as an amorphous colourless solid; Rf 0.10 (90:10 
DCM–MeOH); δH (500 MHz, CDCl3); 4.97 (1H, bs, NH or OH), 3.66 (2H, m, 
hydroxyethyl 2-H2), 3.23 (2H, dd, J 11.2 and 5.6, 2-H2), 2.78 (4H, m, 1-H2, 
hydroxyethyl 1-H2), 2.07 (2H, bs, NH or OH) 1.47 (9H, s, Boc); δC (75 MHz, 
CDCl3); 156.2 (C=O), 80.6 (Boc 2-C), 61.0 (2-C), 50.7 (hydroxyethyl 2-C), 48.9 
(hydroxyethyl 1-C), 40.4 (1-C), 28.4 (Boc 3-C); νmax/cm-1 (neat); 3329, 2976, 2932, 
1692, 1529, 1366, 1279, 1172; m/z (ES) 205.2; HRMS Found: 205.1555, 
(C9H20N2O3 MH
+ requires 205.1567). 
2-[(But-3-en-1-yl)amino]hydroxyethyl-1-ol (152)91 
 According to the procedure91 sodium iodide (55 mg, 0.37 mmol) 
was added to a solution of 4-bromo-1-butene (0.50 g, 3.7 mmol) 
and 2-aminoethanol (0.89 mL, 18.53 mmol) in MeOH (8 mL). The reaction mixture 
was heated under reflux for 2 hr, then cooled to rt and evaporated in vacuo. The 
residue was partitioned between sat. NH4Cl(aq) (20 mL) and EtOAc (20 mL). The 
aqueous layer was made basic with 40% sodium hydroxide and extracted with 
EtOAc (3 × 15 mL). The combined organic layers were dried (MgSO4) and 
concentrated in vacuo to afford the amino alcohol91 152 (0.20 g, 54%) as a 
colourless oil; Rf 0.10 (90:10 DCM–MeOH); δH (500 MHz, CDCl3); 5.79 (1H, ddt, J 
17.2, 10.1 and 6.7, butenyl 3-H), 5.10 (1H, d, J 17.2, butenyl 4-HA), 5.05 (1H, d, J 
10.1, butenyl 4-HB), 3.64 (2H, dd, J 5.5 and 4.9, hydroxyethyl 2-H2), 2.78 (2H, dd, J 
5.5 and 4.9, hydroxyethyl 1-H2), 2.70 (2H, app t, J 6.7, butenyl 2-H2), 2.26 (2H, dd, 
J 13.6 and 6.7, butenyl 1-H2), 1.82 (2H, bs, NH, OH); m/z (ES) 116.2. 
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2-[(tert-Butylethylcarbamate)2-hydroxyethylamino]but-3-en-1-ol (156) 
 By General Method A4, using amine 150 (70 mg, 0.3 mmol) 
followed by SCX column and flash chromatography, eluting 
with DCM–EtOH–NH4OH (84:14:2), gave the amino alcohol 156 (30 mg, 30%) as a 
brown oil;  Rf 0.20 (90:10 DCM–MeOH); δH (500 MHz, MeOD); 5.64 (1H, ddd, J 
17.5, 10.6 and 8.1, 3-H), 5.16 (1H, d, J 10.6, 4-HA), 5.10 (1H, d, J 17.5, 4-HB), 3.50-
3.45 (2H, m, hydroxyethyl 2-H), 3.42-3.39 (2H, m, 1-H2), 3.38 (1H, dd, J 8.1 and 
5.4, 2-H), 3.20-3.17 (2H, m, ethylcarbamate 2-H2), 3.02-2.97 (2H, m, hydroxyethyl 
1-H2), 2.72-2.65 (2H, m, ethylcarbamate 1-H2), 2.62 (1H, bs, NH), 2.46 (2H, bs, 
OH), 1.32 (9H, s, Boc); δC (75 MHz, MeOD); 158.7 (C=O), 134.9 (hydroxybutene 
3-C), 119.5 (hydroxybutene 4-C), 80.9 (Boc 2-C), 67.0 (ethylcarbamate 2-C), 63.2 
(ethylcarbamate 1-C), 61.4 (hydroxybutene 2-C), 54.1 (hydroxyethyl 2-C), 52.4 
(hydroxybutene 1-C), 49.6 (hydroxyethyl 1-C), 28.9 (Boc 3-C); νmax/cm-1 (neat); 
3335, 3053, 2873, 1454, 1264; m/z (ES) 276.2. 
 (3E)-2-(Allylamino)-4-phenylbut-3-en-1-ol (157) 
 By General Method A3, using allylamine (0.15 mL, 1.69 mmol) 
filtered through a silica plug, eluting with DCM–MeOH (90:10) 
gave the amino alcohol 157 (0.34 g, 64%) as a yellow oil; Rf 0.10 (90:10 DCM–
MeOH); δH (500 MHz, CDCl3); 7.30 (2H, d, J 7.5, Ar), 7.23 (2H, t, J 7.5, Ar), 7.16 
(1H, t, J 7.5, Ar), 6.49 (1H, d, J 16.0, 4-H), 5.94 (1H, dd, J 16.0 and 8.8, 3-H), 5.83 
(1H, dddd, J 17.0, 10.3, 6.3 and 4.7, allyl 2-H), 5.12 (1H, dd, J 17.0 and 1.3, allyl 3-
HA), 5.0 (1H, dd, J 10.3 and 1.3, allyl 3-HB), 3.64 (1H, dd, J 10.6 and 4.4, 1-HA), 
3.43 (1H, dd, J 10.6 and 8.0, 1-HB), 3.31-3.25 (2H, m, 2-H and allyl 1-HA), 3.12 
(1H, d, J 6.3, allyl 1-HB), 2.37 (2H, bs, NH and OH); δC (75 MHz, CDCl3); 149.5 
(Ar), 136.6 (4-C), 132.9 (allyl 2-C), 128.6 (Ar), 128.6 (Ar), 128.6 (Ar), 127.8 (3-C), 
116.17 (allyl 3-C), 64.9 (1-C), 61.7 (2-C), 49.6 (allyl 1-C); νmax/cm-1 (neat); 3436, 
2927, 1642, 1416; m/z (ES) 204.2; HRMS Found: 204.1387, (C13H17NO MH
+ 
requires 204.1383). 
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(3E)-2-[(But-3-en-1-yl)-2-hydroxyethylamino]-4-phenylbut-3-en-1-ol (158) 
By General Method A3, using amine 152 (0.20 g, 1 mmol), 
followed by flash chromatography, eluting with DCM–MeOH 
(90:10) gave the amino alcohol 158 (0.21 g, 62%) as a yellow oil; Rf 0.25 (90:10 
DCM–MeOH); δH (500 MHz, CDCl3); 7.36 (2H, d, J 7.5, Ar), 7.31 (2H, t, J 7.5, 
Ar), 7.25 (1H, d, J 7.5, Ar), 6.52 (1H, d, J 16.0, 4-H), 6.10 (1H, dd, J 16.0 and 8.4, 
3-H), 5.81 (1H, ddt, J 17.2, 10.2 and 6.6, butenyl 3-H), 5.11 (1H, d, J 17.2, butenyl 
4-HA), 5.07 (1H, d, J 10.2, butenyl 4-HB), 3.69-3.55 (4H, m, 1-H, hydroxyethyl 2-
H), 3.52-3.45 (1H, m, 2-H), 2.86 (1H, dt, J 13.6 and 9.2, hydroxyethyl 1-HA), 2.70 
(1H, dt, J 13.6 and 7.8, hydroxyethyl 1-HB), 2.65 (1H, dd, J 13.2 and 6.6, butenyl 2-
HA), 2.59 (1H, dt, J 13.2 and 6.6, butenyl 2-HB), 2.45 (2H, bs, OH), 2.26 (2H, d, J 
13.1 butenyl 1-H2). δC (75 MHz, CDCl3); 136.7 (Ar-C1), 136.5 (C-4), 134.5 
(butenyl C-4), 128.6 (Ar), 127.8 (Ar), 126.4 (Ar), 124.1 (C-3), 116.6 (butenyl C-3), 
64.1 (2-C), 61.7 (1-C), 60.0 (hydroxyethyl 2-C), 51.6 (butenyl 2-C), 50.1 
(hydroxyethyl 1-C), 33.1 (butenyl 1-C); νmax/cm-1 (neat); 3412, 2928, 1612, 1443;  
m/z (ES) 262.2. C16H23NO2 
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4-[(1E)-2-Phenylethenyl]-3-(ally)-1,3-oxazolidin-2-one (162)177 
CDI (0.18 g, 1.1 mmol) and DBU (0.32 mL, 2.2 mmol) were added to 
a solution of 157 (0.20 g, 0.98 mmol) in THF (10 mL) and the 
resulting mixture was stirred at rt for 16 hr under N2. After this time 
the reaction mixture was concentrated in vacuo, re-dissolved in EtOAc (6 mL) and 
washed with brine (3 mL). The organic phase was then dried over MgSO4, filtered 
then concentrated in vacuo and the resulting yellow oil purified by flash 
chromatography eluting with EtOAc–MeOH (100:0 to 95:5) to give the title 
compound177 162 (0.11 g, 49%) as a yellow oil; Rf 0.25 (90:10 DCM–MeOH); δH 
(500 MHz, CDCl3); 7.39 (2H, d, J 7.5, Ar), 7.37-7.33 (2H, m, Ar), 7.32-7.28 (1H, 
m, Ar), 6.60 (1H, d, J 15.7, phenylethenyl 2-H), 5.99 (1H, dd, J 15.7 and 8.9, 
phenylethenyl 1-H), 5.82–5.70 (1H, m, allyl 2-H), 5.23 (1H, d, J 10.2, allyl-3-Ha), 
5.19 (1H, d, J 17.1, allyl 3-HB), 4.48 (1H, app t, J 8.5, 4-H), 4.40 (1H, dd, J 15.8 and 
8.1, allyl 1-HA), 4.11 (1H, dd, J 15.8 and 4.7, allyl 1-HB), 4.04 (1H, dd, J 8.5 and 
7.5, 5-HA), 3.57 (1H, dd, J 15.6 and 7.5, 5-HB); δC (75 MHz, CDCl3); 157.8 (C=O), 
136.0 (Ar), 135.3 (phenylethenyl 2-C), 131.9 (allyl 2-C), 128.8 (Ar), 128.7 (Ar), 
126.7 (Ar), 125.2 (phenylethenyl 2-C), 118.7 (allyl 3-C), 67.3 (5-C), 58.3 (4-C), 
44.6 (allyl 1-C); νmax/cm-1 (neat); 3390, 3252, 2933, 2515, 2029, 1976, 1748; m/z 
(ES) 230.1. 
4,5-Dihydropyrrolo[2,5-a]oxazol-2-one (163)177 
Grubbs' catalyst 2nd gen. (30 mg, 0.034 mmol) was added at rt to a 
solution of 162 (80 mg, 0.34 mmol) in DCM (20 mL). The resulting 
mixture was heated at 55 °C and stirred for 48 hr. After this time the reaction 
mixture was concentrated in vacuo and the resulting oil purified by flash 
chromatography eluting with EtOAc–Petrol (50:50) to give the title compound177 
163 (24 mg, 57 %) as a brown oil; Rf 0.75 (90:10 DCM–MeOH); δH (300 MHz, 
CDCl3); 6.06 (1H, app dt, J 6.0 and 3.3, 4-H), 5.92 (1H, dd, J 6.0 and 3.0, 5-H), 
4.79-4.69 (1H, m, 5a-H), 4.62 (1H, app t, J 8.5, 6-HA), 4.41 (1H, dd, J 3.3 and 2.0, 
3-HA), 4.25 (1H, dd, J 8.5 and 5.1, 6-HB), 3.83 (1H, dd, J 3.3 and 2.0, 3-HB); δC (75 
MHz, CDCl3); 163.3 (C=O), 131.0 (C-4), 128.9 (C-5), 68.7 (C-6), 64.6 (C-5a), 54.8 
(C-3); νmax/cm-1 (neat); 3353, 3005, 2981, 1690, 1275; m/z (ES) 126.05; HRMS 
Found: 126.0545, (C6H7NO MH
+ requires 126.0550). 
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tert-Butyl-N-([2-bromophenyl]{phenylsulfonyl}methyl)carbamate (226) 
By General Method B, using tert‐butyl carbamate (0.50 g, 4.2 
mmol), benzene sulfinic sodium salt (0.84 g, 6.3 mmol) and o-
bromobenzaldehyde (1.16 g, 6.3 mmol), followed by filtration, washing with water 
(100 mL) and hexane (100 mL) gave the title compound (226) (1.57 g, 88%); Rf: 
0.60 (10:90, EtOAc–hexane); δH (500 MHz, CDCl3); 8.04-7.84 (2H, m, Ar), 7.67-
7.51 (2H, m, Ar), 7.48-7.33 (5H, m, Ar), 6.60 (1H, bs, NH), 5.80 (1H, bs, CH), 1.28 
(9H, s, Boc); δC (75 MHz, CDCl3); 153.3 (C=O), 135.3 (Ar), 133.9 (Ar), 133.2 (Ar), 
130.7 (Ar), 129.8 (Ar), 129.2 (Ar), 128.8 (Ar), 127.9 (Ar), 126.7 (Ar), 126.4 (Ar), 
79.9 (Boc 2-C), 72.3 (1-C), 28.01 (Boc 3-C); νmax/cm-1 (neat); 3055, 2978, 2306, 
1726, 1422, 1264; HRMS Found: 227.9652 and 229.9632, (C8H7BrNO2 MH
+ 
requires 227.9654 and 229.9654 MH+ minus tBu–SO2Ph). This compound has 
previously been prepared but characterisation data has not been reported. 
 
tert-Butyl-N-(1-[phenylsulfonyl]pent-4-en-1-yl)carbamate (228)158 
By General Method B, using tert‐butyl carbamate (3.74  g, 31 
mmol), benzene sulfinic sodium salt (8.6 g,  46 mmol) and pentenal 
(5 mL, 35 mmol). After 4 days, followed by filtration, washing with water (5 × 100 
mL) and hexane (5 × 100 mL), and drying to give the title compound158 (228) (8.06 
g, 80%) as an amorphous white solid; Rf: 0.70 (10:90, EtOAc–hexane); δH (500 
MHz, CDCl3); 7.94-7.90 (2H, m, Ar), 7.69-7.51 (3H, m, Ar), 5.77 (1H, m, 4-H), 
5.06 (2H, m, 5-H2), 4.93 (1H, d, NH), 4.87 (1H, d, 1-H), 2.44-2.28 (2H, m, 3-H), 
2.24-2.13 (1H, m, 2-HA), 1.91-1.86 (1H, m, 2-HB), 1.21 (9H, s, Boc); δC (75 MHz, 
CDCl3); 153.5 (C=O), 136.8 (Ar), 135.8 (4-C), 133.8 (Ar), 129.2 (Ar), 129.0 (Ar), 
116.7 (5-C), 80.7 (Boc 2-C), 70.0 (1-C), 29.3 (3-C), 27.9 (Boc 3-C), 25.6 (2-C); 
νmax/cm-1 (neat); 3339, 2978, 1720, 1518, 1309, 1143; HRMS Found: 184.1332 
(C10H18NO2 requires MH
+ 184.1332 minus tBu–SO2Ph). This reaction was 
completed on 4.2 mmol scale with benzene sulfinic sodium salt (6.3 mmol) and 
pentenal (6.3 mmol) using General Method C and the yield was 76%.  
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1‐[(8S, 9S)‐1‐Benzyl‐6’‐methoxycinchonan‐1‐ium‐9‐yl]‐3‐[3,5‐ 
bis(trifluoromethyl)phenyl]urea bromide (222) 143 
To a stirred solution (toluene 0.1 M) of 234 (0.20 g, 0.35 
mmol) was added benzylbromide (1.0 eq.) and the solution 
was heated to 65 °C.  After 12 hr, the mixture was allowed 
to cool to ambient temperature and concentrated in vacuo 
and purified by column chromatography eluting with ether-
MeOH (100:0 to 85:15) the columned eluting with DCM-MeOH (100:0 to 90:10) to 
give the title compound (0.053 mg, 23%) as a yellow solid; Rf: 0.30 (90:10, DCM–
MeOH);δH (500 MHz, CDCl3); 8.69 (1H, d, J 4.7, 2’-H), 7.97 (1H, d, J 9.3, 8’-H), 
7.69 (1H, bs, 5’-H), 7.61 (1H, d, J 4.7, 3’-H), 7.45 (1H, dd, J 9.3 and 2.6, 7’-H), 
5.74 (1H, ddd, J 17.5, 10.3 and 7.5 vinyl 1-H), 4.95-5.10 (2H, m, vinyl 2-H2), 4.72 
(1H, d, J 10.7, 9-H), 4.00 (3H, s, OCH3), 3.32 (1H, ddd, J 15.6, 10.5 and 2.3, 6-HA), 
3.28 (1H, dd, J 13.6 and 9.9, 2-HA), 3.16 (1H, app q, J 10.7, 8-H), 2.79 (1H, ddd, J 
15.6, 13.8 and 4.9, 6-HB), 2.56 (1H, ddd, J 13.6, 4.7 and 2.3, 2-HB), 1.60-1.57 (3H, 
m, 7-HA and 5-HA), 1.56-1.54 (1H, br m, 4-H), 1.53-1.50 (2H, m, 7-HB and 5-HB), 
1.47-1.40 (1H, br m, 3-H), 2 × NH not observed; m/z (ES) 669.3. 
Nitrobut-3-ene (204) 159 
 According to General Method C, using 4-bromobutene (0.75 mL, 7.4 
mmol), sodium nitrite (0.60 g, 8.4 mmol) followed by flash chromatography, eluting 
with ether–Hexane (5:95) gave the title compound159 (0.32 g, 43%) as a yellow oil; 
Rf: 0.20 (5:95, ether–hexane); δH (500 MHz, CDCl3); 5.78 (1H, ddd, J 17.0, 11.2 and 
8.5, 3-H). 5.10 (1H, d, J 11.2, 4-HA), 5.06 (1H, d, J 17.0, 4-HB), 4.46-4.35 (2H, m, 
1-H2), 2.87-2.85 (2H, m, 2-H2); δC (75 MHz, CDCl3); 131.8 (3-C), 118.8 (4-C), 74.7 
(1-C), 31.3 (2-C); Unable to observe MH+ in mass spectrometer. 
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tert-Butyl(2-nitroethoxy)diphenylsilane (231)178 
General Procedure D, using nitroethanol (1.2 mL, 16.8 mmol), 
TBDPS-Cl (3.3 mL, 17.7 mmol), imidazole (2.28 g, 33.6 mmol), followed by flash 
chromatography, eluting with EtOAc–Hexane (10:90) gave the title compound178 
(5.2 g, 93%); Rf: 0.70 (10:90, EtOAc–hexane); δH (500 MHz, CDCl3); 7.35-7.28 
(4H, d, J 7.4, Ar), 7.25-7.10 (6H, m, Ar), 4.78 (2H, t, J 8.7 1-H2), 4.23 (2H, t, J 8.7, 
2-H2), 1.29 (9H, s, 
tBu). m/z (ES) 330.2.  
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9-Amino-(9-deoxy)-epi-quinine (233)179 
Quinidine (6.13 mmol) and triphenylphosphine (2.11 g, 7.35 
mmol) were dissolved in THF (30 mL) and the solution was 
cooled to 0 °C. DIAD (1.52 mL, 7.35 mmol) was added in one 
portion. A solution of diphenyl phosphoryl azide (1.63 mL, 7.35 mmol) in THF (13 
mL) was then added dropwise at 0 °C. The mixture was allowed to warm to rt and 
stirred for 12 hr. The solution was then heated at 50 °C for 2 hr. Triphenylphosphine 
(2.29 g, 7.97 mmol) was then added and heating was maintained until the gas 
evolution had ceased (3 hr). The solution was cooled to rt, water (0.7 mL) was 
added, and the solution was stirred for 12 hr. The reaction mixture was concentrated 
in vacuo and the residue was dissolved in DCM (30 mL), then HCl(aq) (10 %, 30 
mL) was added. The phases were separated then the aqueous phase was washed with 
DCM (3 × 30 mL), then sat. NH4OH was added (pH 12) and the aqueous layer was 
extracted with DCM (330 mL), dried (Na2SO4) and concentrated in vacuo. The 
crude material was purified by flash chromatography, eluting with EtOAc-MeOH 
then DCM–sat. methanolic ammonia-NH4OH (85:15.5:0.5) the title compound179 as 
yellowish viscous oil (0.84g, 40%). Note, some polar impurities were still present 
but it is easier to purify after the next step; Rf: 0.05 (90:10, DCM–MeOH); δH (500 
MHz, CDCl3); 8.69 (1H, d, J 4.7, 2’-H), 7.97 (1H, d, J 9.3, 8’-H), 7.69 (1H, bs, 5’-
H), 7.61 (1H, d, J 4.7, 3’-H), 7.45 (1H, dd, J 9.3 and 2.6, 7’-H), 5.74 (1H, ddd, J 
17.5, 10.3 and 7.5 vinyl 1-H), 4.95-5.10 (2H, m, vinyl 2-H2), 4.72 (1H, d, J 10.7, 9-
H), 4.00 (s, 3H, OCH3), 3.32 (1H, ddd, J 15.6, 10.5 and 2.3, 6-HA), 3.28 (1H, dd, J 
13.6 and 9.9, 2-HA), 3.16 (1H, app q, J 10.7, 8-H), 2.79 (1H, ddd, J 15.6, 13.8 and 
4.9, 6-HB), 2.56 (1H, ddd, J 13.6, 4.7 and 2.3, 2-HB), 1.60-1.57 (3H, m, 7-HA and 5-
HA), 1.56-1.53 (1H, br m, 4-H), 1.52-1.48 (2H, m, 7-HB and 5-HB), 1.47-1.45 (1H, 
br m, 3-H), 2 × NH not observed; m/z (ES) 325.2. 
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1‐[(8S, 9S) ‐6’‐Methoxycinchonan‐1‐ium‐9‐yl]‐3‐[3,5‐ 
bis(trifluoromethyl)phenyl]urea (234)180 
A solution of a 233 (0.9 mmol, 0.26 g) in anhydrous THF (1.1 
mL) was added slowly to a solution of 3,5-
bis(trifluoromethyl)phenyl isocyanate (1.0 mmol, 0.26 g, 0.5) 
in anhydrous THF (3 mL) at 0 °C. The reaction mixture was 
allowed to warm to rt and stirred overnight. The resulting 
mixture was concentrated in vacuo. The residue was purified followed by flash 
chromatography, eluting with DCM–MeOH (90:10) then DCM–EtOH–NH4OH 
(85:15:1) affording the title compound180 as a pale yellow amorphous solid (0.345 g, 
70%): Rf: 0.15 (90:10, DCM–MeOH); Rf 0.25 (90:10 DCM–MeOH); δH (300 MHz, 
MeOH); 8.66 (1H, d, J 4.6, 2’-H), 7.96–7.89 (3H, m, 8’-H, 5’-H, Ar) 7.79 (1H, d, J 
2.8, Ar), 7.55 (1H, d, J 4.7, 3’-H), 7.43 (1H, s, Ar), 7.39 (1H, dd, J 9.2 and 2.6, 7’-
H), 5.90 (1H, ddd, J 17.0, 10.5 and 6.1 vinyl 1-H), 5.65 (1H, dd, J 10.2 and 6.4),  
5.16 (1H, d, J 17.4, vinyl 2-HA),  5.09 (1H, d, J 10.5, vinyl 2-HB), 4.75 (1H, d, J 
10.5, 9-H), 4.01 (3H, s, OCH3), 3.21 (3H, dt, J 14.3, 8.1, 6-HA and 2-HA) 2.98 (3H, 
dd, J 14.4, 9.6, 8-H, 6-HB and 2-HB), 2.71 (1H, m, 4-H), 2.27 (2H, q, J 12.7, 9.2, 7-
HA and 5-HA), 1.19 (2H, m, 7-HB and 5-HB), 2 × NH not observed; m/z (ES) 579.2; 
HRMS Found: 579.2204 (C29H28F6N4O2 MH
+ requires 579.2189) 
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tert-Butyl-N-[(1R, 2S)-1-(2-bromophenyl)-2-nitropent-4-en-1-yl] carbamate 
(221) 
 By General Method E, using amino sulfone (226) (0.213 g, 0.5 
mmol), nitrobutene (0.26 g, 2.5 mmol) and N-benzylquinium 
chloride (12 mol%), followed by flash chromatography, eluting with EtOAc–
Hexane (90:10) gave the title compound (0.11 g, d.r. >95:<5, 59%); [α]D22  -17.3 (c. 
0.5, CHCl3); Rf: 0.40 (10:90, EtOAc–hexane); δH (500 MHz, CDCl3); 7.62 (1H, d, J 
8.0, Ar), 7.34 (1H, t, J 7.3, Ar), 7.31 (1H, d, J 7.3, Ar), 7.23 (1H, d, J 8.0, Ar), 5.75 
(1H, ddd, J 16.9, 9.4, 7.3, 4-H), 5.63 (1H, dd, J 9.4, 1.1, 5-HB), 5.43 (1H, d, J 16.9, 
1.1, 5-HA), 5.21 (1H, d, J 10.1, 1-H), 5.18-5.09 (1H, m, 2-H), 2.81 (1H, ddd, J 13.0, 
10.5, 7.3, 3-HA), 2.69 (1H, dd, J 10.5, 7.3, 3-HB), 1.47 (9H, s, Boc), NH not 
observed; δC (75 MHz, CDCl3); 154.8 (C=O), 133.9 (Ar), 133.4 (2-C), 131.1 (Ar), 
130.3 (Ar), 130.2 (Ar), 129.9 (Ar), 128.1 (Ar), 122.6 (1-C), 89.4 (4-C), 80.6 (Boc 2-
C), 54.8 (5-C), 35.4 (3-C), 28.2 (Boc 3-C).; νmax/cm-1 (neat); 3362, 2854, 1690, 
1518; m/z (ES) 407.1 and 409.2; HRMS Found: 407.0580, 409.0560 (C16H21BrN2O4 
MH+ requires 407.0574, 409.5752). 
There was an additional fraction with syn isomer as the major component (d.r. 
60:40) 13% yield. 
tert-Butyl-N-[(1R, 2R)-1-(2-bromophenyl)-2-nitropent-4-en-1-yl] carbamate 
Rf: 0.40 (10:90, EtOAc–hexane); δH (500 MHz, CDCl3);7.61 (1H, d, 
J 8.0), 7.34 (1H, t, J 7.5, Ar), 7.22 (2H, t, J 7.6, Ar), 6.08 (1H, d, J 
8.6, NH), 5.80 (1H, ddd, J 16.6, 9.6, 7.2, 2-H), 5.57 (1H, dd, J 9.6, 1.5, 1-HA), 5.25 
(1H, dd, J 16.6, 1.5, 1-HB), 5.10 (2H, m, 5-H, 4-H), 2.95-2.86 (1H, m, 3-HA), 2.75-
2.66 (1H, m, 3-HB), 1.47 (9H, s, Boc); δC (75 MHz, CDCl3); 154.8 (C=O), 133.9 
(Ar), 133.4 (2-C), 131.1 (Ar) 129.9 (Ar), 128.1 (Ar), 128.0 (Ar), 127.6 (Ar), 120.5 
(1-C), 88.8 (4-C), 80.5 (Boc 2-C), 54.6 (3-C), 35.5 (3-C), 28.4 (Boc 3-C); νmax/cm-1 
(neat); 3362, 2854, 1690, 1518; m/z (ES) m/z (ES) 407.1 and 409.2; HRMS Found: 
407.0580, 409.0560 (C16H21BrN2O4 MH
+ requires 407.0574, 409.5752). 
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tert-Butyl-N-[(2R, 3R)-1-{(tert-butyldiphenylsilyl)oxy}-2-nitrohept-6-en-3-
yl)carbamate (235)  
 By General Method E, using amino sulfone (228) (0.65 g,  2 
mmol), nitro-compound (231) (3.3 g, 10 mmol) and N-
benzylquinium chloride (12 mol%), followed by two concurrent flash 
chromatography columns; eluting with DCM–Hexane (50:50) gave the title 
compound (0.85 g, d.r. 80:20, 83%) then second column eluting with TBME–
Hexane (8:92) to give the title compound: (0.68 g, d.r. ≥95:≤5, 69%); [α]D22  7.6 (c. 
0.9, CHCl3); Rf: 0.30 (8:92, TBME–hexane); δH (500 MHz, CDCl3); 7.71-7.64 (4H, 
m, Ar), 7.45-7.30 (6H, m, Ar), 5.80-5.67 (1H, ddd, J 16.3, 8.5 and 7.0, 6-H), 5.00 
(1H, d J 8.5, 7-HB), 4.98 (1H, d J 16.3, 7-HA), 4.68 (1H, app bs, 2-H), 4.62 (1H, d, J 
9.4, NH), 4.03-3.97 (1H, m, 3-H), 3.93 (1H, d, J  12.0, 1-HB), 3.72 (1H, d, J 7.5, 1-
HA), 2.11 (1H, dt, J 16.9 and 7.0, 5-HB), 1.99 (1H, dt, J 14.5 and 7.0, 5-HA),  1.47-
1.45 (2H, m, 4-H2), 1.44 (9H, s, Boc), 1.02 (9H, s, 
tBu); δC (125 MHz, CDCl3); 
155.0 (C=O), 136.5 (7-C), 135.6 (Ar), 135.5 (Ar), 135.5 (Ar), 132.3 (Ar), 130.1 
(Ar), 126.0 (Ar), 125.8 (Ar), 124.5 (Ar), 115.3 (7-C), 91.6 (3-C), 80.1 (Boc), 62.4 
(1-C), 50.0 (3-C), 31.4 (5-C), 29.8 (4-C), 28.2 (Boc), 27.3 (SiC(CH3)3), 26.6 (
tBu); 
νmax/cm-1 (neat); 3310, 2980, 1710, 1485; m/z (ES) 513.3; HRMS Found: 513.2782, 
(C28H40N2O5Si MH
+ requires 513.2779). 
The minor diastereoisomer was isolated in 7% yield with >90:<10 d.r. 
  
 118 
 
tert-Butyl-N-[(2S, 3R)-1-{(tert-butyldiphenylsilyl)oxy}-2-nitrohept-6-en-3-
yl) carbamate (235)  
(0.07 g, d.r. 90:10, 7%); Rf: 0.32 (8:92, TBDMS–hexane); δH 
(500 MHz, CDCl3); 7.62 (2H, d, J 7.0, Ar) 7.60-7.56 (2H, m, 
Ar), 7.45-7.30 (2H, m, Ar), 7.39 (4H, d, J 7.0, Ar), 5.72 (1H, ddd, J 16.0, 13.0 and 
6.3, 6-H), 5.01 (1H, d J 13.0, 7-HB), 4.98 (1H, d J 16.0, 7-HA), 4.85 (1H, d, J 10.2, 
NH), 4.77 (1H, dd, J 9.2 and 4.0, 2-H), 4.22-4.14 (1H, m, 3-H), 3.93 (2H, app dd, J 
11.3 and 4.0, 1-H2), 2.09 (2H, dd, J 14.0 and 6.3, 5-H2), 1.35 (2H, m, 4-H2), 1.44 
(9H, s, Boc), 1.02 (9H, s, tBu); δC (125 MHz, CDCl3); 155.2 (C=O), 136.6 (6-C), 
135.4 (Ar), 134.8 (Ar), 132.5 (Ar), 130.2 (Ar), 129.6 (Ar), 127.9 (Ar), 127.7 (Ar), 
127.5 (Ar), 116.1 (7-C), 91.8 (3-C), 80.0 (Boc), 63.1 (1-C), 49.0 (3-C), 30.0 (5-C), 
29.7 (4-C), 28.2 (Boc), 27.8 (SiC(CH3)3), 26.6 (Boc); νmax/cm-1 (neat); 3310, 2980, 
1710, 1485; m/z (ES) 513.3; HRMS Found: 513.2782, (C28H40N2O5Si MH
+ requires 
513.2779). 
In addition a mixture of both diastereoisomers was obtained with d.r. of 50:50 (5% 
yield). 
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N-[1H-1,3-Benzodiazol-2-ylmethyl]quininium chloride (236)160 
 To a suspension of quinine (0.32 g, 1 mmol) in toluene (4 
mL) was added 2-chloromethylbenzimidazole (0.18 g, 1.1 
mmol), and the mixture was stirred at reflux for 3 h then 
cooled to rt and filtered. The crude material was purified by 
flash chromatography, eluting with DCM–MeOH (90:10) gave the title compound160 
(0.32 g, 65%) as a pink solid; Rf: 0.32 (80:20, DCM–MeOH); δH (500 MHz, 
CDCl3); 8.78 (1H, d, J 4.6, 2’-H), 8.03 (1H, d, J 9.4, 8’-H), 7.92 (1H, d, J 4.8, 5’-H), 
7.74-7.13 (5H, m, Ar), 6.76 (1H, d, J 1.7, Ar), 6.12-6.03 (1H, m, vinyl 1-H), 5.35-
5.27-5.18 (2H, m, vinyl 2-H2), 4.76 (1H, t, J 9.5, 9-H), 4.15 (1H, t, J 9.5, 8-H), 3.97 
(3H, s, OMe), 3.90-3.82 (2H, m, benzyl H2), 3.42 (1H, m, 6-HA), 2.79 (1H, m, 6-
HB), 2.41 (2H, m , 2-HA and 3-H), 2.31 (1H, s, 2-HB), 1.89-1.98 (4H, m, 5-H2 and 7-
H2), 1.03 (1H. m, 4-H), NH and OH not observed; m/z (ES) 455.2. 
N-[1H-1,3-Benzodiazol-2-ylmethyl]cinchonium chloride (237)160 
To a suspension of cinchonine (0.29 g, 1 mmol) in toluene 
(4 mL) was added 2-chloromethylbenzimidazole (0.18 g, 
1.1 mmol), and the mixture was stirred at reflux for 3 h 
then cooled to rt and filtered. The crude material was 
purified by flash chromatography, eluting with DCM–MeOH (90:10) gave the title 
compound160 (0.27 g, 58%) as a red solid; Rf: 0.15 (80:20, DCM–MeOH);δH (500 
MHz, CDCl3); 8.87 (1H, d, J 4.6, 2’-H), 7.83-7.80 (2H, m, 8’-H and 5-H), 7.51-7.45 
(3H, m, Ar), 7.27-7.16 (3H, m, Ar), 6.70-6.67 (1H, m, Ar), 6.60 (1H, bs, OH), 5.93 
(1H, m, vinyl 1-H), 5.30-5.23 (2H, m, vinyl 2-H2), 4.85 (1H, m, 9-H), 4.71 (1H, t, J 
5.2, 9-H), 4.07 (1H, t, J 11.2, 8-H), 3.97 (2H, m, benzyl H2), 2.62-2.55 (2H, m, 6-
H2), 2.35-1.78 (4H, m, 5-H2 and 7-H2), 0.87-0.82 (1H, m, 4-H), NH and OH not 
observed; m/z (ES) 425. 
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N-(4-Bromobenzyl)-N,N-dimethyl-2-{(4-nitrophenyl)thioureido}-[tert-
butyl]ethanaminium bromide (238)162 
According to modified166 procedure, di-tert-butyl 
dicarbonate (1.40 g, 6.4 mmol) was added to a 
solution of valine (0.50 g, 4.3 mmol), NaOH (2 eq.) in THF–H2O (50:50, 20 mL) 
and stirred overnight. The reaction mixture was diluted with DCM (100 mL) and 1 
M HCl(aq) (pH 2). The organic layer was washed with 1 M HCl(aq) (3 × 15 mL), brine 
(2 × 10 mL), dried (Na2SO4) and concentrated in vacuo. The crude residue was 
dissolved in DCM (20 mL, 0.3 M) and HCTU (6.4 mmol), DIPEA (8.6 mmol) was 
added at 0 °C. Dimethylamine (4 mL, 1 M in EtOH) was then added dropwise and 
the reaction mixture was vigorously stirred at rt. After 4 hr, the resulting solution 
was diluted with H2O (100 mL) and DCM (100 mL), the organic layer was 
separated, washed with 1 M HCl(aq) (3 × 15 mL), brine (2 × 10 mL), dried (Na2SO4) 
and concentrated in vacuo. The crude product was dissolved TFA–DCM (2:8 mL), 
stirred at rt overnight. The resulting solution was diluted with H2O (100 mL) organic 
layer was extracted with H2O (3 × 50 mL) then the combined aqueous layer was 
basified with sat. NaHCO3(aq) (pH 10) and extracted with DCM (3 × 30 mL). The 
combined organic phases were dried (Na2SO4), concentrated in vacuo. Crude residue 
was filtered through a silica plug, eluting with DCM–MeOH (90:10) then dissolved 
in THF (10 mL) and added dropwise to LiAlH4 (2mL in 1 M THF) at 0 °C. The 
reaction mixture was then heated at 75 °C for 24 h. The reaction mixture was cooled 
to 0 °C and H2O (0.08 mL), NaOH (0.16 mL) then H2O (0.24 mL) was added and 
stirred for 3 hr then filtered through celite and the filtrate concentrated in vacuo. The 
crude residue was then dissolved into DCM (4 mL), and the isothiocyanate (5 mmol) 
was added and stirred overnight. The reaction mixture was concentrated in vacuo 
then dissolved in a solution of MeCN (5.0 mL). Benzyl bromide (2 eq.), was added 
dropwise and the resulting mixture was stirred at rt overnight The reaction mixture 
was concentrated in vacuo residue was purified by flash chromatography eluting 
with DCM–MeOH (100:0 to 90:10) to afford the title compound162 (0.27 g, 11%); 
Rf: 0.40 (90:10, DCM–MeOH); δH (500 MHz, CDCl3); 10.54 (1H, s, NH), 9.42 (1H, 
d, J 12.0, NH), 8.12 (2H, d, J 8.1, Ar), 8.03 (2H, d, J 8.1, Ar), 7.62 (2H, d, J 7.3, 
Ar), 7.41 (2H, d, J 7.3, Ar), 4.97-4.93 (1H, d, J 12.0, benzyl HA), 4.65-4.62 (1H, d, J 
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12.0, benzyl HB), 4.41-4.35 (1H, m, 2-H), 3.61-3.58 (2H, d, J 12.0, 1-H2), 3.25 (3H, 
s, Me), 3.18 (3H s, Me), 1.13 (9H, s, tBu); δC (75 MHz, CDCl3); 181.2 (C=S), 145.6 
(Ar), 134.5 (Ar), 132.7 (Ar), 131.7 (Ar), 130.5 (Ar), 126.1 (Ar), 125.5 (Ar), 124.2 
(Ar), 67.8 (benzyl CH2), 67.5 (1-C), 56.3 (2-C), 50.6 (Me), 49.8 (Me), 37.1 (
tBu 2-
C), 26.4 (tBu 3-C); νmax/cm-1 (neat); 2963, 1575, 1508, 1330, 1257, 1109, 851, 727; 
m/z (ES) 493.1; HRMS Found: 493.1269, (C22H30Br2N4O2S MH
+ requires 
493.1273).  
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(2S)-(3-(3,5-Bis(trifluoromethyl)phenyl)thioureido)-(isopropyl)-N,N, - 
dimethylacetamide (239)161 
According to modified procedure166, di-tert-butyl 
dicarbonate (1.4 g, 6.4 mmol) was added to a solution of 
valine (0.5 g, 4.3 mmol), NaOH (2 eq.) in THF–H2O 
(50:50, 20 mL) and stirred overnight. The reaction mixture was diluted with DCM 
(100 mL) and 1 M HCl(aq) added until pH 2. The organic layer was washed with 1 M 
HCl(aq), brine, dried (Na2SO4) and concentrated in vacuo. The crude residue was 
dissolved in DCM (20 mL) and HCTU (6.4 mmol), DIPEA (8.6 mmol) was added at 
0 °C. Dimethylamine (2 mL, 1 M in EtOH) was then added dropwise and the 
reaction mixture was vigorously stirred at rt. After 4 h, the resulting solution was 
diluted with H2O (100 mL) and DCM (100 mL), the organic layer was separated, 
washed with 1 M HCl(aq) (3 × 30 mL), brine (2 × 15 mL), dried (Na2SO4) and 
concentrated in vacuo. The crude residue was dissolved TFA–DCM (2:4 mL), 
stirred at rt overnight. The reaction solution was diluted with H2O (100 mL) and 
organic layer was extracted with H2O (3 × 30 mL) then the combined aqueous layer 
was basified with sat. NaHCO3(aq) (pH 10) and extracted with DCM (5 × 30 mL). 
The combined organic phases were dried (Na2SO4), concentrated in vacuo. The 
crude residue was filtered through a silica plug, eluting with DCM–MeOH (90:10) 
gave a crude material which was added a solution of isothiocyanate 11 (1.4 g, 5.18 
mmol) in DCM (20 mL) at rt the crude material was added and the reaction was 
stirred at rt overnight, then concentrated in vacuo then purified by flash 
chromatography eluting with DCM–MeOH (100:0 to 90:10) to give the acetamide 
(239)161 (0.58 g, 32%); Rf: 0.15 (90:10, DCM–MeOH) δH (500 MHz, CDCl3); 9.35 
(1H, s, NH), 8.40 (1H, d, J 7.7, NH), 8.03 (2H, s, Ar), 7.47 (1H, s, Ar) 5.25 (1H, app 
t, J 8.1. 1’-H), 3.38 (3H, s, Me), 3.05 (3H, s, Me), 2.08 (1H, tt, J 14.2 and 8.1, 1-H), 
1.12 (3H, d, J 6.8, Me), 1.07 (3H, d, J 6.8, Me); m/z (ES) 416.2; C16H19F6N3O5 
  
 123 
 
(1R,2R)-N,N-Bis(4-chloroquinolin-2-yl)cyclohexane-1,2-diamine (250)163 
A flame-dried flask was charged with Pd(dba)2 (0.057 g, 
0.063 mmol), rac-BINAP (0.039 g, 0.063 mmol), sodium 
tert-butoxide (0.363 g, 3.78 mmol), (R,R)-
diaminocyclohexane (0.143 g, 1.26 mmol), and 2,4-dichloroquinoline (0.5 g, 2.25 
mmol), and the reaction vessel was placed under an argon atmosphere. Toluene (13 
mL) was added, and the resulting red-brown solution was heated at 85 °C, after 3 hr, 
the reaction was cooled to 25 °C and diluted with EtOAc. The reaction mixture was 
washed with sat. NH4Cl(aq) (3 × 30 mL), dried (Na2SO4) and concentrated in vacuo. 
Flash chromatography, eluting with EtOAc–Hexane (10:90) gave the title 
compound163 250 (0.20 g, 36%) as an amorphous yellow powder; Rf: 0.20 (10:90, 
EtOAc–Hexane); δH (500 MHz, CDCl3); 7.91 (2H, d, J 8.2), 7.69 (2H, d, J 8.2), 7.56 
(2H, dd, J 8.2 and 7.3), 7.24 (2H, dd, J 8.2 and 7.3), 6.42 (2H, s), 5.75 (2H, bs), 4.09 
(2H, m), 2.35 (2H, d, J 12.0), 1.83 (2H, m), 1.50-1.34 (4H, m); δC (75 MHz, 
CDCl3); 156.8, 148.9, 142.6, 130.9, 126.5, 124.4, 122.9, 121.9, 112.6, 56.5, 33.1, 
25.2; νmax/cm-1 (neat); 3220, 2930, 1601; m/z (ES) 437.2; HRMS Found: 437.1295, 
(C24H22Cl2N4 MH
+ requires 437.1300). 
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(1R,2R)-N,N-Bis(4-(pyrrolidin-1-yl)quinolin-2-yl)cyclohexane-1,2-diamine 
(251)163 
A microwave vial (10 mL) was charged with 250 (0.1 g, 
0.23 mmol), pyrrolidine (0.6 mL, 4.6 mmol), and 
trifluoromethylbenzene (3 mL, 0.15 M). This suspension 
was heated at 200 °C and stirred in the microwave for 3.5 h. The reaction was then 
concentrated and purified by flash chromatography eluting with DCM–MeOH (95:5, 
to 80:20) to provide a light brown solid. This material was dissolved in 
dichloromethane and then washed with 3 M NaOH (4 × 10 mL), dried (Na2SO4) and 
concentrated in vacuo. The material was then triturated with hexanes to afford the 
diamine (251)163 as a light brown powder (73 mg, 71%); Rf: 0.15 (95:5, DCM–
MeOH)δH (500 MHz, CDCl3); 7.73 (2H, d, J 7.8), 7.40 (2H, d, J 7.5), 7.40 (2H, dd, 
J 8.0 and 7.5), 7.00 (2H, dd, J 8.0 and 7.5), 5.82 (2H, bs), 5.27 (2H, s), 4.10 (2H, 
bs), 3.26 (4H, bs) , 3.10 (4H, bs), 2.32 (2H, s), 1.90-1.70 (10H, m), 1.55-1.35 (4H, 
m); δC (75 MHz, CDCl3); 153.2, 152.0, 125.0, 122.4, 119.9, 115.6, 88.6, 56.6, 53.4, 
52.2, 31.8, 25.4, 24.3, 23.3; νmax/cm-1 (neat); 3259, 3056, 2927, 2855, 2935, 1591, 
1529; m/z (ES) 507.4; HRMS Found: 507.3239, (C38H38N6 MH
+ requires 507.3236). 
tert-Butyl N-[1-(benzenesulfonyl)-(phenyl)methyl]carbamate (253)181 
By General Method B, using tert‐butyl carbamate (0.50 g, 4.2 
mmol), benzene sulfinic sodium salt (1.03 g, 6.3 mmol) and 
benzaldehyde (0.64 g, 6.3 mmol), followed by filtration, washing with water (100 
mL) and hexane (100 mL) gave the amidosulfone181 253 (1.14 g, 78%) an 
amorphous white solid;  Rf: 0.45 (10:90, EtOAc–hexane); δH (500 MHz, CDCl3); 
7.91-7.90 (2H, d, J 7.2, Ar), 7.65-7.63 (1H, m, Ar), 7.55-7.52 (2H, d, J 7.3, Ar), 
7.42-7.39 (5H, m, Ar), 5.93 (1H, d, J 10, NH), 5.74-7.72 (1H, d, J 10, CH), 1.26 
(9H, bs, Boc); δC (75 MHz, CDCl3); 153.5 (C=O), 136.8 (Ar),  133.9 (Ar), 129.8 
(Ar), 129.8 (Ar), 129.4 (Ar), 129.0 (Ar), 128.9 (Ar), 128.7 (Ar), 81.2 (Boc 2-C), 
73.9 (1-C), 28.0 (Boc 3-C); νmax/cm-1 (neat); 3355, 2982, 1698, 1509, 1309, 1144; 
Due to instability, unable to get an accurate high mass for title compound. 
C18H21NO4S 
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tert-Butyl N-[1-(benzenesulfonyl)-3-phenylpropyl]carbamate (255)182 
By General Method B, using tert‐butyl carbamate (0.50 g, 4.2 
mmol), benzene sulfinic sodium salt (1.03 g, 6.3 mmol) and 
hydrocinnamaldehyde (0.84 g, 6.3 mmol), followed by filtration, washing with 
water (100 mL) and hexane (100 mL) gave the amidosulfone182 255 (1.09 g, 69%) 
an amorphous white solid; Rf: 0.40 (10:90, EtOAc–hexane); δH (500 MHz, CDCl3); 
7.90-7.87 (4H, d, J 7.4, Ar), 7.58-7.50 (6H, m, Ar), 7.32-7.16 (10H, m, Ar), 5.18 
(1H, d, J , NHRot A), 5.02 (1H, d, J , NHRot B),  4.86 (1H, d, J , 1-HRot B), 4.59 (1H, d, 
J , 1-HRot A), 2.57-2.97 (6H, m, 3-HRot B, 3-HRot A, 2-HA
Rot B, 2-HA
Rot A), 2.57-2.97 
(2H, m, 2-HB
Rot B, 2-HB
Rot A) 1.22 (9H, s, BocRot B), 1.05 (9H, s, BocRot A); δC (75 
MHz, CDCl3); 153.5 (C=O), 136.8 (Ar),  133.9 (Ar), 129.8 (Ar), 129.8 (Ar), 129.4 
(Ar), 129.0 (Ar), 128.9 (Ar), 128.7 (Ar), 81.2 (1-C), 73.9 (Boc 2-C), 34.8 (3-C), 31.2 
(2-C), 28.0 (Boc 3-C); νmax/cm-1 (neat); 3355, 2982, 1698, 1509, 1309, 1144; Due to 
instability, unable to get an accurate high mass for title compound. C18H21NO4S 
tert-Butyl-N-(2-nitro-3-phenylpropyl)carbamate (257)157 
By General Method E, using amino sulfone (253) (0.173 g, 0.5 mmol), 
nitroethane (0.17 mL, 2.5 mmol) and N-benzylquinium chloride (10 
mol%), filtered through a silica plug, eluting with EtOAc–Hexane (90:10) gave the 
nitro amine157 257 (0.11 g, d.r. 93:7. 82%) an amorphous white solid; Rf: 0.30 
(10:90, EtOAc–hexane); δH (500 MHz, CDCl3); 7.39-7.29 (6H, m, Ar Maj and Min), 
7.27-7.21 (4H, m, Ar Maj and Min), 5.57 (1H, app bs, NHMin), 5.32 (1H, d, J 8.7, 
NHMaj), 5.19 (1H, dd, J 8.9 and 6.4, 2-HMaj), 5.10 (1H, app bs, 2-HMin), 4.92 (2H, 
app bs, 3-HMaj and Min), 1.53 (6H, d, J 6.4, 1-H3
Maj and Min), 1.44 (18H, s, Boc Maj and Min); 
δC (75 MHz, CDCl3); 155.4 (C=OMaj and Min), 140.6 (ArMaj and Min), 129.1 (ArMin), 
129.0 (ArMaj), 128.6 (ArMaj), 128.4 (ArMin), 126.8 (ArMaj), 126.4(ArMin), 86.7 (2-
CMin), 85.7 (2-CMaj), 77.2 (Boc 2-CMaj and Min), 57.4 (3-CMaj and Min), 28.2 (Boc 3-CMaj 
and Min), 17.0 (1-CMaj and Min); νmax/cm-1 (neat); 3345, 1711, 1602, 1508; m/z (ES) 
280.3. 
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tert-butyl N-(2-nitro-4-phenylpentan-3-yl)carbamate (258) 157 
By General Method E, using amino sulfone (255) (0.18 g, 0.5 
mmol), nitroethane (0.17 g, 2.5 mmol) and N-benzylquinium 
chloride (12 mol%), followed by flash chromatography, eluting with EtOAc–
Hexane (90:10) gave the nitro amine157 258 (0.12 g, d.r. 90:10, 63%) an amorphous 
white solid; Rf: 0.40 (10:90, EtOAc–hexane); δH (500 MHz, C6D6); 7.16-7.08 (4H, 
m, Ar), 7.06-7.01 (2H, m, Ar), 6.99 (2H, d, J 7.3, Ar), 6.91 (2H, d, J 7.3, Ar), 4.62 
(1H, d, J 9.9, NHMaj), 4.26 (1H, d, J 9.0, NHMin), 4.23-4.19 (1H, m, 2-HMin), 3.98 
(1H, dq, J 6.8 and 4.6, 2-HMaj), 3.86 (1H, m, 3-HMaj), 3.75-3.67 (1H, m, 3-HMin), 
2.39 (2H, dd, J 14.0 and 7.7, 4-H2
Maj), 2.28-2.20 (2H, m, 4-H2
Min), 1.41 (9H, s, 
BocMin), 1.37 (9H, s, BocMaj), 1.30-1.13 (4H, m, 4-H2
Maj and Min) 1.00 (3H, d, J 6.8, 1-
H3
Maj), 0.84 (3H, d, J 6.8, 1-H3
Maj); δC (75 MHz, C6D6); 155.6 (C=OMaj), 155.2 
(C=OMin), 141.0 (ArMaj), 140.8 (ArMin), 128.6 (ArMaj), 128.5 (ArMin), 128.4 (ArMaj), 
128.2 (ArMin), 127.8 (ArMin), 126.3 (ArMaj), 85.7 (2-CMaj), 85.4 (2-CMin), 79.4 (Boc 
2-CMin), 79.3 (Boc 2-CMaj), 53.0 (3-CMin), 52.2 (3-CMaj), 33.9 (5-CMaj and Min), 32.2 (4-
CMaj), 31.2 (4-CMin), 28.2 (Boc 3-C Maj and Min), 15.9 (1-CMaj), 14.6 (1-CMin); νmax/cm-1 
(neat); 3315, 2985, 1687, 1520; m/z (ES) 381.2; HRMS Found: 381.1784, 
(C16H24N2O4 MNa requires 381.1784). 
Benzyl (2-hydroxyethyl)carbamate (165)183 
 According to the procedure84 a solution of benzyl chloroformate  (4.7 
mL, 3.3 mmol) added dropwise to the stirred solution of ethanolamine (1.81 mL, 30 
mmol), NaHCO3(3 eq.) in DCM (0.2 M) over 1 hr. The reaction mixture was left to 
stir for a further 12 hr and then concentrated in vacuo to give a crude mixture.which 
was ourified by flash chromatography, eluting with EtOAc–Hexane (10:90) gave the 
title compound183 (5.3g g, 91%) as a white amorphous solid; Rf: 0.25 (10:90, 
EtOAc–hexane); δH (500 MHz, CDCl3); 7.48-7.27 (5H, m, Ar), 5.11 (2H, s, benzyl 
H2), 3.73 (2H, d, J 4.8, 1-H2), 3.37(2H, d, J 4.8, 2-H2), 2.04 (1H, bs, OH or NH), 
NH or OH not observed; m/z (ES) 196.2; 
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Benzyl (2-oxoethyl)carbamate (260)184,185 
 To a stirred solution of DMSO (6.4 mL) in DCM (0.3 M) was added 
sulphur trioxide pyridine complex (7.20 g) at 0 °C. The resultant mixture was stirred 
for 15 mins and a solution of benzyl (2-hydroxyethyl)carbamate (2.0 g, 10 mmol),  
(1 eq.) in DCM (0.2 M) was added dropwise. After stirring for 1 hr at 0 °C, Et3N (3 
eq.) was added, and the resulting mixture was allowed to warm into rt. After 
30 mins, the reaction mixture was quenched with 10% HCl(aq) (60 mL) and the 
resulting mixture extracted with ethyl acetate (3 × 200 mL). The combined organic 
layers were washed with sat. NaHCO3(aq), brine then dried (MgSO4) and 
concentrated in vacuo to give a crude mixture which was flash chromatography, 
eluting with EtOAc–Hexane (10:90) gave the title compound184,185 (0.874 g, 45%); 
Rf: 0.10 (10:90, EtOAc–hexane) δH (300 MHz, CDCl3); 9.66 (1H, d, J 5.0, 1-H), 
7.44-7.28 (5H, m, Ar), 5.40 (1H, bs, NH), 5.14 (2H, s, benzyl CH2), 4.16 (2H, d, J 
5.0, 2-H2); δC (125 MHz, CDCl3); 196.2 (1-C), 136.1 (Ar), 128.5 (Ar), 128.3 (Ar), 
128.1 (Ar), 67.2 (2-C), 51.7 (benzyl CH2), C=O not observed; m/z (ES) 194.1. 
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tert-Butyl-N-[1-(benzenesulfonyl)-1-methyl-[N-benzyloxycarbonylamino] 
carbamate (261) 
By General Method B, using tert‐butyl carbamate (0.45 g, 3.8 
mmol), benzene sulfinic sodium salt (0.64 g, 3.8 mmol) and 
aldehyde 260 (0.54 g, 0.37 mmol), followed by filtration, washing with water (100 
mL) and hexane (100 mL) then purified by flash chromatography eluting with 
Petrol–EtOAc (70:30) give the title compound (261) (0.43 g, 36%) an amorphous 
white solid; Rf: 0.15 (10:90, EtOAc–hexane); δH (300 MHz, CDCl3); 7.90 (4H, d, J 
7.5, Ar RotA and RotB), 7.61 (12H, t, J 7.5, Ar RotA and RotB), 7.50 (4H, t, J 7.5, Ar RotA and 
RotB), 5.91 (2H, d, J 10.3, NH RotA and RotB), 5.72 (1H, t, J 8.7, NHRotB), 5.10-4.96 (6H, 
m, benzyl RotA and RotB and 1-H RotA and RotB), 4.01-3.83 (1H, m, 2-HA
 RotA), 3.82-3.75 
(1H, m, 2-HA
RotB), 3.50-3.40 (1H, m, 2-HB
RotA), 3.37-3.30 (1H, m, 2-HB
RotB), 1.43 
(9H, s, BocRotA), 1.20 (9H, s, BocRotB), NHRotA not observed; δC (75 MHz, CDCl3); 
156.8 (C=O RotA and RotB), 153.9 (C=O RotA and RotB), 136.6 (Ar RotA and RotB), 136.1 (Ar 
RotA and RotB), 134.1(Ar RotA and RotB), 129.3 (Ar RotA and RotB), 129.1 (Ar RotA and RotB), 
128.5 (Ar RotA and RotB), 128.1 (Ar RotA and RotB), 128.0 (Ar RotA and RotB), 80.8 (Boc 2-C 
RotA and RotB), 71.0 (1-C RotB), 69.9 (1-CRotA), 67.1 (benzyl CH2
RotA), 66.8 (benzyl 
CH2
RotB), 38.7 (2-C RotA and RotB), 28.3 (Boc 3-C RotB), 27.9 (Boc 3-C RotA); νmax/cm-1 
(neat); 3100, 3090, 1742, 1730, 1450; Unable to observe MH+ in mass spectrometer. 
tert-Butyl(3-bromopropoxy)diphenylsilane (263) 186 
 General Procedure D, using 3-bromopropanol (6.5 mL, 10 
mmol), TBDPS-Cl (3.12 mL, 12 mmol) and imidazole (2.04 g, 30 mmol), filtered 
through a silica plug eluting with EtOAc–Hexane (10:90) gave the title compound186 
(3.20 g, 85%) as a yellow oil; Rf: 0.60 (10:90, EtOAc–hexane); δH (500 MHz, 
CDCl3); 7.48-7.33 (4H, m, Ar), 7.25-7.10 (6H, m, Ar), 3.79 (2H, t, J 8.7, 3-H2), 3.57 
(2H, m, 1-H2), 1.90 (2H, m, 2-H2), 1.32 (9H, s, Boc). Unable to observe MH
+ in 
mass spectrometer.  
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tert-Butyl(3-nitropropoxy)diphenylsilane (264) 178 
 According to General Method C, using tert-butyl(3-
bromopropoxy) diphenylsilane (263) (2.199 g, 5.8 mmol), sodium nitrite (0.80 g, 
11.6 mmol), followed by flash chromatography, eluting with EtOAc–Petrol (20:80) 
gave the title compound178 (0.86 g, 43%) as slight yellow solid; Rf: 0.50 (10:90, 
EtOAc–hexane); δH (500 MHz, CDCl3); 7.48-7.33 (4H, m, Ar), 7.25-7.10 (6H, m, 
Ar), 4.68 (2H, m, 1-H2), 3.79 (2H, t, J 8.7, 3-H2), 1.90 (2H, m, 2-H2), 1.32 (9H, s, 
tBu);.178 
tert-Butyl-N-(2-nitro)hept-6-en-3yl) carbamate (265) 
 By General Method E, using amino sulfone (228) (1.63 g, 5 mmol), 
nitroethane (1.7 mL, 25 mmol) and N-benzylquinium chloride (12 
mol%), followed by flash chromatography, eluting with EtOAc–Hexane (90:10) 
gave the title compound (0.94 g, d.r. 90:10, 73%) as an amorphous solid; Rf: 0.4 
(10:90, EtOAc–hexane); [α]D19 +18.1 (c. 1.59, CHCl3); δH (500 MHz, CDCl3); 5.77 
(2H, ddt, J 17.0, 10.2 and 6.7 6-HMaj and Min), 5.03 (4H, app t, J 14.3, 7-H2
Maj and Min), 
4.88 (2H, d, J 9.1, NHMaj and Min), 4.69 (1H, dd, J 12.1 and 6.4, 2-HMaj), 4.51 (1H, m, 
2-HMin), 3.98 (2H, app t, J 10.0, 3-HMaj and Min), 2.28-2.15 (2H, m, 5-HA
Maj and Min), 
2.15-2.05 (2H, m, 5-HB
Maj and Min), 1.70-1.59 (2H, m, 4-HA
Maj and Min), 1.53 (6H, d, J 
6.4, 1-H3
Maj and Min), 1.45 (9H, s, BocMin), 1.45 (9H, s, BocMaj), 1.39-1.35 (2H, m, 4-
HB
Maj and Min); δC (125 MHz, CDCl3); 155.6 (C=OMin), 155.3 (C=OMaj), 136.80 (6-
CMin), 136.7 (6-CMaj), 116.1 (7-CMin), 115.9 (7-CMaj), 85.64 (2-CMaj and Min), 79.96 
(Boc 2-CMin), 79.83 (Boc 2-CMaj), 53.9 (3-CMin), 53.0 (3-CMaj), 30.0 (5-CMaj), 29.8 
(5-CMin), 28.9 (4-CMaj and Min), 28.25 (Boc 3-CMaj), 28.0 (Boc 3-CMin), 16.3 (1-CMaj and 
Min); νmax/cm-1 (neat); 3327, 2992, 1712, 1530. The minor diastereoisomer of this 
compound was subsequently crystallised from EtOAc:Hexanes. The crystal structure 
showed the syn relationship (see Section 0: Figure 39 and Section 6.8: Appendix 8: 
Table 16). 
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tert-Butyl (1-((tert-butyldiphenylsilyl)oxy)-2-nitro oct-7-en-4-yl)carbamate 
(266) 
 By General Method E, using amino sulfone (228) (0.256 g, 
0.5 mmol), nitro-compound (264) (0.86 g, 2.5 mmol) and N-
benzylquinium chloride (10 mol%), followed by two concurrent flash 
chromatography columns; eluting with DCM–Hexane (25:75) then second column 
eluting with TBME–Hexane (4:96) to give the title compound as an amorphous solid 
(0.19 g, d.r. ≥90:10, 63%); Rf: 0.20 (4:96, TBME–Hexane);δH (500 MHz, CDCl3); 
6.49 (2H, d, J 7.2, NH), 5.72 (1H, ddd, J 16.9, 12.9 and 6.5, 6-H), 5.04–4.98 (2H, m, 
7-H2), 4.51 (1H, app dt, J 15.1 and 7.2, 2-H), 4.27 (1H, app ddd, J 11.3, 8.5 and 3.7, 
5-H), 2.10–2.02 (2H, m, 4-H2), 2.00–1.92 (1H, m, 5-HA), 1.75–1.66 (1H, m, 5-HA), 
1.55 (9H, s, Boc), 1.21 (3H, d, J 7.2, 1-H3); δC (125 MHz, CDCl3); 161.2 (q J 39.1, 
C=O), 150.9 (C=O), 136.3 (6-C), 116.4 (7-C), 87.1 (Boc 2-C), 61.1 (2-C), 48.7 (3-
C), 30.0 (4-C), 27.4 (Boc 3-C), 27.2, (5-C), 17.3 (1-C) νmax/cm-1 (neat); 3100, 3090, 
1742, 1730, 1450. 
tert-Butyl-N-(2-nitro-3-methyl-[N-benzyloxycarbonylamino])carbamate 
(267) 
 By General Method E, using amino sulfone (213) (0.22 g, 0.5 
mmol), nitroethane (0.17 g, 2.5 mmol) and N-benzylquinium chloride 
(12 mol%), followed by flash chromatography, eluting with EtOAc–Hexane (30:70) 
gave title compound (79 mg, d.r. 60:40, 43%) as an amorphous solid;  Rf: 0.15 
(30:70, EtOAc–hexane); δH (500 MHz, CDCl3); 7.33 (10H, m, Ar), 5.54 (1H, bs, 
NH), 5.30 (1H, d, J 10.6 NH), 5.20 (2H, s, benzyloxycarbonylMaj), 5.09 (2H, s, 
benzyloxycarbonylMin), 4.84-4.77 (1H, app bs, 2-HMin), 4.76-4.67 (1H, m, 3-HMaj), 
4.18 (1H, d, J 10.6, 2-HMaj), 4.13 (1H, m, 3-HMin), 3.92-3.84 (1H, m, 1-HA
Maj), 3.79 
(1H, dd, J 14.4 and 7.5, 1-HB
Maj), 3.43 (1H, dd, J 13.6 and 7.5, 1-HA
Min), 3.32 (1H, 
m, 1-HA
Min), 2.19-2.12 (3H, m, 3-H3
Maj), 1.90 (1H, d, J 6.5, 3-H3
Min), 1.59 (9H, s, 
BocMaj), 1.42 (9H, s, BocMin), 2 × NH not observed; δC (75 MHz, CDCl3); 159.7 
(C=OMaj and Min), 158.3(C=OMaj and Min), 129.3 (ArMaj and Min), 128.5 (ArMaj and Min), 
128.2 (ArMin and Min), 128.1 (ArMin and Min), 81.1 (2-CMaj), 81.0 (2-CMin), 78.1 (Boc 2-
CMaj), 78.0 (Boc 2-CMin),69.7 (2-CMaj and Min), 67.2 (3-CMin), 67.0 (3-CMaj), 53.3 (4-
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CMaj), 52.2 (4-CMin), 28.2 (Boc 3-CMaj), 27.9 (Boc 3-CMaj), 16.4 (1-CMaj and Min); 
νmax/cm-1 (neat); 3389, 2997, 1732, 1717, 1640, 1580; m/z (ES) 367.17. 
Benzyl tert-butyl hept-6-ene-2,3-diyldicarbamate (269) 
By General Method F, using nitro adduct (265) (2.6 g, 10 mmol) in 
THF (25 mL), LiAlH4 (21 mL of 1 M solution), H2O (0.8 mL), 
NaOH (1.6 mL), H2O (2.4 mL). The crude material was then dissolved in THF (0.1 
M) and  benzyl chloroformate (14 mL, 10 mmol), E3N (3 eq.) was added and the 
reaction stirred for 18 h. give a crude material which was purified by flash 
chromatography, eluting with DCM–MeOH (100:0 to 95:5) gave the title compound 
(2.14 g, 59%);  Rf: 0.35 (10:90, EtOAc–hexane); δH (500 MHz, MeOH); 7.58 (2H, 
d, J 8.3, Ar), 7.11–7.01 (3H, m, Ar), 5.50 (1H, ddt, J 17.1, 10.4 and 6.6, 6-H), 4.73 
(1H, dd, J 17.1 and 1.4, 7-HA), 4.66 (1H, dd, J 10.4 and 1.4, 7-HB), 4.10 (2H, s, 
benzyl H2), 3.89–3.81 (1H, m, 2-H), 3.48 (1H, m, 3-H), 1.87 (1H, dt, J 14.0 and 6.6, 
5-HA), 1.77 (1H, dt, J 14.0, 6.6, 5-HB), 1.31 (1H, dddd, J 14.0, 9.0, 7.0, 4.1, 4-HA), 
1.20-1.05 (10H, m, 4-HB and Boc), 0.9 (3H, d, J 6.7, 1-H3), 2 × NH not observed; δC 
(125 MHz, MeOH); 169.1 (C=O), 154.2 (C=O), 138.8 (6-C), 136.0 (Ar), 132.2 (Ar), 
129.3 (Ar), 128.7 (Ar), 115.4 (7-C), 75.7 (Boc 2-C), 63.4 (benzyl), 62.3 (3-C), 55.4 
(2-C),  32.2 (4-C), 31.3 (5-C), 28.8 (Boc 3-C), 15.6 (1-C); νmax/cm-1 (neat); 3308, 
2987, 1750, 1712, 1528; m/z (ES) 363.4. 
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tert-Butyl ((2S,3R)-2-benzamidohept-6-en-3-yl)carbamate (270) 
By General Method F, using nitro adduct (265) (2.6 g, 10 mmol) in 
THF (25 mL), LiAlH4 (21 mL of 1 M solution), H2O (0.8 mL), 
NaOH (1.6 mL), H2O (2.4 mL). The crude amine was dissolved in DCM (0.1 M) 
and benzyl anhydride (2.22 g, 10 mmol) and E3N (3 eq.) was added and the was 
stirred for 18 hr. The reaction mixture was then concentrated in vacuo and purified 
by flash chromatography, eluting with EtOAc–Hexane (90:10) gave the title 
compound (1.83 g, 55%); Rf: 0.40 (20:80, EtOAc–Hexane); δH (500 MHz, MeOH); 
7.85 (2H, d, J 7.5, Ar), 7.57 (1H, J 7.5, Ar), 7.49-7.46 (2H, m, Ar) 5.89 (1H, ddt, J 
17.1, 10.2 and 6.6, 6-H), 5.08 (1H, dd, J 17.1 and 1.4, 7-HA), 5.05 (1H, dd, J 10.2 
and 1.4, 7-HB), 4.22-4.20 (1H, m, 3-H), 3.63–3.60 (1H, m, 2-H), 1.87 (1H, dt, J 14.0 
and 6.6, 5-HA), 1.77 (1H, dt, J 14.0 and 6.6, 5-HB), 1.41 (9H, s, Boc), 1.37 (1H, m, 
4-HB), 1.31 (1H, dddd, J 14.0, 9.0, 7.0, 4.1, 4-HA), 1.26 (3H, d, J 6.7, 1-H3), 2 × NH 
not observed; δC (125 MHz, MeOH); 158.2 (C=O), 158.3 (C=O), 148.1 (6-C), 138.0 
(Ar), 128.6 (Ar), 128.4 (Ar), 128.1 (Ar), 115.2 (7-C), 75.7 (Boc 2-C), 62.3 (3-C), 
55.4 (2-C),  32.2 (4-C), 31.3 (5-C), 28.8 (Boc 3-C), 15.6 (1-C); νmax/cm-1 
(neat);3340, 2968, 1703, 1618; m/z (ES) 333.22; HRMS Found: 333.2174, 
(C19H28N2O3 MH
+ requires 333.2172). 
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tert-Butyl (2-(1,3-dioxoisoindolin-2-yl)hept-6-en-3-yl)carbamate (271) 
By General Method F, using nitro adduct (265) (2.6 g, 10 mmol) 
in THF (25 mL), LiAlH4 (21 mL of 1 M solution), H2O (0.8 mL), 
NaOH (1.6 mL), H2O (2.4 mL). The crude amine was dissolved in 
toluene (0.1 M) and phthalic anhydride (2.22 g, 10 mmol) and E3N 
(3 eq.) was added and the reaction mixture was heated to reflux for 48 hrs. The 
reaction mixture was then concentrated in vacuo and purified by flash 
chromatography, eluting with EtOAc–Hexane (50:50) gave the title compound 271 
(1.22 g, 34%) as an amorphous white solid; Rf: 0.40 (20:80, EtOAc–Hexane); δH 
(500 MHz, CDCl3); 8.06–8.03 (2H, m, PhthMin), 7.96–7.93 (2H, m, PhthMin), 7.87–
7.79 (2H, m, PhthMaj), 7.75–7.70 (2H, m, PhthMaj), 5.86–5.69 (2H, m, 6-HMaj and Min), 
5.05–4.99 (4H, m, 7-H2Maj and Min), 4.44 (2H, d, J 9.8, NHMaj), 4.34 (1H, app q, J 7.1, 
2-HMin), 4.18 (1H, app q, J 7.1, 2-HMaj), 4.22–4.14 (1H, m, 3-HMaj), 4.12–4.04 (1H, 
m, 3-HMin), 2.20–2.02 (4H, m, 4-H2Maj and Min), 1.54 (6H, dd, J 7.7, 1-H3Maj and Min), 
1.50-1.42 (4H, m, 5-H2
 Maj and Min), 1.41 (18H, s, Boc Maj and Min); δC (125 MHz, 
CDCl3); 168.9 (C=O
Min), 168.3 (C=OMaj), 155.8 (C=OMin) 155.6 (C=OMaj), 137.6 (6-
CMaj), 137.0 (6-CMin), 136.0 (ArMin), 133.84 (ArMaj), 131.87 (ArMaj), 131.80 (ArMin), 
123.24 (ArMin), 123.13 (ArMaj), (7-CMin), 115.2 (7-CMaj), 79.1 (Boc 2-CMaj), 78.8 
(Boc 2-CMin), 52.6 (2-CMaj), 52.5 (2-CMin), 50.7(3-CMaj), 50. (3-CMin), 31.1 (4-CMaj), 
30.5 (4-CMin), 30.1 (5-CMaj), 29.2 (5-CMin), 28.2 (Boc 3-CMaj), 28.1 (Boc 3-CMin), 
15.6 (1-CMin), 14.0 (1-CMaj); νmax/cm-1 (neat); 3301, 2980, 1730, 1715, 1496; m/z 
(ES) 359.2; HRMS Found: 359.1971, (C20H26N2O4 MH
+ requires 359.1965).  
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tert-Butyl (2-(2,2,2-trifluoroacetamido)hept-6-en-3-yl)carbamate (272) 
By General Method F, using nitro adduct (265) (0.26 g, 1 mmol) 
in THF (25 mL), LiAlH4 (2.1 mL of 1 M solution), H2O (0.08 
mL), NaOH (0.16 mL), H2O (0.24 mL), then trifluoroacetyl 
chloride (1.2 eq.), followed by flash chromatography, eluting with 
EtOAc–Hexane (90:10) gave the title compound (0.11 g, 33%); Rf: 0.30 (20:80, 
EtOAc–Hexane); δH (500 MHz, CDCl3); 6.49 (2H, d, J 7.2, NH), 5.72 (1H, ddd, J 
16.9, 12.9 and 6.5, 6-H), 5.04–4.98 (2H, m, 7-H2), 4.51 (1H, app dt, J 15.1 and 7.2, 
2-H), 4.27 (1H, app ddd, J 11.3, 8.5 and 3.7, 5-H), 2.10–2.02 (2H, m, 4-H2), 2.00–
1.92 (1H, m, 5-HA), 1.75–1.66 (1H, m, 5-HB), 1.55 (9H, s, Boc), 1.21 (3H, d, J 7.2, 
1-H3); δC (125 MHz, CDCl3); 161.2 (q J 39.1, C=O), 150.9 (C=O), 136.3 (6-C), 
116.1 (q, J 288.1, CF3
 Maj), 116.4 (7-C), 87.1 (Boc 2-C), 61.1 (2-C), 48.7 (3-C), 30.0 
(4-C), 27.4 (Boc 3-C), 27.2, (5-C), 17.3 (1-C); νmax/cm-1 (neat); 3290, 2993, 1723, 
1610, 1485; m/z (ES) 325.2. 
tert-Butyl 2-(1-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(pyridin-3-ylmethyl) 
pyrrolidine-1-carboxylate (279) 
By General Method H, using 271 (43 mg, 0.12 mmol), 3-
bromopyridine (0.14 mmol), followed by flash 
chromatography, eluting with DCM–EtOH-NH4OH (97:2:1 to 
84:14:2) gave the title compound (16 mg, d.r. >95:<5, 31%); Rf: 0.1 (97:2:1 DCM–
EtOH-NH4OH); δH (500 MHz, CDCl3); 8.09 (2H, d, J 8.1, pyridinyl 2-H and 4-H), 
7.59–7.49 (4H, m, Ar), 7.42 (1H, m, pyridnyl 6-H), 7.11 (1H, app s, pyridinyl 5-H), 
4.29 (2H, m, 5-H and ethyl 1-C), 3.75 (1H, ddd, J 11.7, 8.0 and 3.5, 2-H), 2.89 (1H, 
d, J 13.6, 5-methyl HB) 2.52 (1H, J 13.6, 5-methyl HA), 1.57 (2H, dd, J 8.2, 5.4, 4-
H2), 1.50–1.37 (2H, m, 3-H2), 1.25 (9H, s, Boc), 1.11 (3H, d, J 8.0, ethyl 2-H3); δC 
(125 MHz, CDCl3); 175.57 (Phth), 173.41 (Phth), 162.0 (C=O) 147.8(pyridinyl 2-
C), 139.2 (pyridinyl 4-C), 135.3 (Phth), 124.9 (Phth), 136.8 (pyridinyl 2-C), 135.3 
(pyridinyl 6-C), 125.7 (pyridinyl 5-C), 77.4 (Boc 2-C), 61.7 (2-C), 49.3 (ethyl 1-C), 
40.8 (benzyl 5-C), 33.5 (3-C), 32.2 (5-C), 28.5 (Boc 3-C), 28.4 (4-C), 15.7 (ethyl 2-
C); νmax/cm-1 (neat); 3330, 2980, 1722,1716, 1601; m/z (ES) 435.3; HRMS Found: , 
(C25H29N3O4 MH
+ requires ). Note: 51% of starting material  was also recovered. 
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 (2R,5R)-tert-Butyl 2-((S)-1-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-ethoxy-2-
oxoethyl)pyrrolidine-1-carboxylate (281) 
To a solution of 271 (0.16 g, 0.4 mmol) in DCM (7 mL), was 
added ethyl acrylate (2.4 mmol), followed by Hoveyda-
Grubbs 2nd generation catalyst (2.5 mol%) as a solid. The 
solution was stirred for 24 h, at which time another portion of catalyst (2.5 mol%) 
was added. The solution stirred for a further 72 h, concentrated  in vacuo. The crude 
material was dissolved in DMF–THF, cooled to -78 °C and NaOEt (1.5 eq.) was 
added. After 40 min, sat. NH4Cl(aq) was added. The aqueous phase was extracted 
with EtOAc (3 × 30 mL) The combined organic layers were washed with water (2 × 
10 mL), brine (1 × 10 mL), dried with MgSO4, filtered and concentrated in vacuo 
followed by flash chromatography, eluting with EtOAc–Hexane (90:10) gave the 
title compound (281) (0.11 g, d.r. 65:35, 59%); Rf: 0.35 (20:80, EtOAc–Hexane); δH 
(500 MHz, CDCl3); 7.85–7.78 (8H, m, Ar), 4.49 (1H, ddd, J 15.5, 9.6 and 1.5, 5-
HMaj), 4.41 (1H, dd, J 15.5, 9.6 and 3.5, 5-HMin), 4.35 (2H, m, 2-HMaj and Min), 4.29 
(2H, dt, J 7.3 and 3.1, ethyl 1-HMaj and Min), 4.18 (1H, q, J 7.2, ethyl 2-HMaj), 4.17 
(1H, q, J 7.2, ethyl 2-HMin), 2.83 (1H, dd, J 15.5 and 3.5, 5’HAMaj), 2.87 (1H, dd, J 
15.5 and 3.5, 5’HAMin), 2.78 (1H, dd, J 15.5 and 3.5, 5’HBMin), 2.74 (1H, dd, J 15.5 
and 3.5, 5’HBMaj), 2.21 (6H, d, J 6.2, ethyl 2-H2), 2.10–1.97 (2H, m, 4-HAMaj and Min), 
1.93 (2H, m, 3-HA
Maj and Min), 1.82–1.71 (4H, m, 3-HBMaj and Min and 4-HBMaj and Min), 
1.52 (9H, s, BocMin), 1.43 (9H, s, BocMaj), 1.26 (3H, d, J 7.1 OCH2CH3
Min), 1.25 
(3H, t, J 7.1 OCH2CH3
Maj); δC (125 MHz, CDCl3); 175.6 (C=OMaj), 175.4 (C=OMin), 
173.4 (Phth C=OMaj and Min) 158.3 (C=OMin), 157.9 (C=OMaj) 137.9 (PhthMaj and Min), 
136.8 (Phth Maj and Min), 126.6 (PhthMaj and Min), 79.2 (BocMaj), 79.0 (BocMaj), 64.6 (5-
CMaj and Min), 64.5 (ethyl 2-CMaj and Min), 59.0 (OCH2CH3
Maj and Min), 54.3 (2-CMin), 53.9 
(2-CMaj), 37.3 (5’ethyl-CMin), 36.5 (5’ethyl-CMaj), 27.3 (3-CMaj and Min), 27.5 (4-CMaj 
and Min), 26.1 (BocMin), 26.0 (BocMaj), 24.5 (2’ ethyl CH3Maj and Min), 17.0 
(OCH2CH3
Maj and Min); νmax/cm-1 (neat); 3289, 1714,1705; m/z (ES) 431.2; HRMS 
Found: 431.1738, (C23H27N2O4 MH
+ requires 431.1732). 
Note: the following conditions were also attempted but the diastereoselectivity 
obtained was the same as above (65:35). (i) NaOMe (1.5 eq.) in DMF–THF -78 °C; 
(ii) KtBu (1.5 eq.) in DMF–THF -78 °C; (iii) KtBu (1.5 eq.) in DMF -78 ˚C. 
 136 
 
Benzyl tert-butyl (1-((tert-butyldiphenylsilyl)oxy)hept-6-ene-2,3-diyl) 
dicarbamate (283) 
By General Method F, using nitro adduct (235) (1.06 g, 2 
mmol), in THF (5 mL), LiAlH4 (5 mL of 1 M solution), H2O 
(0.16 mL), NaOH (0.32 mL), H2O (0.48 mL). Note LiALH4 partially removed 
TBDPS group therefore the crude residue is dissolved in DMF (0.3 M), TBDPS-Cl 
(0.52 mL, 2 mmol), imidazole (3 eq.) were added and stirred for 18 h then water 
(100 mL) and DCM (20 mL) was added. The phases were separated and the aqueous 
phase was extracted with DCM (3 × 20 mL). The combined organic phase was 
washed with sat. NaHCO3(aq) (3 × 20 mL), water (2 × 20 mL), and brine (1 × 20 
mL), then dried (MgSO4) and concentrated in vacuo to give a crude amine which 
was dissolved in DCM (0.1 M). NaHCO3(aq)  (3 eq.) and benzyl chloroformate (0.28 
mL, 2 mmol) were added and the reaction stirred for 18 h. to give a crude material 
which was purified by flash chromatography, eluting with EtOAc–Hexane (90:10) 
gave the title compound 283 (0.59 g, 48%); Rf: 0.30 (20:80, EtOAc–Hexane); δH 
(500 MHz, CDCl3);7.63 (4H, dd, J 7.5 and 1.5, Ar), 7.45–7.30 (11H, m, Ar), 5.86–
5.72 (1H, m, 6-H), 5.38 (1H, t, J 7.8, 2-H), 5.12–4.91 (3H, m, 3-H and 7-H2), 3.86 
(1H, d, J 9.3, benzyl HA), 3.80 (2H, m, 1-H2), 3.75 (1H, d, J 9.3, benzyl HB), 2.17–
2.02 (2H, m, 5-H2), 1.57 (2H, dd, J 12.3, 5.4, 4-H2), 1.43 (9H, s, Boc), 1.08 (9H, s, 
tBu), 2 × NH not observed; δC (125 MHz, CDCl3); 156.3 (C=O), 156.0 (C=O), 137.7 
(6-C), 135.7 (Ar), 132.6 (Ar), 130.4 (Ar), 135.5 (Ar), 134.9 (Ar) 130.3 (Ar), 130.1 
(Ar), 129.8 (Ar), 128.6 (Ar), 128.4 (Ar), 128.2 (Ar), 128.1 (Ar), 115.3 (7-C), 79.2 
(Boc 2-C), 66.9 (benzyl CH2), 63.7 (1-C), 53.5 (2-C), 52.8 (3-C), 32.5 (4-C), 30.3 
(5-C), 30.0 (SiC(CH3)3), 28.4 (Boc 3-C), 26.9 (SiC(CH3)3); νmax/cm-1 (neat); 3297, 
2993, 1720, 1601; m/z (ES) 617.2; HRMS Found: 617.3419, (C36H48N2OsSi MH
+ 
requires 617.3405). 
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tert-Butyl ((2R)-1-((tert-butyldiphenylsilyl)oxy)-2-((2,4-dimethoxy 
benzyl)amino)hept-6-en-3-yl)carbamate (282) 
By General Method F, using nitro adduct (235) (3.08 g, 6 
mmol), in THF (15 mL), LiAlH4 (13 mL of 1 M solution), 
H2O (0.54 mL), NaOH (0.96 mL), H2O (1.44 mL). Note LiALH4 partially removed 
TBDPS group therefore the crude residue is dissolved in DMF (0.3 M), TBDPS-Cl 
(1.56 mL, 6 mmol), imidazole (3 eq.) were added and stirred for 18 h then water 
(100 mL) and DCM (40 mL) was added. The phases were separated and the aqueous 
phase was extracted with DCM (3 × 40 mL). The combined organic phase was 
washed with sat. NaHCO3(aq) (3 × 40 mL), water (2 × 40 mL), and brine (1 × 40 
mL), then dried (MgSO4) and concentrated in vacuo to give a crude amine which 
was dissolved in MeOH (0.2 M) and 2,4-dimethoxybenzaldehyde (0.33 g) was 
added then the reaction heated to reflux for 12 hr. After the reaction had cooled to rt, 
NaBH4 (5eq.) was added and left to stir for 3 hours. The reaction mixture was 
concentrated in vacuo, partitioned between EtOAc (40 mL) and water (40 mL), the 
organic layer was extracted with 0.5 M HCl(aq) (5 × 30 mL) and the combined 
aqueous layers were neutralised by the addition of 2 M NH4OH(aq) (pH 10). The 
aqueous layer was then extracted with chloroform (5 × 30 mL), combined, dried 
(MgSO4), filtered and concentrated in vacuo followed by flash chromatography, 
eluting with EtOAc–DCM (90:10) gave the title compound (1.63 g, 43%); Rf: 0.10 
(20:80, EtOAc–Hexane); δH (500 MHz, CDCl3);7.66–7.60 (4H, m, Ar), 7.45–7.33 
(6H, m, Ar), 7.10 (1H, d, J 8.1, DMB 6-H), 6.42 (1H, d, J 2.4, DMB 3-H), 6.40 (1H, 
dd, J 8.1 and 2.4, DMB 5-H), 5.79 (1H, ddt, J 17.0, 9.9 and 6.6, 6-H), 5.41 (1H, bs, 
NH), 4.97 (1, d. J 17.0, 7-HA), 4.92 (1H, d. J 9.9, 7-HB), 3.81-3.78 (4H, m, 3-H, 
OMe), 3.75 (3H, s, OMe), 3.78-3.74 (3H, m, 2-H, 1-H2), 3.68 (2H, s, benzyl), 2.07 
(2H, dd, J 13.7 and 6.8 5-HA), 2.01 (1H, dd, J 14.9 and 6.8, 5-HA), 1.53-1.46 (2H, 
m, 4-H2), 1.43 (9H, s, Boc), 1.08 (9H, s, 
tBu), NH not observed; δC (125 MHz, 
CDCl3); 163.7 (C=O), 159.1 (DMB 4-C), 155.9 (DMB 2-C), 137.7 (6-C), 134.9 
(Ar), 133.9 (Ar), 132.3 (Ar), 129.2 (DMB 6-C), 128.9 (Ar), 126.9 (Ar), 126.9 (Ar), 
127.9 (Ar), 127.8 (Ar), 127.8 (Ar), 120.5 (DMB 1-C), 113.7 (7-C), 102.9 (DMB 6-
C), 97.7 (DMB 3-C), 76.4 (Boc), 63.0 (1-C), 55.3 (2-C), 55.2 (3-C), 30.7 (5-C), 29.7 
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(4-C), 27.6 (Boc 3-C), 26.8 (tBu), 25.7 (tBu); νmax/cm-1 (neat); 3310, 2983, 1716, 
1620; m/z (ES) 632.9; C37H52N2O5Si. 
tert-Butyl ((R)-1-((R)-3-(2,4-dimethoxybenzyl)-2-oxooxazolidin-4-yl)pent-4-
en-1-yl)carbamate (284) 
TBAF (2.5 mL, 1 M in THF) was added to 282 (1.21 g, 2 mmol) in 
THF (0.5 M) and stirred for 2 h. H2O (5 ml) was added and the 
aqueous layer was extracted with DCM (3 × 15 mL), dried (MgSO4), concentrated 
in vacuo then filtered through a plug of silica eluting with DCM-EtOAc (75:25) to 
give the crude amino alcohol. The amino alcohol was dissolved in DMF (0.13 M) 
and CDI (4.5 eq.) was added then mixture was heated at 110 °C for 18 h until 
consumption. The reaction mixture was then concentrated in vacuo and purified by 
SCX solid phase extraction eluting with sat NH3 in MeOH then flash column 
chromoatography eluting with EtOAc–Hexane (50:50) gave 284 (0.52 g, 62%); δH 
(500 MHz, MeOH) 7.24 (1H, d, J 8.2, DMB 6-H), 6.59 (1H, d, J 2.4, DMB 3-H), 
6.53 (1H, dd, J 8.2, 2.4, DMB 5-H), 5.84 (1H, ddt, J 17.0, 10.1, 6.0, pentenyl 4-H), 
5.18–4.92 (2H, m, pentenyl 5-H2), 4.58 (1H, d, J 14.8, 3-benzyl HA), 4.42 (1H, d, J 
14.8, 3-benzyl HB), 4.24 (1H, dd, J 9.2, 5.7, 1-HA), 4.16–4.07 (2H, m, 1-HB, 
pentenyl 1-H), 3.86 (3H, s, OMe), 3.82 (3H, s, OMe), 3.60 (1H, ddd, J 9.2, 5.1 and 
1.9, 2-H), 2.18 (1H, dt, J 14.2 and 6.0, pentenyl 3-HB), 2.10 (1H, dt, J 14.2 and 6.0, 
pentenyl 3-HB), 1.49 (9H, s, Boc), 1.42-1.30 (2H, m, pentenyl 2-H2). δ C (75 MHz, 
MeOD) 162.7 (C=O), 160.7 (DMB 4-C), 160.4 (DMB 2-C), 158.4 (Boc), 138.6 
(pentenyl 4-C), 132.5 (DMB 1-C), 117.4 (DMB 6-C), 116.1 (pentenyl 5-C), 105.8 
(DMB 5-C), 99.4 (DMB 3-C), 72.8 (Boc 3-C), 64.3 (1-C), 59.1 (2-C), 56.0 (OMe), 
55.9 (OMe), 49.8 (3-C), 40.8 (benzyl 1-C), 31.4 (4-C), 30.7 (5-C), 28.8 (Boc 3-C); 
m/z (ES) 421.7% C22H32N2O6 
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(4R,5R)-4-(But-3-en-1-yl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-1-(2,4-
dimethoxybenzyl)imidazolidin-2-one (285) 
A solution of 282 in DCM (125 mL) at 0 °C was treated with 
thioanisole (2.00 mL, 19.0 mmol) and trifluoroacetic acid (30.6 
mL, 0.456 mol). The mixture was stirred at rt for 40 min. The 
reaction mixture was quenched with saturated NaHCO3 (60 mL) at 0 °C and 
extracted with DCM (3 × 50 mL). The organic layers were combined, dried 
(MgSO4), then concentrated in vacuo to give the crude amino alcohol. The amino 
alcohol was dissolved in DMF (0.13 M) and CDI (1.3 eq.) was added then mixture 
was heated at 110 °C for 18 h until consumption of the starting material. The 
reaction mixture was then concentrated in vacuo and purified by SCX solid phase 
extraction eluting with sat NH3 in MeOH then flash column chromoatography 
eluting with EtOAc–Hexane (50:50) gave 285 (0.52 g, 62%); 7.52 (2H, dd, J 8.1, 1.6 
ArRot A and Rot B), 7.49–7.46 (6H, m, ArRot A and Rot B), 7.33–7.22 (12H, m, ArRot A and Rot 
B), 6.90 (1H, d, J 8.1, DMB 6-HRot A), 6.86 (1H, d, J 8.1, DMB 6-H Rot B), 6.35 (1H, 
d, J 2.4, DMB 3-HRot A), 6.33 (1H, d, J 2.4, DMB 3-H Rot B), 6.31 (1H, d, J 8.4, DMB 
5-HRot A) 6.30 (1H, d, J 8.2, DMB 5-H Rot B), 5.73–5.60 (2H, m, 3-H Rot A and Rot B), 
4.90 (1H, d, J 17.1, 4-HA
 Rot B), 4.90 (1H, d, J 17.2, 4-HA
Rot A), 4.82–4.79 (2H, m. 4-
HB
Rot A and Rot B), 4.22 (1H, t, J 15.1, 2-methyl HA
Rot A), 3.93 (1H, d, J 15.1, 2-methyl 
HA
Rot B), 3.89 (2H, d, J 15.5, 2-methyl HA
 Rot B), 3.79 (2H, bs, NH Rot A and Rot B), 3.65 
(3H, s, OMeRot A), 3.65 (6H, s, OMeRot A and Rot B), 3.62 (1H, d, J 5.2, 5-H Rot B), 3.61 
(1H, d, J 5.2, 5-HRot A), 3.59 (1H, d, J 5.7, 4-HRot A), 3.56 (1H, d, J 5.7, 4-HRot B), 
3.50 (3H, s, OMe Rot B), 2.75 (1H, d, J 8.5, 1-methylHB
Rot A), 2.66–2.49 (1H, m, 1-
methylHA
Rot A), 2.36 (1H, t, J 8.5, 1-methylHB
Rot B), 2.29 (1H, t, J 7.9, 1-methylHA
 
Rot B), 1.95–1.84 (2H, m, butenyl 3-HARot A and Rot B), 1.77–1.66 (2H, m, butenyl 3-
HB
Rot A and Rot B), 1.62 (2H, m, butenyl 2-HB
Rot A and Rot B), 1.37 (2H, m, butenyl 2-HA
Rot 
A and Rot B), 1.10 (9H, s, tBuRot A), 0.97 (9H, s, tBuRot B); δC (125 MHz, CDCl3); 163.7 
(C=ORot A and B), 159.1 (DMB 4-CRot A and B), 157.7 (DMB 2-CRot B), 157.6 (DMB 2-
CRot A), 136.9 (ArRot A), 136.6 (Ar Rot B), 134.9 (Ar Rot B), 134.8 (ArRot A), 134.7 (ArRot 
A), 134.3 (Ar Rot B), 133.9 (Ar Rot B), 132.27 (ArRot A), 132.1 (DMB 1-C Rot A and B), 
129.3 (ArRot A), 128.9 (ArRot A), 128.8 (Ar Rot B), 128.5 (Ar Rot B), 126.9 (Ar Rot B), 
126.8 (ArRot A), 126.5 (Ar Rot B), 126.1 (ArRot A), 120.5 (DMB 3-CRot A and B), 113.7 (7-
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CRot A and B), 102.9 (DMB 5-CRot A and B), 97.7 (DMB 6-CRot A), 96.9 (DMB 6-C Rot B), 
63.0 (4-C Rot B), 62.8 (4-CRot A), 59.8 (5-CRot A and B), 55.5 (OMeRot A), 55.4 (OMe Rot 
B), 54.5 (5-methyl C), 54.3 (5-methyl C Rot B), 54.0 (OMeRot A and B), 38.7 (2-methyl 
CRot A and B),  30.7 (butenyl 2-CRot A), 29.7 (butenyl 2-C Rot B), 27.6 (butenyl 1-CRot A 
and B) 26.0 (Si(CH3)3
Rot A), 25.9 (Si(CH3)3
Rot B), 21.80 (
tBuRot A and B); νmax/cm-1 (neat) ; 
m/z (ES) 559.7. 
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(1R,5R,7aR)-5-[(2-Chlorophenyl)methyl]-2-(2,4-dimethoxybenzyl)-1-
(hydroxymethyl)tetrahydro-1H-pyrrolo[1,2-c]imidazolidin-3-one (289) 
By General Method H, using 285 (0.20 g, 0.45 mmol), 1-
bromo-2-chlorobenzene (0.54 mmol), followed by flash 
chromatography, eluting with EtOAc–Hexane (90:10) gave 288 (0.21 g, 71%) 
however analysis of 500 MHz 1H NMR  spectrum was non trivial; 1 M TBAF (0.12 
mL) was added to 288 in THF (0.5M) and stirred for 2 h. H2O (5 ml) was added and 
the aqueous layer was extracted with DCM (3 × 5 mL), dried (MgSO4) and passed 
through a plug of silica eluting with DCM-EtOH-Et3N (90:9:1) to give the title 
compound (65 mg, d.r. 65:35, 46%); After purification, the sample became 
contaminated with grease from the highvac. Rf: 0.15 (97:2:1 DCM–EtOH-NH4OH); 
δH (500 MHz, CDCl3); 7.40 (1H, dd, J 8.0 and 1.8, chlorobenzyl 3-HMaj), 7.38 (1H, 
dd, J 8.0 and 1.8, chlorobenzyl 3-HMin), 7.33 (2H, dt, J 8.0 and 1.8, chlorobenzyl 5-
HMaj and Min), 7.19 (2H, m, ArMaj and Min), 7.14 (2H, m, ArMaj and Min), 7.13 (2H, t, J 8.0, 
DMB 6-HMaj and Min), 6.47 (1H, d, J 2.4, DMB 5-HMin), 6.46 (1H, d, J 2.4, DMB 5-
HMaj), 6.43 (2H, dd, J 8. and 2.4, DMB 3-HMaj and Min), 4.58 (1H, d, J 14.9, 2-benzyl 
HB
Maj), 4.51 (1H, d, J 15.0, 2-benzyl HB
Min), 4.28 (1H, d, J 14.9, 2-benzyl HA
Maj), 
4.23 (2H, ddd, J  11.5, 7.0 and 4.8, 7-HMaj and Minor), 4.18 (1H, d, J 15.0, 2-benzyl 
HA
Min), 3.79 (3H, s, OMe), 3.78 (3H, s, OMe), 3.78 (6H, s, OMe), 3.72–3.65 (4H, m, 
1-methyl H2
Min and 1-CMaj and Min) 3.51 (2H, ddd, J 9.8, 5.7 and 2.7, 1-methy H2
Maj), 
3.26 (2H, dt, J 4.5 and 3.2, 4-HMaj and Min), 3.13 (1H, dd, J 13.8 and 6.4, 4-benzyl 
HA
Maj), 3.08 (1H, dd, J 13.8 and 6.5, 4-benzyl HA
Min), 2.91 (1H, dd, J 13.8 and 6.4, 
4-benzyl HB
Maj), 2.90 (1H, dd, J 13.8 and 6.5, 4-benzyl HB
Maj), 2.27 (2H, dtd, J 14.2, 
7.2, 6.6 and 1.7, 5-HB
Maj and Min), 2.04 (2H, ddd, J 6.6, 4.8 and 1.7, 6HB
Maj and min), 
2.00–1.93 (2H, m, 5-HAMaj and Min), 1.93–1.82 (2H, m, 6-HAMaj and Min), 2× OH not 
observed; δC (125 MHz, CDCl3); 164.3 (3-C (C=O)Maj), 163.7 (3-C (C=O)Min), 160.5 
(DMB 4-CMin), 160.4 (DMB 4-CMaj), 158.3 (DMB 1-CMin), 158.1 (DMB 1-CMin), 
135.9 (ArMin) 135.8 (ArMaj), 133.8 (ArMaj), 133.7 (Ar), 130.8 (DMB 2-CMin), 130.7 
(DMB 1-CMaj), 130.3 (ArMin), 130.2 (ArMaj), 128.6 (ArMin), 126.9 (ArMaj), 126.8 
(ArMin), 126.6 (ArMaj), 125.9 (ArMin), 125.8 (ArMaj), 117.8 (DMB 6-CMin), 117.8 
(DMB 6-CMaj), 104.8 (DMB 5-CMaj), 104.2 (DMB 5-CMin), 98.5 (DMB 3-CMaj and 
Min), 62.8 (1-methylMaj), 62.5 (1-methylMin), 60.3 (5-CMin), 59.7 (5-CMaj), 59.1 (1-
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CMaj ), 59.0 (1-CMin ), 58.2 (7a-CMaj), 58.1 (7a-CMaj), 55.3 (OMeMaj), 54.8 (OMeMin), 
54.7 (OMeMaj), 54.6 (OMeMin) 39.6 (2-benzylMaj), 39.2 (2-benzylMin), 38.7 (5-
methylMaj), 38.6 (5-methylMin), 31.0 (6-CMin), 30.9 (6-CMaj), 28.2 (7-CMin), 27.9 (7-
CMaj); HRMS Found: 431.1738 (C23H27ClN2O4 MH
+ requires 431.1732).  
 143 
 
Benzyl tert-butyl (1-((tert-butyldiphenylsilyl)oxy)hept-6-ene-2,3-diyl) 
dicarbamate (292)  
 By General Method H, using 285 (0.14 g, 0.26 mmol), 1-
bromo-2-chlorobenzene (0.54 mmol), followed by flash 
chromatography, eluting with EtOAc–Hexane (90:10) gave 291 (94 mg, 57%). 
However analysis of 500 MHz 1H NMR  spectrum was non trivial; 1 M TBAF (0.12 
mL) was added to 291 in THF (0.5M) and stirred for 2 h. H2O (5 ml) was added and 
the aqueous layer was extracted with DCM (3 × 5 mL), dried (MgSO4) and passed 
through a plug of silica eluting with DCM-EtOH-Et3N (90:9:1) to give 292 (32 mg, 
d.r. 65:35, 54%); Rf: 0.15 (97:2:1 DCM–EtOH-NH4OH); δH (500 MHz, CDCl3); 
8.49 (1H, dd, J 2.0 and 0.8, pyridinyl 2-H), 8.46 (1H, dd, J 4.8 and 2.0, pyridinyl 6-
H), 7.68 (1H, dt, J 7.8 and 2.0, pyridinyl 4-H), 7.23 (1H, ddd, J 7.8, 4.8 and 0.8 , 
pyridinyl 3-H), 7.04 (1H, d, J 8.3, DMB 6-HMin), 6.98 (1H, d, J 8.3, DMB 6-HMaj), 
6.37 (1H, dd, J 8.3 and 2.4, DMB 4-H), 6.31 (1H, d, J 2.4, DMB 2-H), 4.54 (1H, d, 
J 15.2, 2’ benzyl HA), 4.17–4.07 (1H, m, 2’ benzyl HB), 3.94 (2H, d, J 13.7 and 9.6, 
4-HMaj), 3.91 (2H, d, J 15.2, 1HMaj and Min), 3.80 (3H, s, OMeMaj), 3.77 (3H, s, 
OMeMinor), 3.64–3.60 (2H, m, 3’ benzyl), 3.59 (1H, d, J 5.0 , 1-methy HBMaj), 3.56 
(1H, d, J 8.6 , 1-methy HB
Min), 3.45 (3H, s, OMe), 2.96 (1H, dd, J 13.8 and 6.0, 6’ 
benzyl HB), 2.80 (1H, dd, J 13.8 and 7.3 , 6’ benzyl HA), 1.80 (1H, dt, J 9.8, 5.0, 
6HB), 1.61–1.44 (2H, m, 5-HA and 6-HA), 1.26 (1H, t, J 7.1, 5-HB), 1.04 (9H, s, tBu), 
0.98 (9H, s, tBu); δC (125 MHz, CDCl3); 164.3 (C=OMaj), 163.7 (C=OMin), 160.5 
(DMB 4-CMin), 160.4 (DMB 4-CMaj), 158.2 (DMB 1-CMin), 158.1 (DMB 1-CMin), 
150.8.0 (pyridinyl 2-C), 147.6 (pyridinyl 4-C), 136.8 (pyridinyl 6-C), 135.3 
(pyridinyl 6-C), 133.1 (DMB 1-C), 125.7 (pyridinyl 5-C), 117.9 (DMB 1-CMin), 
117.8 (DMB 1-CMaj), 104.8 (DMB 5-CMaj), 104.2 (DMB 5-CMin), 98.5 (DMB 3Min), 
98.5 (DMB 3Maj), 62.8 (4-C) 62.5 (4-CMaj), 61.0 (4-CMin), 59.7 (1-CMin), 58.9 (1-
CMaj), 58.3 (7-CMin), 58.2(7-CMaj), 55.4 (OMeMaj), 54.1 (1-methylMin and Maj), 55.5 
(OMeMin), 55.4(OMeMaj), 55.4 (OMeMin), 40.2 (2-benzyl), 39.7 (5-methyl), 31.6 (5-
C), 26.8 (tBu), 26.1 (6-C); νmax/cm-1 (neat); ; m/z (ES) 398.2; HRMS Found: 
398.2064, (C22H27N3O4 MH
+ requires 398.2074). 
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(1R,5R,7aR)-1-(((tert-Butyldiphenylsilyl)oxy)methyl)-2-(2,4-
dimethoxybenzyl)-5-(pyridin-3-ylmethyl)tetrahydro-1H-pyrrolo[1,2-c]imidazol-
3(2H)-one (295) 
By General Method H, using 285b (0.25 g,  0.45 mmol), 
1-bromo-2-chlorobenzene (0.54 mmol), followed by flash 
chromatography, eluting with EtOAc–Hexane (90:10) gave the title compound (0.14 
g, d.r. 93:7, 50%); Rf: 0.1 (97:2:1 DCM–EtOH-NH4OH); δH (500 MHz, CDCl3); 
8.49 (1H, dd, J 2.0 and 0.8, pyridinyl 2-HMaj and Min), 8.46 (1H, dd, J 4.8 and 2.0, 
pyridinyl 4-HMaj and Min), 7.68 (1H, dt, J 7.8 and 2.0, pyridinyl 6-HMaj and Min), 7.60–
7.56 (2H, m, ArMaj and Min), 7.52–7.48 (2H, m, ArMaj and Min), 7.46–7.30 (6H, m, ArMaj 
and Min), 7.23 (1H, ddd, J 7.8, 4.8 and 0.8 , pyridinyl 5-HMaj and Min), 7.04 (1H, d, J 8.3, 
DMB 6-HMin), 6.98 (1H, d, J 8.3, DMB 6-HMaj), 6.37 (1H, dd, J 8.3 and 2.4, DMB 
4-HMaj and Min), 6.31 (1H, d, J 2.4, DMB 2-HMaj and Min), 4.54 (1H, d, J 15.2, 2-methyl 
HA
Maj), 4.53 (1H, d, J 14.7, 2-methyl Ha
Min) 4.12 (1H, ddd, J 10.2, 6.9 and 3.0, 7-H), 
4.05 (1H, d, J 14.7, 2-methyl HB
Min), 3.94 (1H, dt, J 13.6 and 9.6, 4-H
Maj and Min), 3.91 
(1H, d, J 15.2, 2-methyl HB
Maj), 3.80 (3H, s, OMeMaj and Min), 3.65-3.54 (3H, m, 1-
methyl H2 and 1-H
Maj and Min), 3.45 (3H, s, OMeMaj and Min), 2.96 (dd, J 13.8 and 6.0, 5-
methyl HB
Maj and Min), 2.80 (1H, dd, J 13.8 and 7.3 , 5-methyl HA
Maj), 2.73 (1H, dd, J 
13.8 and 7.3, 5-methyl HB
Min), 2.08-2.00 (1H, m, 5HA
Maj and Min), 1.80 (1H, dt, J 10.2, 
5.0, 6HB
Maj and Min), 1.61–1.44 (2H, m, 5-HA and 6-HAMaj and Min), 1.04 (9H, s, tBuMaj and 
Min), 0.98 (9H, s, tBuMaj and Min); δC (125 MHz, CDCl3); 164.2 (C=O), 160.2 (DMB 4-
C), 158.2 (DMB 1-C), 150.8 (pyridinyl 2-C), 147.6 (pyridinyl 4-C), 137.0 (pyridinyl 
6-C), 135.5 (pyridinyl 1-C), 135.4 (Ar), 134.7 (Ar), 133.1 (DMB 2-C), 133.0 (Ar), 
130.5 (Ar), 129.8 (Ar), 129.7 (Ar), 127.8 (Ar), 127.5 (Ar), 123.6 (pyridinyl 5-C), 
117.8 (DMB 6-C), 104.8 (DMB 5-C), 98.5 (DMB 3-C), 62.8 (4-C), 59.7 (1-C), 58.6 
(7-C), 55.4 (OMe), 55.0 (1-methyl), 54.9 (OMe), 40.2 (2-benzyl), 39.7 (5-methyl), 
31.6 (5-C), 26.8 (tBu), 26.1 (6-C) 19.1 (tBu); νmax/cm-1 (neat); ; m/z (ES) 636.3; 
HRMS Found: 636.3257, (C38H46N3O4Si MH
+ requires 636.3252). 
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6 Appendices 
6.1 Appendix 1: Cyclisation reactions  
Ketopiperazine/Ketomorpholine187,188 Carmamate/Urea formation93 
    
Carbamate cyclisation189    Iodine-mediated amination92 
    
Iodine-mediated urea cyclisation87   Pd-catalysed aminoarylation190,191 
    
Mitsunobu/Appel192,193   Sulfurea formation194 
    
Pd-catalysed urea-arylation195,196   Ring-closing metathesis96–98 
     
Lactamisation197    Heck198 
    
Figure 47: Choice of cyclisations used in the computational analysis. 
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6.2 Appendix 2: Diversification reactions 
Following the enumeration; a series of functional group interconversions 
remove undesirable functional groups. 
 
Figure 48: Functional group interconversions used in the protocol 
Next, the scaffolds were decorated with capping groups (GSK provided a list of 
commonly used groups).  
 
N-Alkylation    Reductive amination 
   
Amide coupling   Urea formation 
   
N-arylation    Sulfonamide coupling 
   
Suzuki coupling   Sn2 Etherification 
   
Azide displacement   SN2 Sulfone 
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Sn2 Amination    O-Alkylation 
   
 
Figure 49: Summary of chemistries used in generating final compounds from scaffolds. 
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6.3 Appendix 3: Capping groups 
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Figure 50: Capping groups used in the computational protocol 
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6.4 Appendix 4: Novelty Assessment 
Novelty was assessed at the scaffold level by way of a substructure count 
against a reference database (Figure 51). Murcko fragments107 without α-
attachments are generated for each scaffold and these are compared with Murcko 
fragments without α-attachments  generated from a random 2% of compounds 
(~150,000 compounds) from the ZINC database of commercially available 
compounds.108 A penalty is incurred for the scaffold each time a match within the 
ZINC database is found. In addition, Murcko fragments with α-attachments are 
generated and these are also compared with the same randomly selected compounds 
from the ZINC database. With these two scores, it is possible to investigate both 
skeletal novelty (is the specific known without substituents) and appendage novelty 
(is the scaffold substitution pattern of the scaffold known) . 
 
Figure 51: Novelty assessment. Two fragments are generated for each scaffold and compared with 
the ZINC database. Demonstrated with two exemplar scaffolds 
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Appendix 5: Individual cyclisation data 
From the large nitro-Mannich reaction library, 42 cyclisation precursors were 
identified having significant potential for the synthesis of a library of scaffolds to be 
used in the generated of interrogating lead-like chemical space. It should be noted, 
that given the limitations of the protocol, that before synthetic effort was undertaken 
the precursor would be entered into pipeline pilot as a single entry. This ensures not 
potential scaffolds are lost due to identical scaffold from a different precursor 
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 154 
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6.5 Appendix 6: Data for Molecular weight, FSP3 plots 
ALogP and number of heavy atoms were calculated using the tools within 
Pipeline Pilot. The fraction of sp3-hybridised carbon atoms (Fsp3) was calculated 
using Dotmatics Vortex (Vortex v2013.12.25046). The data were visualized and 
analysed using Vortex and Origin Pro v9.  
The structural filtering was performed by interrogating two sets of SMARTS 
definitions with each of the final compounds using the substructure search tool 
within Pipeline Pilot. The first set contained 240 definitions as compiled by 
Shoichet, Simeonev et al. and used at the NIH Chemical Genomics Centre.27 The 
second set contained 36 definitions and are examples from the ‘GSKB’ filter as 
described by Churcher et al.7 In addition, the structural element of the high 
throughput screening filter embedded in Pipeline Pilot was also used that comprised 
the filters for undesirable functionality outlined in Table 15. 
Data from the lead-likeness assessment of both the ZINC database of 
compounds ‘available now’ and the virtual library (as summarised in Figure 42) are 
provided in Table 13-14. The distribution of the molecular properties of the virtual 
library based upon each scaffold is shown in Table 13. 
For the purposes of the novelty assessment scaffolds were virtually deprotected 
but did not undergo manipulation. In each case, a substructure search was performed 
against the ZINC database (90 911).  
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Scaffold 
Number of Final 
Compounds 
Number of 
Lead-like 
Compounds 
% Lead-like 
Compounds 
Mean Fsp3 
Substructure 
Hits 
ZINC 
(random 1%) 
90911 20 932 23 0.335 n/a 
Virtual 
Library 
2414 1112 46 0.520 1733 
1 33 6 19 0.539 0 
2 40 7 18 0.509 0 
3 16 12 86 0.458 0 
4 9 6 67 0.470 0 
5 66 34 57 0.549 1 
6 633 312 50 0.471 142 
7 1617 715 44 0.616 1592 
Table 13: Number of final compounds derived from each scaffold, together with the number and 
percentage of compounds that are lead-like (i.e. pass all filters). Fsp3 data illustrated in Figure 43, 
Novelty assessment data as compared with random 2% of ZINC database. 
Filter 
Random 2% of ZINC Database (90911) Virtual Library (19530) 
Successive Filtering Successive Filtering 
14 ≤ nHA ≤ 26 43971 1048 
–1 ≤ ALogP ≤ 3 17828 200 
Structural filter 8180 78 
Pass All 20932 (23%) 1128 (46%) 
Table 14: Lead-likeness assessment data. The data shown in Figure 42, Panels A and B was obtained 
by successive filtering by the number of heavy atoms, lipophilicity and structural filters.  
Filter 
Acyl halide Disulfide Dicarbonyl 
Aldehyde Hydrazine (terminal) Quaternary ammonium 
Alkyl halide Isocyanate Peroxide 
Anhydride Isothiocyanate Diazo 
Table 15: Undesirable functionality filters used in the ‘HTS Filter’ embedded in Pipeline Pilot. 
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6.6 Appendix 7: Shape Analysis – Principal Moments of Inertia  
3D structures were generated from the 2D Pipeline Pilot and the lowest energy 
conformer selected output using LLAMA.199 The 3D structures were used to generate the 
three Principal Moments of Inertia (I1, I2 and I3) using LLAMA which then normalised the 
plots by dividing the two lower values by the largest (I1/I3 and I2/I3).199 These Normalised 
PMI plots generate a triangular plot with the corners defined by a perfect sphere, a perfect 
disk and a perfect rod shape.200 
Scaffold 279 
 
Scaffold 281 
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Scaffold 284 
 
 
Scaffold 289 
 
 
Scaffold 292 
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Scaffold 293 
 
Scaffold 294 
 
Figure 52: Distribution of the molecular properties of the virtual library on a scaffold basis. 
Compounds are successive filtering by molecular size (14 ≤number of heavy atoms ≤26; failures 
shown in red) and lipophilicity (−1 ≤ALogP ≤3; failures shown in orange) and various structural 
filters (failures shown in black) to give portion of lead-like compounds (green). A normalised 
principal moment of inertia plot to show the shapes of the 2413 virtual library on a scaffold basis in 
relation to three idealised shapes; a rod, disk and sphere.  
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6.7 Appendix 8: Crystallographic informations 
The candidate crystallised 265 from EtOAc:Petrol. The crystals was 
subsequently assessed by Dr Chris Pask and a suitable crystal was selected and data 
obtained. 
Measurements were carried out at 120K on an Agilent SuperNova 
diffractometer equipped with an Atlas CCD detector and connected to an Oxford 
Cryostream low temperature device using mirror monochromated Cu K radiation 
( = 1.54184 Å from a Microfocus Nova X-ray source. The structure was solved by 
direct methods using SHELXS201 and refined by a full matrix least squares 
technique based on F2 using SHELXL97.201 
The compound crystallised as colourless needles. The compound crystallised in 
a monoclinic cell and was solved in the P21/c space group, with one molecule in the 
asymmetric unit.  
All non-hydrogen atoms were located in the Fourier Map and refined 
anisotropically. All hydrogen atoms were placed in calculated positions and refined 
isotropically using a “riding model”. 
Pictures are presented with non-hydrogen atoms displayed as displacement 
ellipsoids, which are set at the 50% probability level. 
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Table 16: Crystal data and structure refinement for 265 
Empirical formula   C12H22N2O4 
Formula weight   258.32 
Temperature/K   121(2) 
Crystal system   monoclinic 
Space group   P21/c 
a/Å   9.7870(10) 
b/Å   16.958(2) 
c/Å   9.1099(7) 
α/°   90.00 
β/°   94.166(9) 
γ/°   90.00 
Volume/Å3   1507.9(3) 
Z   4 
ρcalcg/cm3   1.138 
μ/mm-1   0.704 
F(000)   560.0 
Crystal size/mm3   0.11 × 0.03 × 0.03 
Radiation   CuKα (λ = 1.54184) 
2Θ range for data collection/°   9.06 to 100.84 
Index ranges   -8 ≤ h ≤ 9, -16 ≤ k ≤ 14, -9 ≤ l ≤ 8 
Reflections collected   3306 
Independent reflections   1554 [Rint = 0.0372, Rsigma = 0.0605] 
Data/restraints/parameters   1554/0/167 
Goodness-of-fit on F2   1.127 
Final R indexes [I>=2σ (I)]   R1 = 0.0478, wR2 = 0.0998 
Final R indexes [all data]   R1 = 0.0707, wR2 = 0.1151 
Largest diff. peak/hole / e Å-3   0.26/-0.17 
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6.8 Appendix 9: NOESY Spectra for 295 
 
5-HB  
6-HB 
4-methyl H2: 7-H  
7-H: 4-methyl H2 
5-HA   6-HA        7-H 
 164 
 
7 References 
1 F. Pammolli, L. Magazzini and M. Riccaboni, Nat. Rev. Drug Discov., 2011, 
10, 428–38. 
2 D. Robbins, A. F. Newton, C. Gignoux, J.-C. Legeay, A. Sinclair, M. Rejzek, 
C. a. Laxon, S. K. Yalamanchili, W. Lewis, M. a. O’Connell, et al., Chem. 
Sci., 2011, 2, 2232–35. 
3 J. P. Hughes, S. S. Rees, S. B. Kalindjian and K. L. Philpott, Br. J. 
Pharmacol., 2011, 162, 1239–1249. 
4 G. L. Patrick, An Introduction to Medicinal Chemistry, Oxford University 
Press, 2005. 
5 L. J. Gershell and J. H. Atkins, Nat. Rev. Drug Discov., 2003, 2, 321–7. 
6 A. K. Ghose, V. N. Viswanadhan and J. J. Wendoloski, J. Comb. Chem., 
1998, 1, 55–68. 
7 A. Nadin, C. Hattotuwagama, I. Churcher, A. Nadin, C. Hattotuwagama and 
I. Churcher, Angew. Chemie Int. Ed., 2012, 51, 1114–22. 
8 J. P. Garnier, Harv. Bus. Rev., 2008, 68–76. 
9 I. Kola and J. Landis, Nat. Rev. Drug Discov., 2004, 3, 711–5. 
10 P. D. Leeson and J. R. Empfield, Annu. Rep. Med. Chem, 2010, Volume 45, 
pp. 393–407. 
11 C. a Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Adv. Drug 
Deliv. Rev., 1997, 23, 3–25. 
12 T. I. I. Oprea, A. M. M. Davis, S. J. J. Teague and P. D. D. Leeson, J. Chem. 
Inf. Comput. Sci., 2001, 41, 1308–15. 
13 S. S. J. Teague, A. A. M. Davis, P. P. D. Leeson and T. Oprea, Angew. 
Chemie - Int. Ed., 1999, 38, 3743–3748. 
14 J. F. Blake and B. James F, Curr. Opin. Biotechnol., 2000, 11, 104–107. 
16 M. J. Waring, Bioorg. Med. Chem. Lett., 2009, 19, 2844–2851. 
17 M. J. Waring, Expert Opin. Drug Discov., 2010, 5, 235–48. 
18 M. J. Waring and C. Johnstone, Bioorg. Med. Chem. Lett., 2007, 17, 1759–
1764. 
19 P. D. Leeson and B. Springthorpe, Nat Rev Drug Discov, 2007, 6, 881–890. 
20 H. van de Waterbeemd, D. A. Smith, K. Beaumont and D. K. Walker, J. Med. 
Chem., 2001, 44, 1313–1333. 
21 J. Gasteiger, Handbook of Chemoinformatics: From Data to Knowledge, 
Wiley-VCH, 2003. 
22 R. Mannhold, H. Kubinyi and G. Folkers, Molecular Drug Properties: 
Measurement and Prediction, John Wiley & Sons, 2008. 
 165 
 
23 C. A. Lipinski, J. Pharmacol. Toxicol. Methods, 2000, 44, 235–249. 
24 P. Ertl, B. Rohde and P. Selzer, J. Med. Chem., 2000, 43, 3714–3717. 
25 A. Chuprina, O. Lukin, R. Demoiseaux, A. Buzko and A. Shivanyuk, J. 
Chem. Inf. Model., 2010, 50, 470–479. 
26 G. M. Rishton and R. Gilbert M, Drug Discov. Today, 2003, 8, 86–96. 
27 A. Jadhav, R. S. Ferreira, C. Klumpp, B. T. Mott, C. P. Austin, J. Inglese, C. 
J. Thomas, D. J. Maloney, B. K. Shoichet and A. Simeonov, J. Med. Chem., 
2009, 53, 37–51. 
28 R. Gilbert M and G. M. Rishton, Drug Discov. Today, 1997, 2, 382–384. 
29 S. L. McGovern, E. Caselli, N. Grigorieff and B. K. Shoichet, J. Med. Chem., 
2002, 45, 1712–1722. 
30 E. Kerns and L. Di, Drug-like Properties: Concepts, Structure Design and 
Methods: From ADME to Toxicity Optimization, Elsevier Science, 2008. 
31 P. D. Dobson and D. B. Kell, Nat. Rev. Drug Discov., 2008, 7, 205–20. 
32 S. Oswald, M. Grube, W. Siegmund and H. K. Kroemer, Xenobiotica, 2007, 
37, 1171–1195. 
33 U. Norinder and M. Haeberlein, Adv. Drug Deliv. Rev., 2002, 54, 291–313. 
34 H. van de Waterbeemd, G. Camenisch, G. Folkers, J. R. Chretien and O. A. 
Raevsky, J. Drug Target., 1998, 6, 151–165. 
35 S. G. Summerfield, A. J. Stevens, L. Cutler, M. del Carmen Osuna, B. 
Hammond, S.-P. Tang, A. Hersey, D. J. Spalding and P. Jeffrey, J. 
Pharmacol. Exp. Ther., 2006, 316, 1282–1290. 
36 W.E. Glover, A.D.M. Greenfield and R.G. Shanks, Br. J. Pharmacol. 
Chemother., 1962, 19, 235–244. 
37 J. W. Black, A. F. Crowther, R. G. Shanks, L. H. Smith and A. C. Dornhorst, 
Lancet, 1964, 283, 1080–1081. 
38 C. Hamlett, Drug Discovery Using a Fragment-based Approach, University 
of Leeds, 2011. 
39 M. M. Hann and T. I. Oprea, Curr. Opin. Chem. Biol., 2004, 8, 255–263. 
40 P. J. Hajduk, W. R. J. D. Galloway and D. R. Spring, Nature, 2011, 470, 42–
43. 
41 R. A. E. Carr, M. Congreve, C. W. Murray and D. C. Rees, Drug Discov. 
Today, 2005, 10, 987–992. 
42 D. C. Rees, M. Congreve, C. W. Murray and R. Carr, Nat Rev Drug Discov, 
2004, 3, 660–672. 
43 M. M. Hann, A. R. Leach and G. Harper, J. Chem. Inf. Model., 2001, 41, 
856–864. 
44 G. Bollag, P. Hirth, J. Tsai, J. Zhang, P. N. Ibrahim, H. Cho, W. Spevak, C. 
Zhang, Y. Zhang, G. Habets, et al., Nature, 2010, 467, 596–599. 
45 J. Tsai, J. T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. 
Gillette, J. Kong, N. K. Haass, et al., Proc. Natl. Acad. Sci., 2008, 105, 3041–
 166 
 
3046. 
46 A. H. Lipkus, Q. Yuan, K. Lucas, S. Funk, W. F. Bartelt, R. J. Schenck and 
A. J. Trippe, J. Org. Chem., 2008, 73, 4443–51. 
47 R. J. Spandl, M. Díaz-Gavilán, K. M. G. O’Connell, G. L. Thomas and D. R. 
Spring, Chem. Rec., 2008, 8, 129–142. 
48 D. Morton, S. Leach, C. Cordier, S. Warriner and A. Nelson, Angew. Chemie 
Int. Ed., 2009, 48, 104–109. 
49 M. Dow, M. Fisher, T. James, F. Marchetti and A. Nelson, Org. Biomol. 
Chem., 2012, 10, 17–28. 
50 K. H. Bleicher, H.-J. Bohm, K. Muller and A. I. Alanine, Nat Rev Drug 
Discov, 2003, 2, 369–378. 
51 D. S. Tan, Nat Chem Biol, 2005, 1, 74–84. 
52 M. D. Burke and S. L. Schreiber, Angew. Chem. Int. Ed. Engl., 2004, 43, 46–
58. 
53 H. Oguri and S. L. Schreiber, Org. Lett., 2004, 7, 47–50. 
54 R. J. Spandl, A. Bender and D. R. Spring, Org. Biomol. Chem., 2008, 6, 
1149–1158. 
55 T. E. E. Nielsen and S. L. L. Schreiber, Angew. Chem. Int. Ed. Engl., 2008, 
47, 48–56. 
56 S. L. Schreiber, Science (80-. )., 2000, 287, 1964–1969. 
57 D. R. Spring, Org. Biomol. Chem., 2003, 1, 3867–3870. 
58 N. Kumagai, G. Muncipinto and S. L. Schreiber, Angew. Chem. Int. Ed. 
Engl., 2006, 45, 3635–8. 
59 G. L. Thomas, R. J. Spandl, F. G. Glansdorp, M. Welch, A. Bender, J. 
Cockfield, J. A. Lindsay, C. Bryant, D. F. J. Brown, O. Loiseleur, et al., 
Angew. Chemie Int. Ed., 2008, 47, 2808–2812. 
60 S. Sirois, G. Hatzakis, D. Wei, Q. Du and K.-C. Chou, Comput. Biol. Chem., 
2005, 29, 55–67. 
61 C.-V. T. Vo, G. Mikutis and J. W. Bode, Angew. Chem. Int. Ed. Engl., 2013, 
52, 1705–8. 
62 C.-V. T. Vo, M. U. Luescher and J. W. Bode, Nat. Chem., 2014, 6, 310–4. 
63 M. He and J. W. Bode, J. Am. Chem. Soc., 2008, 130, 418–9. 
64 S. M.-C. Pelletier, P. C. Ray and D. J. Dixon, Org. Lett., 2009, 11, 4512–5. 
65 R. G. Doveston, P. Tosatti, M. Dow, D. J. Foley, H. Y. Li, A. J. Campbell, D. 
House, I. Churcher, S. P. Marsden and A. Nelson, Org. Biomol. Chem., 2015, 
13, 859–865. 
66 A. Dömling and I. Ugi, Angew. Chem. Int. Ed. Engl., 2000, 39, 3168–3210. 
67 N. R. Candeias, F. Montalbano, P. M. S. D. Cal and P. M. P. Gois, Chem. 
Rev., 2010, 110, 6169–93. 
68 J. Zhu and H. Bienaym, Multicomponent Reactions, John Wiley & Sons, 
 167 
 
2006. 
69 E. Ascic, S. T. Le Quement, M. Ishoey, M. Daugaard, T. E. Nielsen, S. T. Le 
Quement, M. Ishoey, M. Daugaard and T. E. Nielsen, ACS Comb. Sci., 2012, 
14, 253–7. 
70 N. R. Candeias, L. F. Veiros, C. a. M. Afonso and P. M. P. Gois, European J. 
Org. Chem., 2009, 1859–1863. 
71 E. Ascic, S.T. Le Quement, M. Ishoey, M. Daugaard and T. E. Nielsen, ACS 
Comb. Sci., 2012, 17, 19–23. 
72 M. Ayaz, J. Dietrich and C. Hulme, Tetrahedron Lett., 2011, 52, 4821–4823. 
73 F. Berre, Tetrahedron Lett., 2001, 42, 3591–3594. 
74 T. J. Southwood, M. C. Curry and C. a. Hutton, Tetrahedron, 2006, 62, 236–
242. 
75 N. A. Petasis and I. A. Zavialov, J. Am. Chem. Soc., 1997, 7863, 445–446. 
76 N. A. Petasis, Tetrahedron, 1997, 53, 16463–16470. 
77 T. Koolmeister, M. Södergren and M. Scobie, Tetrahedron Lett., 2002, 43, 
5969–5970. 
78 G. Muncipinto, P. N. Moquist, S. L. Schreiber and S. E. Schaus, Angew. 
Chem. Int. Ed. Engl., 2011, 50, 8172–5. 
79 P. Wu, M. Å. Petersen, A. E. Cohrt, R. Petersen, M. H. Clausen and T. E. 
Nielsen, European J. Org. Chem., 2015, n/a–n/a. 
80 T. Flagstad, M. R. Hansen, S. T. Le Quement, M. Givskov and T. E. Nielsen, 
ACS Comb. Sci., 2015, 17, 19–23. 
81 S. T. Le Quement, T. Flagstad, R. J. T. Mikkelsen, M. R. Hansen, M. C. 
Givskov and T. E. Nielsen, Org. Lett., 2012, 14, 640–643. 
82 G. Muncipinto, T. Kaya, J. A. Wilson, N. Kumagai, P. a. Clemons and S. L. 
Schreiber, Org. Lett., 2010, 12, 5230–3. 
83 K. K. Nanda and B. Wesley Trotter, Tetrahedron Lett., 2005, 46, 2025–2028. 
84 S. Wertz, S. Kodama and A. Studer, Angew. Chemie - Int. Ed., 2011, 50, 
11511–11515. 
85 S. Urig, J. Jacob, E. Amtmann, J. Moulinoux, S. Gromer, K. Becker and E. 
Davioud-charvet, J. Med. Chem., 2005, 48, 7024-7039. 
86 W. M. Meylan and P. H. Howard, J. Pharm. Sci., 1995, 84, 83–92. 
87 C. J. Moody, P. A. Hunt and C. Smith, ARKIVOC, 2000, v, 698–706. 
88 M. D. Burke, E. M. Berger and S. L. Schreiber, Science (80-. )., 2003, 302, 
613–618. 
89 Z. Hong, L. Liu, C.-C. Hsu and C.-H. Wong, Angew. Chem. Int. Ed. Engl., 
2006, 45, 7417–21. 
90 F. Dioury, E. Guéné, A. Di Scala-Roulleau, C. Ferroud, A. Guy and M. Port, 
Tetrahedron Lett., 2005, 46, 611–613. 
91 S. Ahmad and A. Sutherland, Org. Biomol. Chem., 2012, 10, 8251–9. 
 168 
 
92 S. Bera and G. Panda, ACS Comb. Sci., 2012, 14, 1–4. 
93 H. A. Staab, Justus Liebigs Ann. Chem., 1957, 609, 75–83. 
94 D. Zhang, X. Xing and G. D. Cuny, J. Org. Chem., 2006, 71, 1750–3. 
95 B. M. Bhanage, S. Fujita, Y. Ikushima and M. Arai, Green Chem., 2004, 6, 
78. 
96 L. a Marcaurelle, E. Comer, S. Dandapani, J. R. Duvall, B. Gerard, S. 
Kesavan, M. D. Lee, H. Liu, J. T. Lowe, J.-C. Marie, et al., J. Am. Chem. 
Soc., 2010, 132, 16962–76. 
97 A. Fürstner and K. Langemann, J. Am. Chem. Soc., 1997, 119, 9130–9136. 
98 R. H. Grubbs, S. J. Miller and G. C. Fu, Acc. Chem. Res., 1995, 28, 446–452. 
99 G. O. Wilson, K. A. Porter, H. Weissman, S. R. White, N. R. Sottos and J. S. 
Moore, Adv. Synth. Catal., 2009, 351, 1817–1825. 
100 C. C. and L. A. Oro, Wiley: Iridium Complexes in Organic Synthesis - Luis A. 
Oro, Carmen Claver, 2008. 
101 J. F. Hartwig and L. M. Stanley, Acc. Chem. Res., 2010, 43, 1461–75. 
102 G. Helmchen, A. Dahnz, P. Dübon, M. Schelwies and R. Weihofen, Chem. 
Commun. (Camb)., 2007, 675–91. 
103 R. Takeuchi and S. Kezuka, Synthesis (Stuttg)., 2006, 2006, 3349–3366. 
104 R. Takeuchi, Synlett, 2002, 2002, 1954–1965. 
105 J. P. Janssen and G. Helmchen, Tetrahedron Lett., 1997, 38, 8025–8026. 
106 R. Takeuchi and M. Kashio, Angew. Chemie Int. Ed. English, 1997, 36, 263–
265. 
107 G. W. Bemis and M. A. Murcko, J. Med. Chem., 1996, 39, 2887–2893. 
108 J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad and R. G. Coleman, J. 
Chem. Inf. Model., 2012, 52, 1757–68. 
109 H. Fujieda, M. Kanai, T. Kambara and M. Dekker, J. Am. Chem. Soc. 1997, 
119, 2060-2061. 
110 Z. Chen, L. Lin, M. Wang, X. Liu and X. Feng, Chem. Eur. J, 2013, 19, 
7561–7567. 
111 M. M. C. Lo and G. C. Fu, J. Am. Chem. Soc., 2002, 124, 4572–4573. 
112 E. C. Lee, B. L. Hodous, E. Bergin, C. Shih and G. C. Fu, J. Am. Chem. Soc., 
2005, 127, 11586–11587. 
113 B. L. Hodous and G. C. Fu, J. Am. Chem. Soc., 2002, 124, 1578–1579. 
114 S. Chen, E. C. Salo, K. a. Wheeler and N. J. Kerrigan, Org. Lett., 2012, 14, 
1784–1787. 
115 S. France, H. Wack, A. M. Hafez, A. E. Taggi, D. R. Witsil and T. Lectka, 
Org. Lett., 2002, 4, 1603–1605. 
116 H. M. L. Davies and C. Venkataramani, Org. Lett., 2001, 3, 1773–1775. 
117 H. M. L. Davies, R. E. J. Beckwith, E. G. Antoulinakis and Q. Jin, J. Org. 
Chem., 2003, 68, 6126–6132. 
 169 
 
118 S. F. Zhu, B. Xu, G. P. Wang and Q. L. Zhou, J. Am. Chem. Soc., 2012, 134, 
436–442. 
119 H. M. L. Davies, T. Hansen and M. R. Churchill, J. Am. Chem. Soc., 2000, 
122, 3063–3070. 
120 B. Liu, S. Zhu, W. Zhang, C. Chen and Q. Zhou, J. Am. Chem. Soc., 2007, 
5834–5835. 
121 H. M. L. Davies, C. Venkataramani, T. Hansen and D. W. Hopper, J. Am. 
Chem. Soc., 2003, 125, 6462–6468. 
122 Z. Hou, J. Wang, P. He, J. Wang, B. Qin, X. Liu, L. Lin and X. Feng, Angew. 
Chemie - Int. Ed., 2010, 49, 4763–4766. 
123 H. Finch, G. Nogami, M. Yokoyama, M. Barta and J.L. Havens, ACS Comb. 
Sci., 2002, 30, 2197–2199. 
124 H. M. L. Davies, D. W. Hopper, T. Hansen, Q. Liu and S. R. Childers, 
Bioorg. Med. Chem. Lett., 2004, 14, 1799–1802. 
125 N. T. Jui, J. a O. Garber, F. G. Finelli and D. W. C. MacMillan, J. Am. Chem. 
Soc., 2012, 134, 11400–11403. 
126 H. Y. Jang, J. B. Hong and D. W. C. MacMillan, J. Am. Chem. Soc., 2007, 
129, 7004–7005. 
127 T. H. Graham, C. M. Jones, N. T. Jui and D. W. C. MacMillan, J. Am. Chem. 
Soc., 2008, 130, 16494–16495. 
128 K. A. and D. W. C. M. T D. Beeson, A Mastracchio, J. B. Hong, Science (80-. 
)., 2007, 316, 582–586. 
129 H. Kim and D. W. C. Macmillan, J. Am. Chem. Soc., 2008, 130, 398–399. 
130 J. F. Bower, P. Szeto and T. Gallagher, Org. Lett., 2007, 9, 4909–4912. 
131 M. Eskici, A. Karanfil, M. S. Özer and C. Sarikürkcü, Tetrahedron Lett., 
2011, 52, 6336–6341. 
132 T. a. Moss, D. M. Barber, A. F. Kyle and D. J. Dixon, Chem. - A Eur. J., 
2013, 19, 3071–3081. 
133 J. F. Bower, P. Szeto and T. Gallagher, Org. Biomol. Chem., 2007, 5, 143–
150. 
134 A. J. Williams, S. Chakthong, D. Gray, R. M. Lawrence and T. Gallagher, 
Org. Lett., 2003, 5, 811–814. 
135 J. F. Bower, J. Švenda, A. J. Williams, J. P. H. Charmant, R. M. Lawrence, P. 
Szeto and T. Gallagher, Org. Lett., 2004, 6, 4727–4730. 
136 J. F. Bower, P. Szeto and T. Gallagher, Tetrahedron, 2007, 10–13. 
137 A. Noble and J. C. Anderson, Chem. Rev., 2013, 113, 2887−2939. 
138 H. G. Johnson, J. Am. Chem. Soc., 1946, 68, 12–14. 
139 E. L. Hirst, J. K. N. Jones, S. Minahan, F. W. Ochynski, A. T. Thomas and T. 
Urbanski, J. Chem. Soc., 1947, 924. 
140 H. Adams, J. C. Anderson, S. Peace and A. M. K. Pennell, J. Org. Chem., 
1998, 63, 9932–9934. 
 170 
 
141 C.-J. Wang, X.-Q. Dong, Z.-H. Zhang, Z.-Y. Xue and H.-L. Teng, J. Am. 
Chem. Soc., 2008, 130, 8606–7. 
142 D. M. Barber, H. J. Sanganee, D. J. Dixon and A. Park, Org. Lett., 2012, 
4064–4067. 
143 K. M. Johnson, M. S. Rattley, F. Sladojevich, D. M. Barber, M. G. Nuñez, A. 
M. Goldys, D. J. Dixon, M. G. Nu, A. M. Goldys and D. J. Dixon, Org. Lett., 
2012, 14, 2492–5. 
144 J. M. B. Vu and J. L. Leighton, Org. Lett., 2011, 13, 4056–9. 
145 J. C. Anderson, L. R. Horsfall, A. S. Kalogirou, M. R. Mills, G. J. Stepney 
and G. J. Tizzard, J. Org. Chem., 2012, 77, 6186–98. 
146 T. Okino, S. Nakamura, T. Furukawa and Y. Takemoto, Org. Lett., 2004, 6, 
625–7. 
147 Z. Wang, Comprehensive Organic Name Reactions and Reagents, Wiley, 
2009. 
148 B. M. Nugent, R. a Yoder and J. N. Johnston, J. Am. Chem. Soc., 2004, 126, 
3418–9. 
149 N. Ono, in The Nitro Group in Organic Synthesis, John Wiley & Sons, Inc., 
2002, pp. 159–181. 
150 P. Ceccherelli, M. Curini, M. C. Marcotullio, F. Epifano and O. Rosati, Synth. 
Commun., 2006, 28, 3057–3064. 
151 J. C. Anderson and H. a Chapman, Org. Biomol. Chem., 2007, 5, 2413–2422. 
152 K. Yamada, G. Moll and M. Shibasaki, Synlett, 2001, 2001, 980–982. 
153 L. Bernardi, F. Fini, R. P. Herrera, A. Ricci and V. Sgarzani, Tetrahedron, 
2006, 62, 375–380. 
154 E. Marqués-López, P. Merino, T. Tejero and R. P. Herrera, European J. Org. 
Chem., 2009, 2009, 2401–2420. 
155 E. Gomez-Bengoa, A. Linden, R. López, I. Múgica-Mendiola, M. Oiarbide 
and C. Palomo, J. Am. Chem. Soc., 2008, 130, 7955–66. 
156 C. Palomo, M. Oiarbide, R. Halder, A. Laso and R. López, Angew. Chemie - 
Int. Ed., 2005, 45, 117–120. 
157 C. Palomo, M. Oiarbide, A. Laso and R. López, J. Am. Chem. Soc., 2005, 
127, 17622–3. 
158 J. S. Bandar and T. H. Lambert, J. Am. Chem. Soc., 2013, 135, 11799–802. 
159 G. P. Marsh, P. J. Parsons, C. McCarthy and X. G. Corniquet, Org. Lett., 
2007, 9, 2613–6. 
160 W. He, Q. Wang, Q. Wang, B. Zhang, X. Sun and S. Zhang, Synlett, 2009, 
1311–1314. 
161 J. C. Anderson and P. J. Koovits, Chem. Sci., 2013, 4, 2897. 
162 H. Y. Wang, Z. Chai and G. Zhao, Tetrahedron, 2013, 69, 5104–5111. 
163 T. a Davis, J. C. Wilt and J. N. Johnston, J. Am. Chem. Soc., 2010, 132, 
2880–2. 
 171 
 
164 C. A. Brown and V. K. Ahuja, J. Org. Chem., 1973, 38, 2226–2230. 
165 Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd, 
Chichester, UK, 2001. 
166 P. G. M. Wuts and T. W. Greene, Greene’s Protective Groups in Organic 
Synthesis, Wiley, 2006. 
167 G. S. Lemen and J. P. Wolfe, Org. Lett., 2010, 12, 2322–5. 
168 L. Bagnoli, S. Cacchi, G. Fabrizi, A. Goggiamani, C. Scarponi and M. 
Tiecco, J. Org. Chem., 2010, 75, 2134–7. 
169 F. Lovering, J. Bikker and C. Humblet, J. Med. Chem., 2009, 52, 6752–6. 
170 N. R. Candeias, P. M. S. D. Cal, V. André, M. T. Duarte, L. F. Veiros and P. 
M. P. Gois, Tetrahedron, 2010, 66, 2736–2745. 
171 H. Jourdan, G. Gouhier, L. Van Hijfte, P. Angibaud and S. R. Piettre, 
Tetrahedron Lett., 2005, 46, 8027–8031. 
172 C. Gnamm, G. Franck, N. Miller, T. Stork, K. Brödner and G. Helmchen, 
Synthesis (Stuttg)., 2008, 2008, 3331–3350. 
173 H.-O. Kim, D. Friedrich, E. Huber and N. P. Peet, Synth. Commun., 1996, 26, 
3453–3469. 
174 PCT, 9 167 193, 1999. 
175 R. Gosain, A. M. Norrish and M. E. Wood, Tetrahedron, 2001, 57, 1399–
1410. 
176 M. Nagarajan, X. Xiao, S. Antony, G. Kohlhagen, Y. Pommier and M. 
Cushman, J. Med. Chem., 2003, 46, 5712–24. 
177 A. J. Murray, P. J. Parsons, E. S. Greenwood and E. M. E. Viseux, Synlett, 
2004, 1589–1591. 
178 A. S. Kende and J. S. Mendoza, Tetrahedron Lett., 1991, 32, 1699–1702. 
179 C. G. Oliva, A. M. S. Silva, D. I. S. P. Resende, F. A. A. Paz and J. A. S. 
Cavaleiro, European J. Org. Chem., 2010, 2010, 3449–3458. 
180 A. F. Kyle, P. Jakubec, D. M. Cockfield, E. Cleator, J. Skidmore and D. J. 
Dixon, Chem. Commun. (Camb)., 2011, 47, 10037–9. 
181 L. Huang and W. D. Wulff, J. Am. Chem. Soc., 2011, 133, 8892–5. 
182 Q. Wang, M. Leutzsch, M. van Gemmeren and B. List, J. Am. Chem. Soc., 
2013, 135, 15334–7. 
183 D. J. Miller, M. Bashir-Uddin Surfraz, M. Akhtar, D. Gani and R. K. 
Allemann, Org. Biomol. Chem., 2004, 2, 671–88. 
184 L. Espelt, T. Parella, J. Bujons, C. Solans, J. Joglar, A. Delgado and P. 
Clapés, Chemistry, 2003, 9, 4887–99. 
185 N. Bischofberger, H. Waldmann, T. Saito, E. S. Simon, W. Lees, M. D. 
Bednarski and G. M. Whitesides, J. Org. Chem., 1988, 53, 3457–3465. 
186 Y. Meyer, J.-A. Richard, M. Massonneau, P.-Y. Renard and A. Romieu, Org. 
Lett., 2008, 10, 1517–20. 
 172 
 
187 A. Viso, R. Fernández de la Pradilla, A. Flores and A. García, Tetrahedron, 
2007, 63, 8017–8026. 
188 S. Dugar, A. Sharma, B. Kuila, D. Mahajan, S. Dwivedi and V. Tripathi, 
Synthesis, 2014, 47, 712–720. 
189 S. G. Davies, J. R. Haggitt, O. Ichihara, R. J. Kelly, M. A. Leech, A. J. Price 
Mortimer, P. M. Roberts and A. D. Smith, Org. Biomol. Chem., 2004, 2, 
2630. 
190 M. L. Leathen, B. R. Rosen and J. P. Wolfe, J. Org. Chem., 2009, 5107–
5110. 
191 J. S. Nakhla, D. M. Schultz and J. P. Wolfe, Tetrahedron, 2009, 65, 6549–
6570. 
192 T. Ayad, Y. Génisson and M. Baltas, Org. Biomol. Chem., 2005, 3, 2626. 
193 D. Savoia, S. Grilli and A. Gualandi, Org. Lett., 2010, 12, 4964–7. 
194 M. C. Manfredi, Y. Bi, A. A. Nirschl, J. C. Sutton, R. Seethala, R. Golla, B. 
C. Beehler, P. G. Sleph, G. J. Grover, J. Ostrowski, et al., Bioorg. Med. 
Chem. Lett., 2007, 17, 4487–90. 
195 D. Schultz, J. Wolfe, D. Schultz M. and J. Wolfe P., Synthesis (Stuttg)., 2012, 
44, 351,361. 
196 J. D. Neukom, A. S. Aquino and J. P. Wolfe, Org. Lett., 2011, 13, 2196–
2199. 
197 M. Kunishima, K. Hioki, T. Moriya, J. Morita, T. Ikuta and S. Tani, Angew. 
Chemie, Int. Ed., 2006, 45, 1252–1255. 
198 T. W. Liwosz and S. R. Chemler, J. Am. Chem. Soc., 2012, 134, 2020–3. 
199 A. Nelson, C. Empson, P. Craven, Z. Owen, I. Churcher, R. Doveston, S. 
Warriner, M. Dow and A. Horton, Org. Biomol. Chem., 2015, 13, 859-865. 
200 W. H. B. Sauer and M. K. Schwarz, J. Chem. Inf. Comput. Sci., 2003, 43, 
987. 
201 G. M. Sheldrick, Acta Crystallogr. A., 2008, 64, 112–22. 
 
